Gastroretentive system having release rate controlling film

A gastroretentive system with a release rate controlling polymer film and degradable linkers addresses stability and drug release control, ensuring safe gastric retention and passage, enhancing therapeutic efficacy.

JP7588177B2Active Publication Date: 2024-11-21NORTIVA BIO INC
View PDF 6 Cites 0 Cited by

Patent Information

Application Number
JP2023075680
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2018-04-03
Filing Date
2023-05-01
Publication Date
2024-11-21
Estimated Expiration
2038-06-08

AI Technical Summary

Technical Problem

Existing gastroretentive systems face challenges in maintaining mechanical stability in the stomach for extended periods, controlling drug release rates, and ensuring safe passage through the pylorus without causing intestinal obstruction.

Method used

A gastroretentive system with a release rate controlling polymer film covering segments or elongate members, comprising a central elastomer and elongate members connected by linkers that degrade or weaken after a specified gastric residence period, allowing controlled drug release and safe passage.

Benefits of technology

The system provides sustained drug release over 4 to 10 days with minimal burst release, maintains mechanical stability in the stomach, and ensures safe passage through the pylorus, reducing the risk of intestinal obstruction.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007588177000021
    Figure 0007588177000021
  • Figure 0007588177000022
    Figure 0007588177000022
  • Figure 0007588177000023
    Figure 0007588177000023
Patent Text Reader

Abstract

To provide use of release rate-modulating films for use in gastric residence systems, which provide good control over release rates of agents from the systems.SOLUTION: The invention provides gastric residence systems, or components of gastric residence system such as segments or elongate members of gastric residence systems, with release rate-modulating films and methods for making and using such systems. The release rate-modulating films provide good control over release of agents (such as therapeutic, diagnostic, or nutritional agents) present in the gastric residence system. The films also permit higher drug loading in the gastric residence systems and components of gastric residence systems while maintaining good control over release of agents. Some embodiments of the films can provide resistance against burst release of agent upon exposure to alcohol.SELECTED DRAWING: Figure 30
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] FIELD OF THEINVENTION The present invention relates to a system that remains in the stomach for an extended period of time for the sustained release of a pharmaceutical agent, and a method for using the same. [Background technology]

[0002] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims the benefit of priority to U.S. Provisional Patent Application No. 62 / 517,732, filed June 9, 2017, U.S. Provisional Patent Application No. 62 / 566,111, filed September 29, 2017, and U.S. Provisional Patent Application No. 62 / 652,128, filed April 3, 2018, the entire contents of which are hereby incorporated by reference herein.

[0003] A gastroretentive system is a delivery system for a drug that remains in the stomach for a period of days to weeks or even longer, during which time the drug or other agent can elute from the system for absorption in the gastrointestinal tract. Examples of such systems are described in International Patent Applications WO2015 / 191920, WO2015 / 191925, WO2017 / 070612, WO2017 / 100367, and PCT / US2017 / 034856.

[0004] A gastroretentive system is designed to be administered to the patient's stomach, typically a capsule that is swallowed or introduced into the stomach by alternative administration methods (e.g., feeding tube or stomach tube). When the capsule dissolves in the stomach, the system expands or unfolds to a size that will remain in the stomach for the desired retention period (e.g., 3 days, 7 days, 2 weeks, etc.) and resist passage through the pyloric sphincter. This requires mechanical stability over the desired retention period. Over the retention period, the system releases one or more agents, such as one or more drugs, preferably with a minimal burst release, which requires careful selection of carrier materials for the agents to provide the desired release profile. During retention in the stomach, the system should not interfere with the normal passage of food or other stomach contents. The system should pass from the stomach at the end of the desired retention time and be easily removed from the patient. If the system passes too quickly from the stomach to the small intestine, it should not cause an ileus, and it should also be easily removed from the patient. These characteristics require careful selection of the materials from which the system is constructed, as well as the system's dimensions and configuration.

[0005] The present invention describes the use of release rate controlling films for use in gastroretentive systems that provide good control over the release rate of drug from the system. Summary of the Invention [Means for solving the problem]

[0006] The present invention provides a gastric retention system having a segment covered with a release rate modifying polymer film. The present invention also provides an elongate member of a gastric retention system having a segment covered with a release rate modifying polymer film. The present invention also provides a segment covered with a release rate modifying polymer film suitable for use in a gastric retention system. The present invention also provides an elongate member covered with a release rate modifying polymer film suitable for use in a gastric retention system. Methods of making the segments, elongate members, and gastric retention systems are also provided. Methods of using the gastric retention systems are also provided.

[0007] In some embodiments, the present invention provides a gastric retention system comprising a therapeutically effective amount of a drug or a pharma- ceutically acceptable salt thereof, the gastric retention system having a compacted configuration and a non-compacted configuration, the gastric retention system comprising a plurality of elongated members attached to a central elastomer, each elongated member comprising at least two segments connected by a linker, the linker configured to no longer connect the at least two segments of each elongated member after a designated gastric retention period; and the elongated members comprising a carrier polymer and a drug or a pharma- ceutically acceptable salt thereof; the gastric retention system configured to release the drug or a pharma- ceutically acceptable salt thereof over the designated gastric retention period. At least one of the linkers may comprise an enteric polymer or may comprise a polymer that degrades in a time-dependent manner in an aqueous environment. The gastric retention period of the system may be about 4 days, at least about 4 days, about 7 days, or at least about 7 days. In some embodiments, the gastric retention systems disclosed herein may have a gastric retention period of about 4 to about 8 days when administered to a human patient. In some embodiments, the gastric retention systems disclosed herein may have a gastric retention period of about 4 to about 10 days when administered to a human patient. In some embodiments, the gastric retention systems disclosed herein may have a gastric retention period of about 7 days, or at least about 7 days, when administered to a human patient. In some embodiments, the gastric retention systems disclosed herein may have a gastric retention period of about 7 to about 10 days when administered to a human patient.

[0008] In any of the embodiments described herein, the invention provides a gastric retention system comprising a therapeutically effective amount of a drug or a pharma- ceutically acceptable salt thereof, the gastric retention system having a miniaturized configuration and a non-miniaturized configuration, the gastric retention system comprising a plurality of elongate members attached to a central elastomer, each elongate member comprising at least two segments connected by a linker, the linker being configured to weaken or degrade to permit the gastric retention system to pass through the pylorus after a designated gastric retention period (e.g., the linker is configured to soften or degrade to permit the gastric retention system to pass through the pylorus after a designated gastric retention period). and the linker may become flexible or the linker may no longer connect at least two segments of each elongate member after the designated gastric retention period; and the segments of the elongate member comprise a carrier polymer and an adamantane-based drug or a pharma- ceutically acceptable salt thereof, or the segments of the elongate member comprise a) a carrier polymer, b) at least one excipient, and c) a drug or a pharma- ceutically acceptable salt thereof; and the gastric retention system is configured to release the drug or a pharma- ceutically acceptable salt thereof over the designated gastric retention period. At least one of the linkers may comprise an enteric polymer or may comprise a polymer that degrades in a time-dependent manner in an aqueous environment. The gastric retention period of the system may be about 4 days, at least about 4 days, about 7 days, or at least about 7 days. The gastric retention period of the system may be about 4 to about 10 days, about 4 to about 8 days, or about 7 to about 10 days.

[0009] In any of the embodiments described herein, the invention may provide a gastroretention system comprising a therapeutically effective amount of an adamantane-based drug or a pharma- ceutically acceptable salt thereof, the gastroretention system having a miniaturized configuration and a non-miniaturized configuration, the gastroretention system comprising a plurality of elongate members attached to a central elastomer by linkers, the linkers being configured to weaken or degrade to allow the gastroretention system to pass through the pylorus after a designated gastroretention period (e.g., the linkers may soften and become pliable, or the linkers may no longer connect the elongate members to the central elastomer after a designated gastroretention period). The elongate members comprise a carrier polymer and an adamantane-based drug or a pharma- ceutically acceptable salt thereof. In another embodiment, the elongate members further comprise at least one excipient. The gastroretention system is configured to release the adamantane-based drug or a pharma- ceutically acceptable salt thereof over a designated gastroretention period. The adamantane drug or a pharma- ceutically acceptable salt thereof can be memantine or a pharma- ceutically acceptable salt thereof. At least one of the linkers can include an enteric polymer or can include a polymer that degrades in a time-dependent manner in an aqueous environment. The gastric retention period of the system can be about 4 days, at least about 4 days, about 7 days, or at least about 7 days. The gastric retention period of the system can be about 4 to about 10 days, about 4 to about 8 days, or about 7 to about 10 days.

[0010] In any of the embodiments described herein, the invention may provide a gastroretention system comprising a therapeutically effective amount of risperidone or a pharma- ceutically acceptable salt thereof, the gastroretention system having a miniaturized configuration and a non-miniaturized configuration, the gastroretention system comprising a plurality of elongate members attached to a central elastomer by linkers, the linkers being configured to weaken or degrade to allow the gastroretention system to pass through the pylorus after a designated gastroretention period (e.g., the linkers may soften and become pliable, or the linkers may no longer connect the elongate members to the central elastomer after a designated gastroretention period). The elongate members comprise a carrier polymer and risperidone or a pharma- ceutically acceptable salt thereof. In another embodiment, the elongate members further comprise at least one excipient. The gastroretention system is configured to release risperidone or a pharma- ceutically acceptable salt thereof over a designated gastroretention period. At least one of the linkers may comprise an enteric polymer or may comprise a polymer that degrades in a time-dependent manner in an aqueous environment. The gastric retention period of the system may be about 4 days, at least about 4 days, about 7 days, or at least about 7 days. The gastric retention period of the system may be about 4 to about 10 days, about 4 to about 8 days, or about 7 to about 10 days.

[0011] In any of the embodiments described herein, the invention may provide a gastroretention system comprising a therapeutically effective amount of doxycycline or a pharma- ceutically acceptable salt thereof, the gastroretention system having a miniaturized configuration and a non-miniaturized configuration, the gastroretention system comprising a plurality of elongate members attached to a central elastomer by linkers, the linkers being configured to weaken or degrade to allow the gastroretention system to pass through the pylorus after a designated gastroretention period (e.g., the linkers may soften and become pliable or the linkers may no longer connect the elongate members to the central elastomer after a designated gastroretention period). The elongate members comprise a carrier polymer and doxycycline or a pharma- ceutically acceptable salt thereof. In another embodiment, the elongate members further comprise at least one excipient. The gastroretention system is configured to release doxycycline or a pharma- ceutically acceptable salt thereof over a designated gastroretention period. At least one of the linkers may comprise an enteric polymer or may comprise a polymer that degrades in a time-dependent manner in an aqueous environment. The gastric retention period of the system may be about 4 days, at least about 4 days, about 7 days, or at least about 7 days. The gastric retention period of the system may be about 4 to about 10 days, about 4 to about 8 days, or about 7 to about 10 days.

[0012] In any of the embodiments described herein, the invention may provide a gastroretention system comprising a therapeutically effective amount of donepezil or a pharma- ceutically acceptable salt thereof, the gastroretention system having a miniaturized configuration and a non-miniaturized configuration, the gastroretention system comprising a plurality of elongate members attached to a central elastomer by linkers, the linkers being configured to weaken or degrade to allow the gastroretention system to pass through the pylorus after a designated gastroretention period (e.g., the linkers may soften and become pliable, or the linkers may no longer connect the elongate members to the central elastomer after a designated gastroretention period). The elongate members comprise a carrier polymer and donepezil or a pharma- ceutically acceptable salt thereof. In another embodiment, the elongate members further comprise at least one excipient. The gastroretention system is configured to release donepezil or a pharma- ceutically acceptable salt thereof over a designated gastroretention period. At least one of the linkers may comprise an enteric polymer or may comprise a polymer that degrades in a time-dependent manner in an aqueous environment. The gastric retention period of the system may be about 4 days, at least about 4 days, about 7 days, or at least about 7 days. The gastric retention period of the system may be about 4 to about 10 days, about 4 to about 8 days, or about 7 to about 10 days.

[0013] In some embodiments, the present invention provides a gastric retention system comprising a drug or a pharma- ceutically acceptable salt thereof, the gastric retention system having a compacted configuration and a non-compacted configuration, the gastric retention system comprising a plurality of elongated members attached to a central elastomer by a linker, the linker configured to no longer connect the elongated members to the central elastomer after a designated gastric retention period. The elongated members comprise a carrier polymer and a drug or a pharma- ceutically acceptable salt thereof. In another embodiment, the elongated members further comprise at least one excipient. The gastric retention system is configured to release the drug or a pharma- ceutically acceptable salt thereof over a designated gastric retention period. At least one of the linkers may comprise an enteric polymer or may comprise a polymer that degrades in a time-dependent manner in an aqueous environment. The gastric retention period of the system may be about 4 days, at least about 4 days, about 7 days, or at least about 7 days. The gastric retention period of the system can be from about 4 to about 10 days, from about 4 to about 8 days, or from about 7 to about 10 days.

[0014] In any of the gastroretentive systems disclosed herein, the carrier polymer may be polycaprolactone. One or more additional excipients may be mixed with the carrier polymer. The one or more additional excipients may be selected from the group consisting of soluble excipients, insoluble wicking excipients, degradable excipients, insoluble swelling excipients, and surfactants. The one or more additional excipients may be P407, Eudragit E, PEG, polyvinylpyrrolidone (PVP), polyvinyl acetate (PVAc), polyvinyl alcohol (PVA), Eudragit RS, Eudragit RL, PLA, PLGA, PLA-PCL, polydioxanone, crospovidone, croscarmellose, HPMCAS, lecithin, taurocholate, SDS, Soluplus, fatty acids, Kolliphor RH40; and linear block copolymers of dioxanone and ethylene glycol; linear block copolymers of lactide and ethylene glycol; linear block copolymers of lactide, ethylene glycol, trimethyl carbonate, and caprolactone; linear block copolymers of lactide, glycolide, and ethylene glycol; linear block copolymers of glycolide, polyethylene glycol, and ethylene glycol; linear block copolymers of caprolactone and glycolide. polymers; polyaxial block copolymers of glycolide, caprolactone, and trimethylene carbonate; polyaxial block copolymers of glycolide, trimethylene carbonate, and lactide; polyaxial block copolymers of glycolide, trimethylene carbonate, and polypropylene succinate; polyaxial block copolymers of caprolactone, lactide, glycolide, and trimethylene carbonate; polyaxial block copolymers of glycolide, trimethylene carbonate, and caprolactone; and linear block copolymers of lactide, caprolactone, and trimethylene carbonate, such as a linear block copolymer of dioxanone (80%) and ethylene glycol (20%); a linear block copolymer of lactide (60%) and ethylene glycol (40%); a linear block copolymer of lactide (68%), ethylene glycol (20%), trimethyl carbonate (10%), and caprolactone (2%);Linear block copolymer of lactide (88%), glycolide (8%), and ethylene glycol (4%); linear block copolymer of glycolide (67%), polyethylene glycol (28%), and ethylene glycol (5%); linear copolymer of caprolactone (95%) and glycolide (5%); polyaxial block copolymer of glycolide (68%), caprolactone (29%), and trimethylene carbonate (3%); polyaxial block copolymer of glycolide (86%), trimethylene carbonate (9%), and lactide (5%); glycol polyaxial block copolymers of caprolactone (35%), lactide (34%), glycolide (17%), and trimethylene carbonate (14%); polyaxial block copolymers of glycolide (55%), trimethylene carbonate (25%), and caprolactone (20%); and linear block copolymers of lactide (39%), caprolactone (33%), and trimethylene carbonate (28%);

[0015] In any of the gastroretentive systems disclosed herein, when at least one of the linkers is an enteric polymer, the enteric polymer may be selected from the group consisting of poly(methacrylic acid-co-ethyl acrylate), cellulose acetate phthalate, cellulose acetate succinate, hydroxypropyl methylcellulose phthalate, methylcellulose phthalate, ethylhydroxycellulose phthalate, polyvinyl acetate phthalate, polyvinyl butyrate acetate, vinyl acetate-maleic anhydride copolymer, styrene-maleic acid monoester copolymer, methacrylate methyl methacrylate copolymer, methyl acrylate-methacrylic acid copolymer, methacrylate-methacrylic acid-octyl acrylate copolymer; and copolymers, mixtures, blends, and combinations thereof. Hydroxypropyl methylcellulose acetate succinate (HPMCAS) is a particularly useful enteric polymer, and may be used alone or in copolymers, mixtures, blends, or combinations with any one or more of the other above enteric polymers.

[0016] In any of the gastroretentive systems disclosed herein having a central elastomer, the central elastomer may comprise silicone rubber.

[0017] In any of the gastroretentive systems disclosed herein, the system may further comprise a dispersing agent selected from the group including silicon dioxide, hydrophilic fumed silicon dioxide, stearates, calcium stearate, magnesium stearate, microcrystalline cellulose, carboxymethylcellulose, hydrophobic colloidal silica, hypromellose, magnesium aluminum silicate, phospholipids, polyoxyethylene stearate, zinc acetate, alginic acid, lecithin, fatty acids, sodium lauryl sulfate, non-toxic metal oxides, aluminum oxide, porous inorganic materials, and polar inorganic materials.

[0018] In any of the gastroretentive systems disclosed herein, the drug or pharma- ceutically acceptable salt thereof may comprise particles of the drug or pharma- ceutically acceptable salt thereof in the form of particles disposed in a carrier polymer, at least about 80% of the mass of the particles having a size of about 1 to about 50 microns in diameter.

[0019] In any of the gastroretentive systems disclosed herein, the gastroretentive system may contain from about 10 to about 600 mg of a drug or a pharma- ceutically acceptable salt thereof.

[0020] In one embodiment, the present invention provides a formulation for sustained release of a drug or a pharma- ceutically acceptable salt thereof, comprising about 10 to about 30% of the drug or a pharma- ceutically acceptable salt thereof, about 0.1 to about 4% of silica, about 5 to about 30% of an acrylate polymer or copolymer, and about 0.2 to about 10% of a polyalkylene glycol, with the remainder of the composition comprising a polylactone. The formulation may further comprise about 0.1 to about 2% of an antioxidant. The antioxidant may include one or more compounds selected from the group consisting of vitamin E, tocopherol, vitamin E esters, tocopherol esters, ascorbic acid, or carotenes, such as alpha-tocopherol, vitamin E succinate, alpha-tocopherol succinate, vitamin E acetate, alpha-tocopherol acetate, vitamin E nicotinate, alpha-tocopherol nicotinate, vitamin E linoleate, or alpha-tocopherol linoleate. (Vitamin E can refer to alpha-tocopherol, beta-tocopherol, gamma-tocopherol, delta-tocopherol, alpha-tocotrienol, beta-tocotrienol, gamma-tocotrienol, or delta-tocotrienol, or any combination of any two or more of the above.) The silica may include hydrophilic fumed silica particles. The acrylate polymer or copolymer may include a copolymer of ethyl acrylate, methyl methacrylate, and trimethylammonioethyl methacrylate, for example, a copolymer including ethyl acrylate, methyl methacrylate, and trimethylammonioethyl methacrylate in a molar ratio of about 1:2:0.1. The polyalkylene glycol may be selected from the group consisting of polyethylene glycol (PEG), polypropylene glycol (PPG), and block copolymers of PEG and PPG. When the polyalkylene glycol includes a block copolymer of PEG and PPG, it may be represented by the formula H-(OCH2CH2) x -(O-CH(CH3)CH2) y -(OCH2CH2) z-OH, where x and z are about 101 and y is about 56. The polylactone may include polycaprolactone, for example, polycaprolactone having an average Mn of about 60,000 to about 100,000, an average Mn of about 75,000 to about 85,000, or an average Mn of about 80,000 (80k PCL).

[0021] In some embodiments, the present invention provides one or more elongate members formed from a material comprising a formulation for sustained release of a drug or a pharma- ceutically acceptable salt thereof as described herein.In some embodiments, the present invention provides a gastroretentive system comprising one or more elongate members formed from a material comprising a formulation for sustained release of a drug or a pharma- ceutically acceptable salt thereof as described herein.

[0022] In one embodiment, the present invention provides a method for manufacturing a gastroretention system, the method comprising: creating at least three elongate members formed from a material comprising any of the formulations for sustained release of a drug or a pharma- ceutically acceptable salt thereof as described herein; and attaching the elongate members to a central elastomer to form a gastroretention system having elongate members protruding radially from the central elastomer.

[0023] In any embodiment of the methods of treatment disclosed herein, the gastroretentive system may be administered to the patient approximately weekly for at least about 1 month, at least about 2 months, at least about 3 months, or indefinitely, or for a period of up to about 1 month, about 2 months, or about 3 months.

[0024] The present invention additionally provides gastric retention systems for administration of a drug or its salts, having segments or elongated members covered with a release rate modifying polymer film, elongated members of such gastric retention systems having segments covered with a release rate modifying polymer film, segments covered with a release rate modifying polymer film suitable for use in such gastric retention systems, and elongated members covered with a release rate modifying polymer film suitable for use in such gastric retention systems. Methods of making the segments, elongated members, and gastric retention systems containing the drug and its salts are also provided. Methods of using the gastric retention systems containing the drug and its salts are also provided.

[0025] In one embodiment, the invention provides a segment of a gastroretentive system, the segment comprising a carrier polymer; a drug or a salt thereof; and a release rate controlling polymer film configured to control the release rate of the drug, wherein over a 7 day incubation of the segment in simulated gastric fluid, the amount of the drug or a salt thereof released during the 5th day is at least about 40% of the amount of the drug or a salt thereof released during the 2nd day; and at least about 7% of the total amount of the drug in the segment is released on the 2nd day and at least about 7% of the total amount of the drug is released on the 5th day.

[0026] In one embodiment, the invention provides a segment of a gastroretentive system, the segment comprising a carrier polymer; a drug or salt thereof; and a release rate controlling polymer film configured to control the release rate of the drug, wherein over a 7 day incubation of the segment in simulated gastric fluid, the amount of drug or salt thereof released from the segment during the 7th day is at least about 20% of the amount of drug or salt thereof released during the 1st day; and at least about 4% of the total amount of drug in the segment is released on the 1st day and at least about 4% of the total amount of drug is released on the 7th day.

[0027] In one embodiment, the invention provides a segment of a gastroretentive system, the segment comprising a carrier polymer, a drug or a salt thereof; and a release rate controlling polymer film configured to control the release rate of the drug, wherein the release rate controlling polymer film is configured such that release of the drug from the segment in 40% ethanol / 60% simulated gastric fluid over 1 hour is not more than about 40% higher than release of the drug from a comparable segment in 100% simulated gastric fluid over 1 hour.

[0028] In one embodiment, the invention provides a segment of a gastroretentive system, the segment comprising a carrier polymer, a drug or a salt thereof; and a release rate controlling polymer film configured to control the release rate of the drug, wherein the release rate controlling polymer film is configured such that release of the drug from the segment in 40% ethanol / 60% simulated gastric fluid over 1 hour is at least about 40% lower than release of the drug from a second segment in 40% ethanol / 60% simulated gastric fluid over 1 hour, and the second segment comprises the same combination of carrier polymer and drug or a salt thereof but lacks the release rate controlling polymer film.

[0029] In one embodiment, the invention provides a segment of a gastroretentive system, the segment comprising a carrier polymer, a drug or a salt thereof; and a release rate controlling polymer film configured to control the release rate of the drug, wherein the release rate controlling polymer film is configured such that the release of the drug from the segment in simulated gastric fluid over an initial 6 hour period is at least about 40% lower than the release of the drug from a second segment in simulated gastric fluid over an initial 6 hour period, the second segment comprising the same combination of carrier polymer and drug or a salt thereof but lacking the release rate controlling polymer film; and the release of the drug from the segment in simulated gastric fluid over a 7 day period is at least about 60%, at least 70%, or at least 80% of the total amount of drug originally present in the segment.

[0030] In one embodiment, the present invention provides a segment of a gastroretentive system, the segment comprising a carrier polymer; a drug or a salt thereof; and a release rate controlling polymer film, wherein a best fit linear regression model of the release rate of the drug from the segment in simulated gastric fluid has a coefficient of determination R of at least about 0.8, at least 0.85, or at least 0.9 over an initial 7 day period. 2 the polymer film is configured to control the release rate of the drug so that the polymer film has a release rate of about 40 to about 60% of the drug or a salt thereof in about 40 to about 60% of the time over a 7-day period.

[0031] In one embodiment, the invention provides a segment of a gastroretentive system, the segment comprising: a carrier polymer; a drug or a salt thereof; and a release rate controlling polymer film, wherein the polymer film is configured to control the release rate of the drug from the segment over a 7 day period in simulated gastric fluid such that the release rate from the segment over any one day of the 7 days varies by no more than about 25% from the average total daily release from the segment over the 7 days.

[0032] In any of the embodiments of the invention described herein, the release rate modifying polymer film may comprise one or more polyester materials. 1 -OC(=O)-(where R 1 is C1~C 12The polyester may include polyesters having repeating units of the form selected from the group consisting of alkylene groups, ethers containing 2 to 12 carbon atoms, and polyethers containing 3 to 12 carbon atoms. The polymer film may comprise polycaprolactone or polydioxanone, for example, polycaprolactone of about 10,000 to about 150,000 Mn, polycaprolactone of about 50,000 to about 110,000 Mn, polycaprolactone of about 80,000 to about 110,000 Mn, polycaprolactone of about 60,000 to about 100,000 Mn, polycaprolactone of about 90,000 Mn, polycaprolactone of about 80,000 Mn, polycaprolactone of about 70,000 Mn, or polycaprolactone having an intrinsic viscosity of about 1.0 to about 2.5 dL / g, about 1.0 to about 2.1 dL / g, or about 1.5 to about 2.1 dL / g.

[0033] In any of the embodiments of the invention described herein, the release rate controlling polymer film may include one or more porogens. The porogens may include water soluble polymers, water soluble small molecules, inorganic salts, or organic salts. The porogens may comprise about 1 to about 40% of the weight of the film. The porogens may comprise about 1 to about 30% of the weight of the film. The porogens may comprise about 5 to about 40% of the weight of the film. The porogens may comprise about 5 to about 30% of the weight of the film. Porogens include alkali metal salts, sodium chloride, sodium bromide, potassium chloride, potassium sulfate, potassium phosphate, sodium benzoate, sodium acetate, sodium citrate, potassium nitrate, alkaline earth metal salts, calcium chloride, calcium nitrate, transition metal salts, ferric chloride, ferrous sulfate, zinc sulfate, cupric chloride, saccharides, sugars such as sucrose, glucose, fructose, mannose, galactose, aldohexose, altrose, talose, lactose, cellulose, monosaccharides, disaccharides, water-soluble polysaccharides, sorbitol, mannitol, organic fatty and aromatic oils, diols and polyols, polyhydric alcohols, poly(alkylene glycols), polyglycols, alkylene glycols, poly(a,m) alkylene diol esters, alkylene glycols, polyvinyl alcohols, polyvinylpyrrolidone. , water-soluble polymeric materials, poloxamers, hypromellose (HPMC), corifol RH40, polyvinyl caprolactam, polyvinyl acetate (PVAc), polyethylene glycol (PEG), Soluplus (copolymer of polyvinyl caprolactam, polyvinyl acetate, and polyethylene glycol), copovidone, Eudragit (E, RS, RL), poly(methyl vinyl ether-alt-maleic anhydride), polyoxyethylene alkyl ethers, polysorbates, polyoxyethylene stearates, polydextrose, polyacrylic acid, alginates, sodium starch glycolate, cross-linked polyacrylic acid (Carbopol), cross-linked PVP (crospovidone), cross-linked cellulose (croscarmellose), calcium silicate, xanthan gum, and gellan gum. The porogen may be selected from the group consisting of povidone, copovidone, and polyoxyl castor oil.

[0034] In one embodiment, the present invention provides a segment of a gastroretentive system, the segment comprising a carrier polymer; a drug or a salt thereof; and a release rate controlling polymer film, the polymer film comprising a material selected from the group consisting of polycaprolactone, cellulose acetate, and ethylcellulose.

[0035] In any of the embodiments disclosed herein, the release rate modifying polymer film may comprise about 0.1 to about 20% of the total weight of the segment. In any of the embodiments disclosed herein, the release rate modifying polymer film may comprise about 0.1 to about 15% of the total weight of the segment. In any of the embodiments disclosed herein, the release rate modifying polymer film may comprise about 0.1 to about 10% of the total weight of the segment, about 0.1 to about 5% of the total weight of the segment, about 0.5 to about 5% of the total weight of the segment, about 0.5 to about 2% of the total weight of the segment, or about 1 to about 2% of the total weight of the segment.

[0036] In any of the embodiments disclosed herein, the release rate modifying polymer film may comprise a thickness of from about 1 to about 20 microns, for example, from about 5 to about 15 microns.

[0037] In any of the embodiments disclosed herein, the release rate modifying polymer film may further comprise a plasticizer. The plasticizer may comprise about 1 to about 40% by weight of the film, for example, about 1 to about 30%, or about 1 to about 20%, or about 1 to about 15%, or about 5 to about 20%, or about 10 to about 20%. The plasticizer may be selected from the group consisting of phthalates, phosphates, citrates, tartrates, adipates, sebacates, sulfonamides, succinates, glycolates, glycerolates, benzoates, myristates, phenyl halides, triacetin, triethyl citrate, PEG, and poloxamers. The plasticizer may be selected from the group consisting of triethyl citrate and triacetin.

[0038] In any of the embodiments disclosed herein, the release rate controlling polymer film may further comprise a permeable component that is permeable to the drug or its salt and permeable to water. The permeable component may be a polymer or a swellable material. The permeable component may comprise about 1 to about 30% of the weight of the film. The permeable component may be selected from the group consisting of SSG, crospovidone, croscarmellose, and carbopol (PAA; polyacrylic acid). At least one of the water passage rate and the drug or its salt passage rate through the permeable component should be higher than the water passage rate or the drug passage rate through a release rate controlling polymer film lacking the permeable agent and lacking the pores generated by removal of the porogen. In various embodiments, the rate of water passage and the rate of passage of the drug or salt thereof through the permeable component is up to about 1.5 times, up to about 2 times, up to about 3 times, up to about 4 times, up to about 5 times, up to about 6 times, up to about 7 times, up to about 8 times, up to about 10 times, up to about 15 times, up to about 20 times, up to about 25 times, up to about 50 times, or up to about 100 times faster than the rate of water passage or the rate of passage of the drug through a release rate controlling polymer film lacking the permeation agent and lacking pores generated by removal of the porogen.

[0039] The present invention further provides a gastroretentive system for administration to a patient comprising at least one segment of any of the segment embodiments disclosed herein.

[0040] The present invention further provides a gastric retention system for administration to a patient, the gastric retention system comprising an elastomer component and at least three elongated members attached to the elastomer component, each elongated member comprising a proximal end, a distal end and an outer surface therebetween, the proximal end of each elongated member being attached to the elastomer component and projecting radially from the elastomer component, each elongated member having a distal end not attached to the elastomer component and located at a greater radial distance from the elastomer component than the proximal end; at least one elongated member comprises any of the segments of the embodiments of the segments disclosed herein, for example a segment coated with a release rate modifying polymer film, or at least one elongated member is coated with a release rate modifying polymer film. The central elastomer of the gastric retention system may be formed from liquid silicone rubber. The elongated members of the gastric retention system may be attached to the central elastomer via a degradable matrix, for example a degradable matrix comprising HPMC-AS and polycaprolactone.

[0041] The present invention further provides a method for producing a segment of a gastroretentive system, comprising: coating a segment comprising a carrier polymer and a drug or its salt with a solution of a polymeric film formulation to produce a film-coated segment; and drying the film-coated segment. The coating can be performed by dip coating, pan coating, spray coating, or fluidized bed coating. The solvent used in the solution of the polymeric film formulation can include an organic solvent, such as ethyl acetate, dichloromethane, acetone, isopropyl alcohol, or any combination thereof.

[0042] The present invention further provides a method for producing an elongate member of a gastroretentive system, comprising: coating an elongate member comprising a carrier polymer and a drug or a pharma- ceutically acceptable salt thereof with a solution of a polymeric film formulation to produce a film-coated elongate member; and drying the film-coated elongate member. Coating can be performed by dip coating, pan coating, spray coating, or fluidized bed coating. The solvent used in the solution of the polymeric film formulation can comprise an organic solvent, for example, ethyl acetate, dichloromethane, acetone, isopropyl alcohol, or any combination thereof. The present invention further provides a method for producing an elongate member of a gastroretentive system, comprising co-extruding a mixture of a polymeric film and a carrier polymer with a drug or a pharma- ceutically acceptable salt thereof.

[0043] The present invention further provides a method for producing a segment of a gastroretentive system, comprising co-extruding a polymer film and a mixture of a carrier polymer and a drug or a salt thereof.

[0044] The invention further includes a method of administering a gastroretention system to a patient, comprising administering to the patient a container containing the gastroretention system disclosed herein in a miniaturized state of any embodiment, wherein the container enters the patient's stomach and dissolves after entering the stomach to release the gastroretention system, which then assumes a non-miniaturized state. Preferably, the patient is a human. The container containing the gastroretention system may be administered by swallowing, a feeding tube, or a gastrostomy tube.

[0045] In any of the embodiments of the gastroretention system, the drug in the elongate member, segment, or the segment, system, member, or segment covered with the release rate modifying polymer film of the gastroretention system does not include an adamantane drug or a pharma- ceutically acceptable salt thereof. In any of the embodiments of the gastroretention system, the drug in the elongate member, segment, or the segment, system, member, or segment covered with the release rate modifying polymer film of the gastroretention system does not include memantine; amantadine; adapromine; nitromemantine; rimantadine; bromantan; tromantadine; neramexane; or a pharma- ceutically acceptable salt of memantine, amantadine, adapromine, nitromemantine, rimantadine, bromantan, tromantadine, or neramexane.

[0046] In any of the embodiments of the release rate controlling polymer film or any of the embodiments of the segment covered with the release rate controlling polymer film, the release rate controlling polymer film does not contain a drug; i.e., the film does not contain any substance intended for therapeutic, diagnostic, or nutritional use.

[0047] In any of the embodiments of the release rate controlling polymer film or any of the embodiments of the segment covered with a release rate controlling polymer film, the release rate controlling polymer film does not substantially add strength to the carrier polymer-drug segment that it covers.

[0048] It is contemplated that any feature from any embodiment disclosed herein may be combined, where possible, with any feature from any other embodiment disclosed herein, and in this manner, hybrid configurations of the disclosed features are within the scope of the invention.

[0049] In any of the embodiments disclosed herein, the term "about" used in connection with a numerical value can indicate the inclusion of both the stated value and a value reasonably close to the stated value. [Brief description of the drawings]

[0050] [Figure 1A] FIG. 1A shows the star-shaped design of the gastroretentive system in an unminiaturized state. [Figure 1B] FIG. 1B shows the star-shaped design of the gastroretentive system in a compacted or folded state. [Figure 1C] FIG. 1C shows the ring design of the gastroretentive system in an uncompacted state. [Figure 2A] FIG. 2A shows the tapered release profile for a representative formulation of memantine hydrochloride over time. [Figure 2B] FIG. 2B shows a linear relationship between the square of the cumulative release amount and time for a representative monolithic matrix-based formulation, which fits the Higuchi model for matrix-based drug release. [Figure 2C] FIG. 2C shows the linearity of release for approximately 50 formulations of memantine hydrochloride tested. [Figure 3A] FIG. 3A shows the composition of the coating solution used in the ethanol release test. [Figure 3B] FIG. 3B shows the drug release profile for coating C5 (1 g Eudragit RS in 3 mL dichloromethane) (FIG. 3B) for M18 release in FaSSGF for 7 days and in FaSSGF for a residual period of 7 days after 1 hour of 40% ethanol, 60% FaSSGF. [Figure 3C] FIG. 3C shows the drug release profile for coating C8 (1 g of 55K PCL in 6 mL of dichloromethane) (FIG. 3C) for M18 release in FaSSGF for 7 days and in FaSSGF for a residual period of 7 days after 1 hour of 40% ethanol, 60% FaSSGF. [Figure 3D]FIG. 3D shows the drug release profile for coating C25 (1 g ethylcellulose in 15 mL acetone) (FIG. 3D) for M18 release in FaSSGF for 7 days and in FaSSGF for a residual period of 7 days after 1 hour of 40% ethanol, 60% FaSSGF. [Figure 3E] FIG. 3E shows the drug release profile for coating C31 (1.5 g cellulose acetate in 15 mL acetone) (FIG. 3E) for M18 release in FaSSGF for 7 days and in FaSSGF for a residual period of 7 days after 1 hour of 40% ethanol, 60% FaSSGF. [Figure 4] Figure 4 shows the solvents used for dip coating of PCL films. Both dichloromethane and ethyl acetate were able to dissolve PCL at high concentrations and form uniform coatings with good performance. [Diagram 5] FIG. 5 shows the release rate profiles of non-M77 coated formulations and M77 formulations with coatings of PCL only and PCL with the porogens (water soluble polymers, WSPs) Kollidon VA64 and Corifol RH40. [Figure 6] FIG. 6 shows the batch-to-batch variability of the release rate profiles of M77 formulations with dip coating of PCL only and PCL with added porogens (Kollidon VA64 and Corifol RH40). [Figure 7] FIG. 7 shows the effect of tailoring the release rate profile for M77 formulations with dip coating of PCL with varying levels of porogen loading. [Figure 8] FIG. 8 shows the release rate profiles for formulations with different levels of PEG6000 in the PCL coating. [Figure 9A] FIG. 9A shows the release rate profiles for formulations with increasing levels of TEC in the PCL coating. [Figure 9B]FIG. 9B shows additional release rate profiles for formulations with increasing levels of TEC in the PCL coating. [Figure 10A] FIG. 10A shows the release rate profiles for formulations with various ratios of PCL:copovidone and 10% or 30% triethyl citrate in the coating. [Figure 10B] FIG. 10B shows additional release rate profiles for formulations with various ratios of PCL:copovidone and 10% or 30% triethyl citrate in the coating. [Figure 11] FIG. 11 shows the effect of low weight coating on drug release rate using various ratios of PCL:copovidone and 10% or 30% triethyl citrate in the coating. [Figure 12] FIG. 12 shows the effect of ethylcellulose coating on consistent drug serum levels of memantine HCl compared to uncoated dosage forms. [Figure 13] Figure 13 shows near constant plasma drug concentrations for the dosing formulation with a PCL coating. The dosage form consisted of a 90A durometer polyurethane elastomer heat welded to an M69 drug arm that was dip coated with a solution of 5% PCL (w / v) in ethyl acetate. [Figure 14] Figure 14 shows near constant plasma drug concentrations for the dosing formulation with a PCL coating. The dosage form consisted of a 50 / 50 PCL / HPMAS degradable matrix coated with a solution of 4.5% PCL / 0.5% Kollidon VA64 (w / v) in ethyl acetate and 60A durometer LSR elastomer IR welded to the M77 drug arm. [Figure 15] FIG. 15 shows a comparison of the linearity of release between coated and uncoated drug formulations. [Figure 16]FIG. 16 shows a comparison of pharmacokinetic parameters for a dosage form consisting of a 50 / 50 PCL / HPMAS degradable matrix coated with a solution of 4.5% PCL / 0.5% Kollidon VA64 (w / v) in ethyl acetate and a 60A durometer LSR elastomer IR welded to an M77 drug arm, against a single dose of Namenda XR, a commercially available sustained release formulation of memantine. The chart on the left shows the variability of a single dose of the Namenda XR reference product, with Cmax (ng / mL) on the left axis and left dots, and AUC (hr-ng / mL) on the right axis and right dots. The chart on the right shows the variability of the dosage form, with Cmax (ng / mL) on the left axis and left dots, and AUC (hr-ng / mL) on the right axis and right dots. Compared to the reference product, the dosage form achieves a lower Cmax and nearly 7-fold higher AUC with potentially lower intersubject variability. [Figure 17] FIG. 17 shows the assay of formulations M105 and M106. [Figure 18] FIG. 18 shows the dissolution of uncoated M103, M104, M105 and M106 formulations in fasted state simulated gastric fluid (FaSSGF). [Figure 19] FIG. 19 shows the dissolution of M103 formulations with various coatings (coated C1, C2 vs. uncoated). [Figure 20] FIG. 20 shows the dissolution of M104 formulations with various coatings (coated C1, C2 vs. uncoated). [Figure 21] FIG. 21 shows the dissolution of M105 formulations with various coatings (coatings C1, C2 vs. uncoated). [Figure 22] FIG. 22 shows the dissolution of M104 formulations with various coatings (coated C3, C4 vs. uncoated). [Diagram 23] FIG. 23 shows the dissolution of M104 formulations with various coatings (coated C5, C6, C7 vs. uncoated). [Figure 24]FIG. 24 shows the dissolution of M107 formulations with various coatings (coated C3, C4, C5 vs. uncoated). [Diagram 25] FIG. 25 shows the dissolution of M107 formulations with various coatings (coated C6, C7, C8 vs. uncoated). [Figure 26] FIG. 26 shows the percent release over time of donepezil from formulations with various coatings (2.5% w / w and 5% w / w) relative to the uncoated formulation. [Figure 27] FIG. 27 shows the percent release of doxycycline over time from formulations with various polycaprolactone-based coatings ("DX21-PCL" coatings) versus uncoated formulations. [Figure 28] FIG. 28 shows the percent release of doxycycline over time from formulations having various ethyl celluose-based coatings ("DX21-EC" coatings) versus uncoated formulations. [Figure 29] FIG. 29 shows the percent release of doxycycline over time from formulations with various polycaprolactone-based coatings ("DX23-PCL" coatings) versus uncoated formulations. [Diagram 30] FIG. 30 shows the percent release of doxycycline over time from formulations with various ethylcellulose-based coatings ("DX23-EC" coatings) versus uncoated formulations. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0051] definition A "carrier polymer" is a polymer suitable for blending with an agent, such as a drug, for use in the present invention.

[0052] A "pharmaceutical agent" is any substance intended for therapeutic, diagnostic, or nutritional use in a patient, individual, or subject. Pharmaceutical agents include, but are not limited to, drugs, nutrients, vitamins, and minerals.

[0053] A "dispersing agent" is defined as a substance that aids in minimizing drug particle size and dispersing the drug particles in the carrier polymer matrix. That is, the dispersing agent helps to minimize or prevent particle aggregation or flocculation during the manufacture of the system. Thus, dispersing agents have anti-agglomeration and anti-flocculant activity and help maintain a uniform distribution of the drug particles in the carrier polymer matrix.

[0054] An "excipient" is any substance added to a drug formulation that is not the drug itself. Excipients include, but are not limited to, binders, coating agents, diluents, disintegrants, emulsifiers, flavoring agents, glidants, lubricants, and preservatives. The specific category of dispersing agents falls within the more general category of excipients.

[0055] An "elastic polymer" or "elastomer" (also called a "tensile polymer") is a polymer that can be deformed from its original shape by an applied force for a period of time, and then substantially return to its original shape when the applied force is removed.

[0056] A "linking polymer" is a polymer suitable for linking together any other polymer, such as linking a first carrier polymer-drug moiety to a second carrier polymer-drug moiety. The linking polymer typically forms a linker region between the other moieties.

[0057] A "time-dependent polymer" or "time-dependent linking polymer" is a polymer that degrades in a time-dependent manner when the gastroretentive system is placed in the stomach. Time-dependent polymers are typically not affected by normal pH changes in the stomach.

[0058] "Approximately constant plasma level" refers to a plasma level that remains within a factor of 2 (i.e., 50-200% of the average plasma level) of the average plasma level measured over the period that the gastroretentive system is in the stomach.

[0059] "Substantially constant plasma level" refers to a plasma level that remains within plus or minus 25% of the average plasma level measured over the period that the gastroretentive system is in the stomach.

[0060] A "hydrophilic therapeutic agent," "hydrophilic drug," or "hydrophilic drug" is a drug that is readily soluble in water. A hydrophilic drug is defined as a drug that has a solubility of 1 mg / ml or greater in water. Alternatively, a hydrophilic drug has a log P of less than 0.5 in a 1-octanol / water system. oct (log partition coefficient P oct , where P oct Solubility or logP = (concentration in 1-octanol) / (concentration in HO). oct The pH at which is measured is 1.6, which approximates the gastric environment.

[0061] A "hydrophobic therapeutic agent," "hydrophobic drug," or "hydrophobic drug" is a drug that does not readily dissolve in water. A hydrophobic drug is defined as a drug that has a solubility in water of less than 1 mg / ml. Alternatively, a hydrophobic drug has a log P > 1 in a 1-octanol / water system. oct A hydrophobic therapeutic agent can be defined as an agent that has a log partition coefficient (log 1 / log 2 ). Alternatively, a hydrophobic therapeutic agent can be defined as an agent that has a higher solubility in ethanol than in water. Alternatively, a hydrophobic therapeutic agent can be defined as an agent that has a higher solubility in 40% ethanol / 60% simulated gastric fluid than in 100% simulated gastric fluid.

[0062] "Biocompatibility," when used to describe a material or system, indicates that the material or system does not induce any adverse reaction, or only minimal and tolerable adverse reactions, when in contact with an organism, such as a human. In the context of gastroretentive systems, biocompatibility is evaluated in the environment of the gastrointestinal tract.

[0063] A "patient," "individual," or "subject" refers to a mammal, preferably a human or a domestic animal, such as a dog or cat. In the most preferred embodiment, the patient, individual, or subject is a human.

[0064] As used herein, the "diameter" of a particle refers to the longest dimension of the particle.

[0065] "Treating" a disease or disorder using the systems and methods disclosed herein is defined as administering one or more of the systems disclosed herein, with or without additional agents, to a patient in need thereof to reduce or eliminate the disease or disorder or one or more symptoms of the disease or disorder, or to slow the progression of the disease or disorder or one or more symptoms of the disease or disorder, or to reduce the severity of the disease or disorder or one or more symptoms of the disease or disorder. "Suppressing" a disease or disorder using the systems and methods disclosed herein is defined as administering one or more of the systems disclosed herein, with or without additional agents, to a patient in need thereof to inhibit the clinical symptoms of the disease or disorder, or to inhibit the development of adverse symptoms of the disease or disorder. The distinction between treatment and suppression is that treatment occurs after adverse symptoms of the disease or disorder appear in a patient, while suppression occurs before adverse symptoms of the disease or disorder appear in a patient. Suppression can be partial, substantially total, or total. Because some diseases or disorders are hereditary, genetic screening can be used to identify patients at risk for the disease or disorder. The systems and methods of the present invention can then be used to treat asymptomatic patients at risk for developing clinical symptoms of the disease or disorder in order to prevent the appearance of any adverse symptoms.

[0066] The "therapeutic use" of the systems disclosed herein is defined as using one or more of the systems disclosed herein to treat a disease or disorder, as defined above. A "therapeutically effective amount" of a therapeutic agent, e.g., a drug, is an amount of the agent that, when administered to a patient, is sufficient to reduce or eliminate a disease or disorder or one or more symptoms of the disease or disorder, or to slow the progression of a disease or disorder or one or more symptoms of the disease or disorder, or to reduce the severity of a disease or disorder or one or more symptoms of the disease or disorder. A therapeutically effective amount can be administered to a patient as a single dose, or can be divided and administered as multiple doses.

[0067] "Prophylactic use" of the systems disclosed herein is defined as using one or more of the systems disclosed herein to inhibit a disease or disorder, as defined above. A "prophylactically effective amount" of an agent is an amount of agent that, when administered to a patient, is sufficient to inhibit the clinical symptoms of a disease or disorder, or inhibit the manifestation of adverse symptoms of a disease or disorder. A prophylactically effective amount can be administered to a patient as a single dose, or can be divided and administered as multiple doses.

[0068] As used herein, the singular forms "a," "an," and "the" include plural referents unless otherwise indicated or the context clearly dictates otherwise.

[0069] When a numerical value is expressed herein using the term "about" or "approximately", it is understood that both the specified value and values ​​reasonably close to the specified value are included. For example, a description of "about 50°C" or "approximately 50°C" includes a disclosure of both 50°C itself and values ​​close to 50°C. Thus, the phrase "about X" or "approximately X" includes a description of the value X itself. When a range such as "approximately 50-60°C" or "approximately 50-60°C" is indicated, it is understood that both values ​​specified by the endpoints are included, and values ​​close to each or both endpoints are included for each or both endpoints, i.e., "approximately 50-60°C" (or "approximately 50-60°C") is equivalent to referring to both "50-60°C" and "approximately 50-approximately 60°C" (or "approximately 50-60°C").

[0070] With respect to the numerical ranges disclosed herein, any disclosed upper limit for an ingredient may be combined with any disclosed lower limit for that ingredient to provide a range (provided that the upper limit is greater than the lower limit with which it is combined). Each of these combinations of the disclosed upper and lower limits is expressly contemplated herein. For example, if a range for the amount of a particular ingredient is given as 10-30%, 10-12%, and 15-20%, then the ranges of 10-20% and 15-30% are also contemplated, while the combination of a lower limit of 15% with an upper limit of 12% is not possible and therefore not contemplated.

[0071] Unless otherwise specified, the percentage of a component in a composition is expressed as weight percent or weight / weight percent. It is understood that a reference to a relative weight percentage in a composition is considered to be the total weight percentage of all components in the composition combined that totals up to 100. It is further understood that the relative weight percentage of one or more components can be adjusted upward or downward so that the weight percentages of the components in the composition together total 100, as long as the weight percentage of any particular component does not fall outside the limits of the range specified for that component.

[0072] The distribution behavior of the drug was measured between a polycaprolactone phase (PCL phase) and a simulated gastric fluid phase (SGF phase), and the partition coefficient P PCL-SGF LogP PCL-SGF can also be calculated. PCL-SGF A 5:1 mixture of polycaprolactone diol (MW 530):ethyl acetate can be used as the PCL phase, and fasted state simulated gastric fluid (FaSSGF) can be used as the SGF phase, such that: (concentration in polycaprolactone diol) / (concentration in FaSSGF)).

[0073] Some embodiments described herein are described as "comprising" or "comprises" with respect to their various elements. In alternative embodiments, the elements may be described with the transitional phrase "consisting essentially of" or "consists essentially of" applied to the elements. In further alternative embodiments, the elements may be described with the transitional phrase "consisting of" or "consists of" applied to the elements. Thus, for example, if a composition or method is disclosed herein as comprising A and B, alternative embodiments of that composition or method "consisting essentially of A and B" and alternative embodiments of that composition or method "consisting of A and B" are also considered to be disclosed herein. Similarly, embodiments described as "consisting essentially of" or "consisting of" with respect to their various elements may also be described as "comprising" applied to those elements. Finally, embodiments described as "consisting essentially of" with respect to their various elements may also be described as "consisting of" applied to those elements, and vice versa.

[0074] When a composition or system is described as "consisting essentially of" listed elements, the composition or system contains the elements explicitly listed and may contain other elements that do not substantially affect the condition being treated (in the case of a composition for treating a condition) or the properties of the described system (in the case of a composition that includes a system). However, the composition or system does not contain any other elements that substantially affect the condition being treated (in the case of a composition for treating a system) or does not contain any other elements that substantially affect the properties of the system (in the case of a composition that includes a system) other than the elements explicitly listed; or, if the composition or system contains additional elements other than the listed elements that may substantially affect the condition being treated or the properties of the system, the composition or system does not contain sufficient concentrations or amounts of those additional elements to substantially affect the condition being treated or the properties of the system. When a method is described as "consisting essentially of" listed steps, the method contains the listed steps and may contain other steps that do not substantially affect the condition being treated by the method or the properties of the system produced by the method, but the method does not contain any other steps other than those explicitly listed that substantially affect the condition being treated or the properties of the system produced.

[0075] The present disclosure provides a number of embodiments, and it is contemplated that any feature from any embodiment may be combined, where possible, with any feature from any other embodiment, and in this manner, hybrid configurations of the disclosed features are within the scope of the invention.

[0076] In addition to the embodiments and methods disclosed herein, additional embodiments of gastroretentive systems and methods of making and using such systems are disclosed in International Patent Applications Nos. WO2015 / 191920, WO2015 / 191925, WO2017 / 070612, WO2017 / 100367, and PCT / US2017 / 034856, which are incorporated by reference in their entireties.

[0077] Drug-Polymer Formulations and Excipients for Gastroretentive Systems The choice of carrier material for the drug or its pharma- ceutically acceptable salt in the gastroretentive system affects the release profile of the drug during gastric retention and is discussed in more detail below in the section "Carrier Polymers for Segments and Elongate Members (Carrier Polymer-Drug Component)". The release of the drug can be modulated by a variety of excipients included in the carrier polymer-drug component. Soluble excipients include P407, Eudragit E, PEG, polyvinylpyrrolidone (PVP), and polyvinyl alcohol (PVA). Insoluble wicking excipients include Eudragit RS and Eudragit RL. Degradable excipients include PLA, PLGA, PLA-PCL, polydioxanone, and linear copolymers of caprolactone and glycolide; polyaxial block copolymers of glycolide, caprolactone, and trimethylene carbonate; polyaxial block copolymers of glycolide, trimethylene carbonate, and lactide; polyaxial block copolymers of glycolide, trimethylene carbonate, and polypropylene succinate; polyaxial block copolymers of caprolactone, lactide, glycolide, and trimethylene carbonate; polyaxial block copolymers of glycolide, trimethylene carbonate, and caprolactone; and linear block copolymers of lactide, caprolactone, and trimethylene carbonate; e.g., a linear copolymer of caprolactone (95%) and glycolide (5%). polyaxial block copolymers of glycolide (68%), caprolactone (29%), and trimethylene carbonate (3%); polyaxial block copolymers of glycolide (86%), trimethylene carbonate (9%), and lactide (5%); polyaxial block copolymers of glycolide (70%), trimethylene carbonate (27%), and polypropylene succinate (2%); polyaxial block copolymers of caprolactone (35%), lactide (34%), glycolide (17%), and trimethylene carbonate (14%); polyaxial block copolymers of glycolide (55%), trimethylene carbonate (25%), and caprolactone (20%); and linear block copolymers of lactide (39%), caprolactone (33%), and trimethylene carbonate (28%).Insoluble swellable excipients include polyvinyl acetate (PVAc), crospovidone, croscarmellose, HPMCAS, and linear block copolymers of dioxanone and ethylene glycol; linear block copolymers of lactide and ethylene glycol; linear block copolymers of lactide, ethylene glycol, trimethyl carbonate, and caprolactone; linear block copolymers of lactide, glycolide, and ethylene glycol; linear block copolymers of glycolide, polyethylene glycol, and ethylene glycol; e.g., dioxanone, ethylene glycol, ethylene glycol, and ethylene glycol. Linear block copolymers of non (80%) and ethylene glycol (20%); linear block copolymers of lactide (60%) and ethylene glycol (40%); linear block copolymers of lactide (68%), ethylene glycol (20%), trimethyl carbonate (10%), and caprolactone (2%); linear block copolymers of lactide (88%), glycolide (8%), and ethylene glycol (4%); linear block copolymers of glycolide (67%), polyethylene glycol (28%), and ethylene glycol (5%). Surfactants include lecithin, taurocholate, SDS, Solplus, fatty acids, and Corifol RH40.

[0078] Release rate controlling polymer film The present invention provides, inter alia, gastroretention systems, elongated members of gastroretention systems, and segments for use in gastroretention systems and elongated members of gastroretention systems coated with a release rate controlling film. The use of a release rate controlling polymer film with a gastroretention system, such as on the carrier polymer-drug segment of a gastroretention system or on the elongated member of a gastroretention system, provides several distinct advantages over systems having a carrier polymer-drug segment lacking a release rate controlling film. The release rate controlling polymer film reduces the burst release of drug upon initial contact with gastric fluid. The linearity of drug release over the retention period is improved by using a release rate controlling polymer film. Both of these advantages provide better control of dosing from the gastroretention system. Some compositions of the release rate controlling polymer film can also significantly reduce the burst release upon exposure to alcohol compared to systems lacking such a film.

[0079] Release rate modifying polymer films are coatings that may coat all or part of the carrier polymer-drug segment. The films may be continuous, discontinuous, flat, or textured. They may be smooth coatings over the segment or may follow the contours of pores that may be present on the surface of the segment.

[0080] In a preferred embodiment, the release rate controlling film of any of the gastroretention systems disclosed herein does not cover the linking polymer, enteric polymer, enteric linker, time dependent linker, degradable polymer, degradable matrix, or other linker of the gastroretention system. When the release rate controlling polymer film is coated on the surface of an elongated member that includes one or more linkers, such as a linking polymer, enteric polymer, enteric linker, time dependent linker, degradable polymer, degradable matrix, or other linker, the film is discontinuous and does not cover or coat the linker. This is easily achieved by applying the release rate controlling film to the segments that will make up the elongated member, and then linking the coated segments together with a linker to form the elongated member; the segment that includes the carrier polymer-drug (or drug salt) is thus coated with the release rate controlling film, but the linker is not coated by the release rate controlling film.

[0081] The film is typically applied to the segments of the gastroretentive system. The film may also be applied to the multi-segment elongate member prior to its attachment to the central elastomer. The film may also be applied to the non-segmented elongate member (i.e., an elongate member that includes only one segment) prior to its attachment to the central elastomer. The non-segmented elongate member may be attached to the central elastomer directly or via a linker, such as a degradable matrix or a linking polymer. An example of a segment of a gastroretentive system is shown in FIG. 1A, in which segment 102 and segment 103 are linked by linker 104 and attached to central elastomer 106. Segments 102 and 104 include a carrier polymer and an agent (e.g., a drug). The use of a release rate controlling polymer film on the segments of the gastroretentive system provides the advantageous features described herein.

[0082] A number of parameters of the film can be tailored to produce the desired drug release profile, which are discussed below.

[0083] Chemical composition of the release rate controlling polymer film A variety of polymers can be used to form release rate controlling polymer films. Polyesters are a useful class of compounds for the preparation of release rate controlling polymer films. Polyesters that can be used in the present invention include polyesters with aliphatic groups as the main chain, such as polylactones, such as polycaprolactone (PCL); polyglycolic acid (PGA); polylactic acid (PLA); poly(lactic acid-co-glycolic acid) (PLGA); polyhydroxyalkanoates (PHAs), such as polyhydroxybutyrate (PHB), polyhydroxyvalerate (PHV), and poly(3-hydroxybutyrate-co-3-hydroxyvalerate) (PHBV); polyethylene adipate (PEA); polybutylene succinate (PBS), and polyesters with aromatic groups in the main chain, such as polyethylene terephthalate (PET), polybutylene terephthalate (PBT), polytrimethylene terephthalate (PTT), and polyethylene naphthalate (PEN). Heteropolymers such as block or random copolymers, for example block or random copolymers incorporating monomeric components of the above polyesters, can also be used, including copolymers of lactide and caprolactone (poly-lactide-co-caprolactone; PLC). Mixtures of two or more polyesters can also be used.

[0084] In addition to polyesters, cellulose acetate (CA), ethyl cellulose (EC), and copolymers of acrylates and methacrylic acid esters (eg, Eudragit RS) can also be used as release rate controlling polymer films.

[0085] A mixture of polymers from two or more different chemical classes of polymers can also be used to form the release rate controlling polymer film.

[0086] The release rate controlling polymer film is -R 1 -OC(=O)-(where R 1 is C1~C 12 The polyester may include polyesters having repeat units in the form of an alkylene group, for example a C1-C8 alkylene group or a C1-C4 alkylene group, an ether containing 2-12 carbon atoms, 2-8 carbon atoms or 2-4 carbon atoms, and a polyether containing 3-12 carbon atoms or 3-8 carbon atoms. The polyester may include, as appropriate, a hydroxy group, a hydrogen, a -C1-C12 alkyl group, a -C1-C8 alkyl group, or a -C1-C4 alkyl group, or a -C1-C 12 In some embodiments, R 1 The group may be the same throughout the polymer to form a homopolymer. 1 Groups may be selected from two or more different moieties to form a heteropolymer, which may be a random copolymer or a block copolymer.

[0087] The release rate controlling polymer film can include at least two different polyesters, each different polyester being -R n -OC(=O)- (wherein, when at least two or more of the different polyesters are homopolymers, R of any one of the homopolymers n The group R n groups; and when at least two or more of the different polyesters are heteropolymers, each heteropolymer is different from the R groups of any other heteropolymer. n The change pattern of the group is different from that of R n having a varying pattern of groups; and each Rn is C1~C 12 The polyesters are different polyesters having repeating units of the form: alkylene groups, ethers containing 2 to 12 carbon atoms, and polyethers containing 3 to 12 carbon atoms.

[0088] Preferred polyesters for use as the release rate controlling polymer film are polycaprolactones and polydioxanones, especially polycaprolactone (PCL). PCL having a number average molecular weight of about 1,000 Mn, about 80,000 Mn, about 90,000 Mn, about 100,000 Mn, about 10,000 to about 100,000 Mn, about 10,000 to about 80,000 Mn, about 40,000 to about 70,000 Mn, about 50,000 to about 60,000 Mn, or about 55,000 Mn can be used for the release rate controlling polymer film. PCL having a number average molecular weight of about 80,000 to about 110,000 Mn, such as about 85,000 to 95,000 Mn, or about 90,000 Mn, is preferred.

[0089] Polycaprolactone can also be characterized by its intrinsic viscosity. PCL of about 1.0 to about 2.5 dL / g or about 1.5 to about 2.1 dL / g can be used. Intrinsic viscosity can be measured in CHCl3 at 25°C.

[0090] Porogens, Plasticizers, and Other Additives to Release Rate Controlling Polymer Films To further tailor the release rate of the drug in the carrier polymer-drug segment, porogens, plasticizers, or both porogens and plasticizers can be added to the release rate controlling polymer film.

[0091] The porogen is a soluble additive that dissolves out of the release rate controlling polymer film and generates pores in the film. In some embodiments, the porogen dissolves out of the film when the gastroretention system is placed in the gastric environment. That is, after the segments are fabricated, the porogen remains in the segments that are assembled into the gastroretention system and in the gastroretention system that is administered to the patient; the porogen then dissolves out of the release rate controlling polymer film when the gastroretention system is administered to the patient and comes into contact with the gastric environment. In other embodiments, the porogen is removed from the film covered carrier polymer-drug segment before the segments are assembled into the gastroretention system, or the porogen is removed from the gastroretention system before the gastroretention system is placed in the gastric environment.

[0092] The porogen can be an organic or inorganic material. Examples of porogens include alkali metal salts such as sodium chloride, sodium bromide, potassium chloride, potassium sulfate, potassium phosphate, sodium benzoate, sodium acetate, sodium citrate, potassium nitrate, and the like; alkaline earth metal salts such as calcium chloride, calcium nitrate, and the like; and transition metal salts such as ferric chloride, ferrous sulfate, zinc sulfate, cupric chloride, and the like. Additional examples of porogens include saccharides and sugars such as sucrose, glucose, fructose, mannose, galactose, aldohexose, altrose, talose, lactose, cellulose, monosaccharides, disaccharides, and water-soluble polysaccharides. Additional examples of porogens include sorbitol, mannitol, organic fatty and aromatic oils including diols and polyols, such as polyhydric alcohols, poly(alkylene glycols), polyglycols, alkylene glycols, poly(a,m) alkylene diol esters or alkylene glycols, polyvinyl alcohol, polyvinylpyrrolidone, and water soluble polymeric materials. Further examples of porogens that can be used include poloxamer; hypromellose (HPMC); corifol RH40; polyvinylcaprolactam; polyvinyl acetate (PVAc); polyethylene glycol (PEG); Soluplus (available from BASF; copolymer of polyvinylcaprolactam, polyvinyl acetate, and polyethylene glycol); copovidone; Eudragit (E, RS, RL); poly(methyl vinyl ether-alt-maleic anhydride); polyoxyethylene alkyl ether; polysorbate; polyoxyethylene stearate; polydextrose; polyacrylic acid; alginate; sodium starch glycolate (SSG); cross-linked polyacrylic acid (Carbopol); cross-linked PVP (crospovidone); cross-linked cellulose (croscarmelose); calcium silicate; xanthan gum; and gellan gum. Some particularly useful porogens include povidone, copovidone, and polyoxyl castor oil.

[0093] The porogen can be added to constitute about 1 to about 30% of the weight of the release rate controlling polymer film. The porogen can be added to constitute about 1 to about 25%, about 1 to about 20%, about 1 to about 15%, about 1 to about 10%, about 1 to about 8%, about 1 to about 5%, about 1 to about 3%, about 5 to about 30%, about 10 to about 30%, about 15 to about 30%, about 20 to about 30%, or about 25 to about 30% of the weight of the release rate controlling polymer film. The preferred range of the porogen is about 5 to about 20%, more preferably about 10 to about 20%, of the weight of the release rate controlling polymer film.

[0094] Plasticizers can also be added to further adjust the properties of the release rate controlling polymer film.Plasticizers that can be used include phthalates, phosphates, citrates, tartrates, adipates, sebacates, sulfonamides, succinates, glycolates, glycerolates, benzoates, myristates, and phenyl halide classes.Specific plasticizers that can be used include triacetin, triethyl citrate, PEG, poloxamer, tributyl citrate, and dibutyl sebacate.Triacetin and triethyl citrate (TEC) are particularly useful.

[0095] A plasticizer may be added to constitute about 1 to about 35%, about 1 to about 30%, about 1 to about 25%, about 1 to about 20%, about 1 to about 15%, about 1 to about 10%, about 1 to about 8%, about 1 to about 5%, about 1 to about 3%, about 5 to about 40%, about 10 to about 40%, about 15 to about 40%, about 20 to about 40%, about 25 to about 40%, about 30 to about 40%, about 10 to about 30%, about 15 to about 30%, about 20 to about 30%, about 25 to about 30%, or about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, or about 40% of the weight of the release rate controlling polymer film. The preferred range of plasticizer is from about 5 to about 20%, more preferably from about 10 to about 20%, by weight of the release rate controlling polymer film.

[0096] Processing aids can also be added to the release rate modifying polymer film. Anti-adherents such as magnesium stearate, talc, or glycerol monostearate can be added to aid in processing of the film. Such anti-adherents can be added in amounts of about 0.5 to about 5%, about 1 to about 3%, or about 2%.

[0097] Permeable components in release rate controlling polymer films The release rate controlling polymer film may further comprise a permeable component that is permeable to the drug or its pharma- ceutically acceptable salt, permeable to water, or permeable to both the drug or its salt and water. The permeable component may thus function to increase the rate of water inflow into the carrier polymer of the gastroretentive system and increase the release rate of the drug or its salt from the gastroretentive system. The permeable component may be a polymer or a swellable material. The permeable component may comprise about 1 to about 30% of the weight of the film. The permeable component may be selected from the group consisting of SSG (sodium starch glycolate), crospovidone, croscarmellose, and carbopol (PAA; cross-linked polyacrylic acid). At least one of the water passage rate and the drug or its salt passage rate through the permeable component should be higher than the water passage rate or the drug passage rate through a release rate controlling polymer film lacking the permeable agent and lacking the pores generated by removal of the porogen. In various embodiments, the rate of passage of water, the rate of passage of the drug or its salt, or both the rates of passage of water and the drug or its salt through the permeable component is up to about 1.5 times, up to about 2 times, up to about 3 times, up to about 4 times, up to about 5 times, up to about 6 times, up to about 7 times, up to about 8 times, up to about 10 times, up to about 15 times, up to about 20 times, up to about 25 times, up to about 50 times, or up to about 100 times faster than the rate of passage of water, or both the rates of passage of the drug or its salt through a release rate controlling polymer film lacking the permeable agent and lacking pores generated by removal of the porogen.

[0098] Film Combination The various options that can be used for the release rate controlling polymer films for the segments and elongate members are as follows (percentages are percentages by weight):

[0099] Polymers used in the film, from about 40 to about 80%; porogens, from about 3 to about 20%; plasticizers, from about 3 to about 20%; antiblocking agents, from about 0.5 to about 5%;

[0100] a polymer used in the film, from about 50 to about 72%; a porogen, from about 5 to about 20%; a plasticizer, from about 5 to about 20%; an antiblocking agent, from about 0.5 to about 5%; or

[0101] Polymer used in the film: about 53 to about 65%; porogen, about 10 to about 20%; plasticizer, about 10 to about 20%; antiblocking agent, about 1 to about 3%.

[0102] Examples of polymers that can be used in either of these options are polycaprolactone and polydioxanone; preferably, polycaprolactone is used as the polymer.

[0103] Examples of porogens that can be used in any of these options are povidone, copovidone, and polyoxyl castor oil.

[0104] Examples of plasticizers that can be used in any of these options include triethyl citrate, triacetin, PEG, poloxamer, tributyl citrate, and dibutyl sebacate.

[0105] Examples of anti-adherents that can be used in any of these options include magnesium stearate, talc, and glycerol monostearate.

[0106] A preferred combination for the release rate controlling polymer film is polycaprolactone, copovidone, triethyl citrate, and magnesium stearate.

[0107] Specific polymer-porogen-plasticizer-antiblocking agent combinations that may be used include: polycaprolactone-povidone-triethyl citrate-magnesium stearate; polycaprolactone-copovidone-triethyl citrate-magnesium stearate; polycaprolactone-polyoxyl castor oil-triethyl citrate-magnesium stearate; polycaprolactone-povidone-triacetin-magnesium stearate; polycaprolactone-copovidone-triacetin-magnesium stearate; polycaprolactone-polyoxyl castor oil-triacetin-magnesium stearate. ;Polycaprolactone-povidone-PEG-magnesium stearate;Polycaprolactone-copovidone-PEG-magnesium stearate;Polycaprolactone-polyoxyl castor oil-PEG-magnesium stearate;Polycaprolactone-povidone-poloxamer-magnesium stearate;Polycaprolactone-copovidone-poloxamer-magnesium stearate;Polycaprolactone-polyoxyl castor oil-poloxamer-magnesium stearate;Polycaprolactone-povidone-tributyl citrate-magnesium stearate;Polycaprolactone-copovidone-tributyl citrate Polycaprolactone-Polyoxyl castor oil-Tributyl citrate-Magnesium stearate;Polycaprolactone-Povidone-Dibutyl sebacate-Magnesium stearate;Polycaprolactone-Copovidone-Dibutyl sebacate-Magnesium stearate;Polycaprolactone-Polyoxyl castor oil-Dibutyl sebacate-Magnesium stearate;Polycaprolactone-Polyoxyl castor oil-Triethyl citrate-Talc;Polycaprolactone-Copovidone-Triethyl citrate-Talc;Polycaprolactone-Polyoxyl castor oil-Triethyl citrate- Talc;Polycaprolactone-povidone-triacetin-talc;Polycaprolactone-copovidone-triacetin-talc;Polycaprolactone-polyoxyl castor oil-triacetin-talc;Polycaprolactone-povidone-PEG-talc;Polycaprolactone-copovidone-PEG-talc;Polycaprolactone-polyoxyl castor oil-PEG-talc;Polycaprolactone-povidone-poloxamer-talc;Polycaprolactone-copovidone-poloxamer-talc;Polycaprolactone-polyoxyl castor oil-poloxamer-talc;Polycaprolactone-povidone-tributyl citrate-talc;Polycaprolactone-copovidone-tributyl citrate-talc;Polycaprolactone-polyoxyl castor oil-tributyl citrate-talc;Polycaprolactone-povidone-dibutyl sebacate-talc;Polycaprolactone-copovidone-dibutyl sebacate-talc;Polycaprolactone-polyoxyl castor oil-dibutyl sebacate-talc;Polycaprolactone-povidone-triethyl citrate-glycerol monostearate;Poly Caprolactone-copovidone-triethyl citrate-glycerol monostearate;Polycaprolactone-polyoxyl castor oil-triethyl citrate-glycerol monostearate;Polycaprolactone-povidone-triacetin-glycerol monostearate;Polycaprolactone-copovidone-triacetin-glycerol monostearate;Polycaprolactone-polyoxyl castor oil-triacetin-glycerol monostearate;Polycaprolactone-povidone-PEG-glycerol monostearate Glycerol;Polycaprolactone-copovidone-PEG-glycerol monostearate;Polycaprolactone-polyoxyl castor oil-PEG-glycerol monostearate;Polycaprolactone-povidone-poloxamer-glycerol monostearate;Polycaprolactone-copovidone-poloxamer-glycerol monostearate;Polycaprolactone-polyoxyl castor oil-poloxamer-glycerol monostearate;Polycaprolactone-povidone-tributyl citrate-monostearate Polycaprolactone-copovidone-tributyl citrate-glycerol monostearate; polycaprolactone-polyoxyl castor oil-tributyl citrate-glycerol monostearate; polycaprolactone-povidone-dibutyl sebacate-glycerol monostearate; polycaprolactone-copovidone-dibutyl sebacate-glycerol monostearate; and polycaprolactone-polyoxyl castor oil-dibutyl sebacate-glycerol monostearate.

[0108] In addition to the coatings listed above, any of the coatings from Tables COAT-1 and COAT-2 can be used as a release rate modifying polymer film, for example, in amounts of 1%, 1.5%, 2%, 2.5%, 3%, 3.5%, 4%, 4.5%, or 5% of the weight of the elongate member or segment to which they are applied. The coatings can be used in any amount disclosed herein for release rate polymer films, such as from about 1 to about 20%. Each row in the table below represents a coating formulation.

[0109] [Table 1]

[0110] Table COAT-2 lists the specific amounts of ingredients that can be used in the film formulation. The amounts listed in Table COAT-2 can vary by plus or minus 20% of each ingredient (e.g., a composition containing 10% P407 can vary from 8% P407 to 12% P407). Coatings can be used in any amount disclosed herein for release rate polymeric films, such as from about 1 to about 20%. Each row in the table below represents a coating formulation.

[0111] [Table 2-1] [Table 2-2]

[0112] Film Thickness The release rate modifying polymer films should be very thin compared to the carrier polymer-drug segments of the gastroretentive systems they cover, allowing diffusion of water into the carrier polymer-drug segments and diffusion of drug out of the segments.

[0113] The thickness of the release rate modifying polymer film can be about 1 to about 40 micrometers, about 1 to about 30 micrometers, or about 1 to about 25 micrometers. The film is typically about 1 to about 20 micrometers, e.g., about 1 to about 20 micrometers, about 1 to about 15 micrometers, about 1 to about 10 micrometers, about 1 to about 5 micrometers, about 1 to about 4 micrometers, about 1 to about 3 micrometers, about 1 to about 2 micrometers, about 2 to about 10 micrometers, about 5 to about 20 micrometers, about 5 to about 10 micrometers, about 10 to about 15 micrometers, or about 15 to about 20 micrometers.

[0114] In further embodiments, the release rate controlling polymer film does not add substantially any strength to the carrier polymer-drug segment it covers. In further embodiments, the release rate controlling polymer film adds less than about 20%, less than about 10%, less than about 5%, or less than about 1% to the strength of the segment. The strength of the segment can be measured by the four-point bending deflection test (ASTM D790) described in Example 18 of International Patent Application No. WO2017 / 070612 and Example 13 of International Patent Application No. WO2017 / 100367.

[0115] Film Weight The release rate modifying polymer film may comprise about 0.1-20% by weight of the carrier polymer-drug segment covered by the film of the gastroretentive system. The release rate modifying polymer film may comprise about 0.1-15% by weight of the carrier polymer-drug segment covered by the film of the gastroretentive system. The release rate modifying polymer film may comprise about 0.1-10% by weight of the carrier polymer-drug segment covered by the film of the gastroretentive system. The weight of the film can comprise about 0.1 to about 8%, about 0.1 to about 5%, about 0.1 to about 4%, about 0.1 to about 3%, about 0.1 to about 2%, about 0.1 to about 1%, about 0.5 to about 10%, about 0.5 to about 8%, about 0.5 to about 5%, about 0.5 to about 4%, about 0.5 to about 3%, about 0.5 to about 2%, about 0.5 to about 1%, about 1 to about 10%, about 1 to about 8%, about 1 to about 5%, about 1 to about 4%, about 1 to about 3%, or about 1 to about 2% of the carrier polymer-drug segment covered by the film of the gastroretentive system.

[0116] Application of release rate controlling polymeric films to segments for use in gastroretentive systems - Patent Application 20070236333 The release rate modifying polymer film can be applied to the segment for use in the gastroretentive system using a variety of techniques. Some of the techniques involve coating a segment containing a carrier polymer and drug with a solution of the release rate modifying polymer film formulation to produce a film-coated segment. The film-coated segment is then dried.

[0117] Various methods of coating a film on an object are known in the art, including dip coating, pan coating, spray coating, and fluidized bed coating. Fluidized bed coating is also known as Wurster coating or air suspension coating. For these coating methods, the release rate controlling polymer film formulation, including the polymer and any porogens and plasticizers, if present, is prepared as a solution. The solvent used for the polymer film formulation solution is typically an organic solvent, such as ethyl acetate, dichloromethane, acetone, methanol, ethanol, isopropanol, or any combination thereof. Preferably, Class 3 solvents (including ethanol, acetone, and ethyl acetate) as listed in the U.S. Food and Drug Administration guidelines at URL www.fda.gov / downloads / drugs / guidances / ucm073395.pdf are used, but Class 2 solvents (including dichloromethane and methanol) can be used if necessary for formulation. Class 1 and Class 4 solvents should only be used if the formulation cannot be prepared using a suitable Class 3 or Class 2 solvent.

[0118] The release rate controlling polymer film can also be integrated into the segment by coextrusion, where the segment blend is coextruded with a thin layer of the surrounding release rate controlling polymer film.

[0119] The following examples illustrate the use of some of these coating techniques for the preparation of segments with release rate controlling polymer films.

[0120] Overall system configuration The present invention provides, inter alia, gastroretentive systems, elongate members of gastroretentive systems, and segments for use in gastroretentive systems and elongate members of gastroretentive systems that are coated with a release rate controlling film. As will be discussed, the release rate controlling film provides a number of advantages.

[0121] Gastroretention systems can be made in different configurations. The "stellate" configuration of a gastroretention system is also known as the "star" (or "asterisk") configuration. An example of a star system 100 is shown diagrammatically in FIG. 1A. A number of elongated members, or "arms" (only one such arm 108 is labeled for clarity) are attached to a disk-shaped central elastomer 106. The elongated members or arms shown in FIG. 1A include segments 102 and 103, which are connected by a linking polymer or linker region 104 that acts as a linker region (again, for clarity, the components are labeled in only one arm). This configuration allows the system to be folded or compacted in the central elastomer. FIG. 1B shows a folded configuration 190 of the gastroretention system of FIG. 1A (only two arms are labeled in FIG. 1B for clarity). Segments 192 and 193, linker region 194, elastomer 196, and arms 198 of FIG. 1B correspond to segments 102 and 103, linker region 104, elastomer 106, and arms 108 of FIG. 1A, respectively. When folded, the overall length of the system is reduced by approximately half, and the system can be conveniently placed into a container, such as a capsule or other container suitable for oral administration. When the capsule reaches the stomach, it dissolves, releasing the gastroretentive system. The gastroretentive system then unfolds to an uncompacted state, which is retained in the stomach for the desired retention period.

[0122] Although linker regions 104 are shown in FIG. 1A as being slightly larger in diameter than segments 102 and 103, they may have the same diameter as the segments, with the entire elongate members 102-104-103 having a smooth outer surface.

[0123] In some embodiments, a star system may have an elongate member or arm made up of only one segment attached to a central elastomer by a linker region. This corresponds to the omission of segment 103 in Figure 1A. The single segment elongate member, including segment 102, is then attached directly to the central elastomer 106 via linker 104. The linker may comprise a connecting polymer or a degradable matrix.

[0124] A star system can be described as a gastroretentive system for administration to a patient's stomach, comprising an elastomeric component and a plurality of at least three carrier polymer-drug components attached to the elastomeric component, the plurality comprising a carrier polymer and a drug or a salt thereof, each of the plurality of carrier polymer-drug components being an elongate member comprising a proximal end, a distal end, and an exterior surface therebetween; the proximal end of each elongate member is attached to the elastomeric component and projects radially from the elastomeric component, each elongate member having a distal end not attached to the elastomeric component and located a greater radial distance from the elastomeric component than the proximal end; each elongate member independently comprises one or more segments, each segment comprising a proximal end, a distal end, and an exterior surface therebetween; and when two or more segments are present in the elongate member, each segment is attached to an adjacent segment via a linker region. The linker region can be a linking polymer or a degradable matrix. The elongate members may be attached to the central elastomer via a linking polymer or degradable matrix and may have intervening portions of connecting polymer. For a plurality of at least three elongate members, or a plurality of elongate members, the preferred number of elongate members is six, although 3, 4, 5, 7, 8, 9, or 10 elongate members may be used. The elongate members should be equally spaced about the central elastomer, and if there are N elongate members, the angle between adjacent elongate members will be approximately 360 / N degrees.

[0125] 1C shows another possible overall configuration 120 for the gastroretentive system, a ring configuration. Segments 122 are linked by a linking polymer or linker region 124 (for clarity, only one segment and one coupling link is labeled). The linking polymer / linker region in this design must also act as an elastomer, allowing the ring to be twisted into a compacted state for placement in a container such as a capsule.

[0126] In one embodiment of the star configuration, segments 102 and 103 include a carrier polymer blended with a drug or agent. In one embodiment of the ring configuration, segment 122 includes a carrier polymer blended with a drug or agent.

[0127] The linking polymer of the gastroretentive system, which acts as a linker region, is designed to degrade gradually in a controlled manner during the system's residence time in the stomach. If the gastroretentive system passes too quickly in its intact form into the small intestine, the system is designed to degrade more quickly to avoid ileus. This is easily achieved by using an enteric polymer as the linking polymer. The enteric polymer is relatively resistant to the acidic pH levels encountered in the stomach, but dissolves quickly at the higher pH levels found in the duodenum. The use of an enteric linking polymer as a safety element protects against the undesired passage of the gastroretentive system intact into the small intestine. The use of an enteric linking polymer also provides a way to remove the gastroretentive system before its designed residence time; if the system needs to be removed, the patient can drink a mild alkaline solution such as sodium bicarbonate solution or ingest an antacid preparation such as hydrated magnesium hydroxide (milk of magnesia) or calcium carbonate, which raises the pH level in the stomach and causes rapid degradation of the enteric linking polymer. The gastroretentive system then breaks apart and is removed from the patient.In the system shown in Figure 1A, at least the linking polymer 104 used for linking is made from such an enteric polymer.

[0128] In additional embodiments, a time-dependent linking polymer or linker can be used. Such a time-dependent linking polymer or linker degrades in a predictable, time-dependent manner. In some embodiments, the degradation of the time-dependent linking polymer or linker can be unaffected by fluctuations in pH in the gastrointestinal system.

[0129] In additional embodiments, different types of linkers can be used in the gastroretentive system, i.e., both enteric linkers (or enteric linking polymers) and time-dependent linkers (or time-dependent linking polymers) can be used. In some embodiments, a single multi-segment elongate member (arm) of a star system can use both enteric linkers in some linker regions between segments, and time-dependent linkers in other linker regions between segments.

[0130] The linker region is typically about 100 to about 1 millimeter wide, for example, about 200 to about 1000 um, about 300 to about 1000 um, about 400 to about 1000 um, about 500 to about 1000 um, about 600 to about 1000 um, about 700 to about 1000 um, about 800 to about 1000 um, or about 900 to about 1000 um; or about 100 to about 900 um about 100 to about 800 um, about 100 to about 700 um, about 100 to about 600 um, about 100 to about 500 um, about 100 to about 400 um, about 100 to about 300 um, or about 100 to about 200 um. The linker region may be about 100 um, about 200 um, about 300 um, about 400 um, about 500 um, about 600 um, about 700 um, about 800 um, about 900 um, or about 1000 um in width, each value being plus or minus 50 um (±50 um).

[0131] The central elastomeric polymer of a star system is typically not an enteric polymer, although the central elastomeric polymer may also be made from such an enteric polymer if this is desirable and practical.

[0132] The central elastomer should have a particular durometer and compression set. Durometer is important as it determines the folding force of the dosage form and whether it will remain in the stomach, with a preferred range of about 60 to about 90A. Compression set should be as low as possible to avoid permanently deforming the gastroretentive system when stored as a capsule in a compacted configuration. A preferred range is about 10 to about 20%. A material that meets these requirements is Dow Corning's QP1 range of liquid silicone rubber. In any embodiment that uses a central elastomer, QP1-270 (70A durometer) liquid silicone rubber can be used.

[0133] The segments and elongate members of the gastric retention system may have a circular (in which case the segment is cylindrical), polygonal (e.g., a segment having a triangular, rectangular, or square cross-section), or pie-shaped (in which case the segment is a cylindrical section) cross-section. Segments with polygonal or pie-shaped cross-sections, and ends of cylindrical sections that will come into contact with gastric tissue, may have their sharp ends rounded to provide rounded corners and ends to promote safety in vivo. That is, instead of making abrupt transitions between intersecting ends or planes, an arc is used to transition from one end or plane to another. Thus, a "triangular cross-section" includes a cross-section that has an approximate triangular shape, such as a triangle with rounded corners. An arm with a triangular cross-section includes an arm with rounded ends and rounded corners at the ends of the arm. Rounded corners and edges are also referred to as fillet corners, filleted corners, fillet ends, or filleted ends.

[0134] As discussed herein, the segment of the gastroretentive system comprising the carrier polymer and the drug can be covered with a release rate controlling polymer film. In some embodiments, any linking polymer, degradable matrix, or one or more of the connecting polymers attached to the segment are also covered with a release rate controlling polymer film. In some embodiments, any linking polymer, degradable matrix, or one or more of the connecting polymers attached to the segment are not covered with a release rate controlling polymer film. When the linking polymer (which may be an enteric polymer) or the degradable matrix is ​​covered with a release rate controlling polymer film, the delinking or degradation kinetics should be determined for the film-covered linking polymer or the film-covered degradable matrix.

[0135] Emission characteristics evaluation The release characteristics of the drug from the segments, elongated members, and gastroretention systems can be evaluated by various assays. Drug release assays are described in detail in the Examples. In vitro drug release from the segments, elongated members, and gastroretention systems can be measured by immersing the segments, elongated members, or gastroretention systems in liquids such as water, 0.1N HCl, fasted-state simulated gastric fluid (FaSSGF), or fed-state simulated gastric fluid (FeSSGF). Fasted-state simulated gastric fluid (FaSSGF) is preferred for release assays. Simulated gastric fluid refers to either fasted-state simulated gastric fluid (FaSSGF) or fed-state simulated gastric fluid (FeSSGF), and when a limit is specified as being measured in simulated gastric fluid (SGF), the limit is met if the limit is met in either fasted-state simulated gastric fluid (FaSSGF) or fed-state simulated gastric fluid (FeSSGF). For example, if a segment is designated as releasing at least 10% of the drug over the first 24 hours in simulated gastric fluid, the limitation is met if the segment releases at least 10% of the drug over the first 24 hours in fasted state simulated gastric fluid or if the segment releases at least 10% of the drug over the first 24 hours in fed state simulated gastric fluid.

[0136] Ethanol burst release is typically measured by immersing a segment, elongate member, or gastroretention system in a solution of 40% ethanol and 60% fasted-state simulated gastric fluid for one hour, and then immersing the same segment, elongate member, or gastroretention system in 100% fasted-state simulated gastric fluid for the remainder of the test period and measuring drug release at the appropriate time points. This test is designed to simulate the effect of consumption of an alcoholic beverage by a patient with the gastroretention system of the present invention placed in the patient's stomach.

[0137] In vitro testing can be performed using segments, elongated members, or gastroretention systems, but using segments for in vitro testing is most convenient for rapid evaluation of release characteristics. When in vitro testing is performed to compare release rates under different conditions (e.g., release in 100% FaSSGF vs. release in 40% ethanol / 60% FaSSGF), the solutions being compared are kept at the same temperature, such as room temperature, 25° C., or 37° C. Room temperature (ambient temperature) is the preferred temperature for comparison, and in one embodiment, ambient temperature is not below 20° C. or above 25° C. (but can vary from 20° C. to 25° C.).

[0138] In vivo testing can be performed in animals such as dogs (e.g., beagles or hounds) and pigs. A gastric retention system is used for in vivo testing since the individual segments or elongated members are not retained in the animal's stomach. Blood samples can be obtained at appropriate time points and, if desired, stomach contents can be sampled by cannula or other techniques.

[0139] Clinical trials in humans, conducted in accordance with appropriate legal, regulatory, and institutional guidelines, also provide in vivo data.

[0140] Release Profile The increased linearity profile of the segment having the release rate modifying polymer film provides advantageous release characteristics relative to a segment having the same carrier polymer-drug composition but lacking the release rate modifying polymer film. For example, a segment of a gastroretentive system comprising a carrier polymer, a drug or salt thereof, and a release rate modifying polymer film configured to control the release rate of the drug may have a release profile in which the release rate modifying polymer film is configured such that over a 7-day incubation in simulated gastric fluid, the amount of drug or salt thereof released during the 5th day is at least about 40% of the amount of drug or salt thereof released during the 2nd day. That is, over a 7-day incubation period, the amount of drug or salt thereof released between 96 and 120 hours (day 5) is at least about 40% of the amount of drug or salt released between 24 and 48 hours (day 2) of incubation. In some embodiments, the release over the 5th day is at least about 50%, at least about 60%, at least about 70%, at least about 80%, or at least about 90% of the amount of drug or salt released over the 2nd day. In some embodiments, the release over the 5th day is at least about 40 to about 90%, at least about 50 to about 90%, at least about 60 to about 90%, at least about 70 to about 90%, at least about 80 to about 90%, or at least about 40 to about 100% of the amount of drug or salt released over the 2nd day. In any of these embodiments, at least about 5% of the total amount of drug is released on the 2nd day and at least about 5% of the total amount of drug is released on the 5th day, at least about 5% of the total amount of drug is released on the 2nd day and at least about 7% of the total amount of drug is released on the 5th day, or at least about 7% of the total amount of drug is released on the 2nd day and at least about 7% of the total amount of drug is released on the 5th day. "Total amount of drug" refers to the amount of drug originally present in the segment.

[0141] In another embodiment, a segment of a gastroretentive system comprising a carrier polymer, a drug or salt thereof, and a release rate controlling polymer film configured to control the release rate of the drug may have a release profile where the release rate controlling polymer film is configured such that over a 7 day incubation in simulated gastric fluid, the amount of drug or salt thereof released during day 7 is at least about 20% of the amount of drug or salt thereof released during day 1. That is, over a 7 day incubation period, the amount of drug or salt thereof released between 144 and 168 hours (day 7) is at least about 20% of the amount of drug or salt released between 0 and 24 hours (day 1) of incubation. In some embodiments, the release over the 7 day period is at least about 30%, at least about 40%, at least about 50%, at least about 60%, or at least about 70% of the amount of drug or salt released over day 1. In some embodiments, the release over 7 days is at least about 20 to about 70%, at least about 30 to about 70%, at least about 40 to about 70%, at least about 50 to about 70%, at least about 60 to about 70%, or at least about 20 to about 100% of the amount of drug or salt released over day 1. In any of these embodiments, at least about 7% of the total amount of drug is released on day 1 and at least about 4% of the total amount of drug is released on day 7, at least about 4% of the total amount of drug is released on day 1 and at least about 4% of the total amount of drug is released on day 7, or at least about 7% of the total amount of drug is released on day 1 and at least about 7% of the total amount of drug is released on day 7. "Total amount of drug" refers to the amount of drug originally present in the segment.

[0142] The segment with the release rate modifying polymer film of the present invention also has a lower burst release when first immersed in simulated gastric fluid.In one embodiment, a segment of a gastroretentive system comprising a carrier polymer and a drug or its salt, the segment with the release rate modifying polymer film configured to control the release rate of the drug, the release of the drug from the segment in simulated gastric fluid over the first 24 hours is at least about 40% lower than the release of the drug from a second segment in simulated gastric fluid over the first 6 hours, the second segment comprising the same combination of carrier polymer and drug or its salt but lacking the release rate modifying polymer film; and the release of the drug from the segment with the polymer film in simulated gastric fluid over a 7 day period is i) at least about 60% of the release of the drug from the second segment lacking the polymer film over a 7 day period, or ii) at least 60% of the total amount of drug originally present in the segment, the release rate modifying polymer film is configured to have a release profile. In further embodiments, the release of drug from the segment having the film over an initial 24 hour period is at least about 40% lower, about 40% to about 50% lower, about 40% to about 60% lower, or about 40% to about 70% lower than the release of drug from the second segment having no film over an initial 6 hour period, and the release of drug from the segment having the film over a 7 day period is i) at least about 60%, at least about 70%, at least about 80%, or about 60% to about 80% of the release of drug from the second segment lacking the polymeric film over a 7 day period, or ii) at least about 60%, at least about 70%, at least about 80%, or about 60% to about 80% of the total amount of drug originally present in the segment.In further embodiments, the release of drug from the segment having the film over a 7 day period in simulated gastric fluid is i) at least about 60%, at least about 70%, at least about 75%, or at least about 80% (e.g., about 60% to about 70%, about 60% to about 80%, about 60% to about 90%, or about 60% to about 99%) of the release of drug from a second segment not having a film over a 7 day period in simulated gastric fluid; or ii) at least about 60%, at least about 70%, at least about 75%, or at least about 80% (e.g., about 60% to about 70%, about 60% to about 80%, about 60% to about 90%, or about 60% to about 99%) of the total amount of drug originally present in the segment.

[0143] The segment having the release rate controlling polymer film of the present invention also has a lower burst release upon ethanol challenge compared to the segment lacking the film. In one embodiment, a segment of a gastroretentive system comprising a carrier polymer and a drug or its salt, the segment having a release rate controlling polymer film configured to control the release rate of the drug, may have a release profile in which the release rate controlling polymer film is configured such that the release of the drug from the segment in 40% ethanol / 60% simulated gastric fluid over 1 hour is at least about 40% lower than the release of the drug from a second segment in 40% ethanol / 60% simulated gastric fluid over 1 hour, the second segment comprising the same combination of carrier polymer and drug or its salt but lacking the release rate controlling polymer film. In further embodiments, the release of drug from the segment having the film over a 7 day period in simulated gastric fluid is i) at least about 60%, at least about 70%, at least about 75%, or at least about 80% (e.g., about 60% to about 70%, about 60% to about 80%, about 60% to about 90%, or about 60% to about 99%) of the release of drug from a second segment not having a film over a 7 day period in simulated gastric fluid; or ii) at least about 60%, at least about 70%, at least about 75%, or at least about 80% (e.g., about 60% to about 70%, about 60% to about 80%, about 60% to about 90%, or about 60% to about 99%) of the total amount of drug originally present in the segment. In one embodiment, a segment of a gastroretentive system comprising a carrier polymer and a drug or a salt thereof, the segment having a release rate controlling polymer film configured to control the release rate of the drug, may have a release profile in which the release rate controlling polymer film is configured such that the release of the drug from the segment in 40% ethanol / 60% simulated gastric fluid over 1 hour is not more than about 40% higher than the release of the drug from a comparable segment in 100% simulated gastric fluid over 1 hour.In further embodiments, the release of drug from the segment having the film over a 7 day period in simulated gastric fluid is i) at least about 60%, at least about 70%, at least about 75%, or at least about 80% (e.g., about 60% to about 70%, about 60% to about 80%, about 60% to about 90%, or about 60% to about 99%) of the release of drug from a second segment not having a film over a 7 day period in simulated gastric fluid; or ii) at least about 60%, at least about 70%, at least about 75%, or at least about 80% (e.g., about 60% to about 70%, about 60% to about 80%, about 60% to about 90%, or about 60% to about 99%) of the total amount of drug originally present in the segment.

[0144] The linearity of drug release from the segment having a release rate modifying polymer film coating is also improved. In one embodiment, a segment of a gastroretentive system comprising a carrier polymer and a drug or a salt thereof, the segment having a release rate modifying polymer film configured to control the release rate of the drug, is characterized in that a best fit linear regression model of the release rate of the drug has a coefficient of determination R of at least about 0.8, at least about 0.85, or at least about 0.9 over an initial 7 day period in simulated gastric fluid. 2 (wherein the initial 7-day period is measured from the start time the segment is first immersed in the simulated gastric fluid; i.e., the 7-day period includes t=0 or the origin of the release profile); and the release rate controlling polymer film may have a release profile configured such that the segment releases about 30 to about 70% of the drug or salt thereof within about 40 to about 60% of the time of the 7-day period.

[0145] In one embodiment, a segment of a gastroretentive system comprising a carrier polymer and a drug or a salt thereof, the segment having a release rate controlling polymer film configured to control the release rate of the drug, may have a release profile in which the release rate controlling polymer film is configured such that the release rate over any one day of seven days varies by no more than about 50%, no more than about 40%, no more than about 30%, no more than about 25%, no more than about 20%, or no more than about 10% from the average total daily release over the seven day period.

[0146] Carrier Polymer for Segments and Elongate Members (Carrier Polymer-Drug Component) The segments and elongate members of the gastroretentive system comprise a carrier polymer-drug component that contains a drug (or a pharma- ceutically acceptable salt of the drug) that is eluted from the gastroretentive system in the gastric environment. The drug is blended into the carrier polymer to form a carrier polymer-drug mixture. This mixture can be formed into a desired shape for use as the carrier polymer-drug component in the system. After the drug or drug salt is blended into the carrier polymer to form the carrier polymer-drug mixture, the drug or drug salt is distributed or dispersed throughout the blended mixture. If excipients, antioxidants, or other ingredients are included in the carrier polymer-drug blend, they are also distributed or dispersed throughout the blended mixture.

[0147] Preferably, the carrier polymer has the following characteristics: The carrier polymer should be thermoplastic to allow extrusion using hot melt extrusion or 3D printing technology. The carrier polymer should also have sufficiently high melt strength and viscosity to allow extrusion into the required geometric shape. The carrier polymer should have a low melt temperature (e.g., less than about 120°C) to avoid exposing the agent or drug to high temperatures during manufacturing. The carrier polymer should have sufficient mechanical strength (Young's modulus, compressive strength, tensile strength) to avoid destruction in the stomach during the desired residence period. The carrier polymer should be able to form a stable blend with the agent, therapeutic agent, drug, excipient, dispersant, and other additives.

[0148] Exemplary carrier polymers suitable for use in the present invention include hydrophilic cellulose derivatives (e.g., hydroxypropyl methylcellulose, hydroxypropyl cellulose, hydroxymethyl cellulose, hydroxyethyl cellulose, carboxymethyl cellulose, sodium carboxymethyl cellulose), cellulose acetate phthalate, poly(vinylpyrrolidone), ethylene / vinyl alcohol copolymer, poly(vinyl alcohol), carboxyvinyl polymers (carbomer), Carbopol® acidic carboxy polymers, polycarbophil, poly(ethylene oxide) (Polyox WSR), polysaccharides and their derivatives, polyalkylene oxides, polyethylene glycols, chitosan, alginates, pectins, acacia, tragacanth, guar gum, locust bean gum, vinylpyrrolidone vinyl acetate copolymers, dextran, natural gums, agar, agarose, sodium alginate, carrageenan, fucoidan, furcellaran, laminaran, hypnea, eucheuma, gum arabic, ghatti gum, karaya gum, arabinogalactan, amylopectin, gelatin, gellan, hyaluronic acid, pullulan, scleroglucan, xanthan, xyloglucan, maleic anhydride copolymers, ethylene maleic anhydride copolymers, poly(hydroxyethyl methacrylate), ammonio methacrylate tocopolymers (e.g., Eudragit RL or Eudragit RS), poly(ethyl acrylate-methyl methacrylate) (Eudragit NE), Eudragit E (cationic copolymer based on dimethylaminoethyl methyl acrylate and neutral methyl acrylic acid ester), poly(acrylic acid), polymethacrylates / polyethacrylates such as poly(methacrylic acid), methyl methacrylate, and ethyl acrylate, polylactones such as poly(caprolactone), polyanhydrides such as poly[bis-(p-carboxyphenoxy)-propane anhydride], poly(terephthalic anhydride), polypeptides such as polylysine, polyglutamic acid, poly(orthoesters) such as copolymers of DETOSU with diols (e.g., hexanediol, decanediol),The carrier polymers include, but are not limited to, cyclohexanedimethanol, ethylene glycol, polyethylene glycol, and poly(ortho)esters, starch, especially pregelatinized starch, and starch-based polymers, carbomer, maltodextrin, amylomaltodextrin, dextran, poly(2-ethyl-2-oxazoline), poly(ethyleneimine), polyurethane, poly(lactic acid), poly(glycolic acid), poly(lactic-co-glycolic acid) (PLGA), polyhydroxyalkanoates, polyhydroxybutyrates, and copolymers, mixtures, blends, and combinations thereof, as described and disclosed in U.S. Pat. No. 4,304,767 and incorporated herein by reference.Polycaprolactone (PCL) is a preferred carrier polymer.In another embodiment, polydioxanone is used as the carrier polymer. In any of the embodiments of the gastroretentive system, the carrier polymer used in the gastroretentive system can include polycaprolactone, for example, a linear polycaprolactone having a number average molecular weight (Mn) range of about 60 kilodaltons (kDa) to about 100 kDa; 75 to 85 kDa; or about 80 kDa; or about 45 to about 55 kDa; or about 50 to about 110,000 kDa, or about 80 to about 110,000 kDa.

[0149] Other excipients can be added to the carrier polymer to modulate the release of the drug. Such excipients can be added in an amount of about 1-15%, preferably about 5-10%, more preferably about 5% or about 10%. Examples of such excipients include Poloxamer 407 (Coriphor P407, available as Sigma product number 62035), poly(ethylene glycol)-block-poly(propylene glycol)-block-poly(ethylene glycol), CAS number 9003-11-6; H-(OCH2CH2)x-(O-CH(CH3)CH2)y-(OCH2CH2)z-OH (wherein x and z are about 101 and y is about 56); Pluronic P407; Eudragit E, Eudragit EPO. (available from Evonik); hypromellose (available from Sigma, product number H3785), Corifol RH40 (available from Sigma, product number 07076), polyvinylcaprolactam, polyvinylacetate (PVAc), polyvinylpyrrolidone (PVP), polyvinylalcohol (PVA), polyethylene glycol (PEG), and Soluplus (available from BASF; copolymer of polyvinylcaprolactam, polyvinylacetate, and polyethylene glycol). Preferred soluble excipients include Eudragit E, polyethylene glycol (PEG), polyvinylpyrrolidone (PVP), polyvinylacetate (PVAc), and polyvinylalcohol (PVA). Preferred insoluble excipients include Eudragit RS and Eudragit RL. Preferred insoluble swellable excipients include crospovidone, croscarmellose, hypromellose acetate succinate (HPMCAS), and carbopol.Eudragit RS and Eudragit RL are registered trademarks of Evonik (Darmstadt, Germany) for copolymers of ethyl acrylate, methyl methacrylate and methacrylic acid esters with quaternary ammonium groups (trimethylammonioethyl methacrylate chloride), with a molar ratio of ethyl acrylate, methyl methacrylate and trimethylammonioethyl methacrylate of about 1:2:0.2 in Eudragit® RL and about 1:2:0.1 in Eudragit® RS. Preferred insoluble swellable excipients include crospovidone, croscarmellose, hypromellose acetate succinate (HPMCAS), carbopol, and linear block copolymers of dioxanone and ethylene glycol; linear block copolymers of lactide and ethylene glycol; linear block copolymers of lactide, ethylene glycol, trimethyl carbonate, and caprolactone; linear block copolymers of lactide, glycolide, and ethylene glycol; linear block copolymers of glycolide, polyethylene glycol, and ethylene glycol; e.g. For example, linear block copolymers of dioxanone (80%) and ethylene glycol (20%); linear block copolymers of lactide (60%) and ethylene glycol (40%); linear block copolymers of lactide (68%), ethylene glycol (20%), trimethyl carbonate (10%), and caprolactone (2%); linear block copolymers of lactide (88%), glycolide (8%), and ethylene glycol (4%); linear block copolymers of glycolide (67%), polyethylene glycol (28%), and ethylene glycol (5%).

[0150] Further examples of excipients that can be used in the segments of the gastroretentive system are listed in the excipient table below.

[0151] [Table 3]

[0152] Drugs for use in gastroretentive systems Any drug that can be administered to or through the gastrointestinal tract can be used in the gastroretentive system of the present invention. The drug is blended with the carrier polymer and any other excipients or other additives to the carrier polymer and formed into a segment for use in the gastroretentive system. Drugs include, but are not limited to, drugs, prodrugs, biologics, and any other substance that can be administered to produce a beneficial effect against a disease or injury. Drugs that can be used in the gastroretentive system of the present invention include statins, such as rosuvastatin; nonsteroidal anti-inflammatory drugs (NSAIDs), such as meloxicam; selective serotonin reuptake inhibitors (SSRIs), such as escitalopram and citalopram; blood thinners, such as clopidogrel; steroids, such as prednisone; antipsychotics, such as aripiprazole and risperidone; analgesics, such as buprenorphine; opioid antagonists, such as naloxone; antiasthmatics, such as montelukast; antidementia drugs, such as memantine; cardiac glycosides, such as digoxin; alpha blockers, such as tamsulosin; cholesterol blockers, such as cholestrol, and the like. Examples of suitable therapeutic agents include acetylcholine, ...Exemplary classes of drugs include analgesics; anti-analgesics; anti-inflammatory drugs; antipyretics; antidepressants; anti-epileptics; anti-psychotics; neuroprotective agents; anti-proliferative agents, e.g., anti-cancer agents; antihistamines; anti-migraine drugs; hormones; prostaglandins; antimicrobial agents, e.g., antibiotics, anti-fungals, anti-virals, and anti-parasitics; anti-muscarinics; anxiolytics; bacteriostatics; immunosuppressants; sedatives; hypnotics; anti-psychotics; bronchodilators; anti-asthmatics; cardiovascular drugs; anesthetics; anticoagulants; enzyme inhibitors; steroids; steroidal or non-steroidal anti-inflammatory agents; corticosteroids; dopaminergic agents; electrolytes; gastrointestinal agents; muscle relaxants; nutritional Agents include, but are not limited to, quinine, lumefantrine, chloroquine, amodiaquine, pyrimethamine, proguanil, chlorproguanil-dapsone, sulfonamides (e.g., sulfadoxine and sulfamethoxypyridazine), mefloquine, atovaquone, primaquine, halofantrine, doxycycline, clindamycin, artemisinin, and artemisinin derivatives (e.g., artemether, dihydroartemisinin, arteether, and artesunate). The term "drug" includes salts, solvates, polymorphs, and cocrystals of the above-mentioned substances. In certain embodiments, the drug is selected from the group consisting of cetirizine, rosuvastatin, escitalopram, citalopram, risperidone, olanzapine, donepezil, and ivermectin. In another embodiment, the drug is a drug used to treat a neuropsychiatric disorder, such as an antipsychotic or antidementia drug, for example memantine.

[0153] In some embodiments of the invention disclosed herein, the drug may exclude adamantane drugs. In some embodiments of the invention disclosed herein, the drug may exclude any one or more of memantine; amantadine; adapromine; nitromemantine; rimantadine; bromantan; neramexane; or tromantadine; or a pharmaceutically acceptable salt of memantine, amantadine, adapromine, nitromemantine, rimantadine, bromantan, or tromantadine. In some embodiments of the invention disclosed herein, the drug may exclude memantine. In some embodiments of the invention disclosed herein, the drug may exclude a salt of memantine or a pharmaceutically acceptable salt of memantine.

[0154] Crystalline and amorphous forms of the drug The drug may be used in the gastroretentive system of the present invention in any suitable crystalline form, or in an amorphous form, or in both one or more crystalline and amorphous forms, i.e., the drug or drug particles contained in the gastroretentive system may be used in a crystalline form, an amorphous form, or a mixture of crystalline forms (either a single crystalline form or multiple crystalline forms) and amorphous forms to provide a desired release rate or desired physical or chemical properties.

[0155] Drug class of interest The gastroretentive system is well suited for use in the treatment of diseases and disorders that present difficulties in patient compliance, and thus in some embodiments, the gastroretentive system is used to treat diseases or disorders that present problems in patient compliance with pharmaceutical regimens. Such diseases and disorders include neuropsychiatric diseases and disorders, dementia and other diseases and disorders that affect memory, Alzheimer's disease, psychosis, schizophrenia, and paranoia. Thus, the drugs that can be used in the gastroretentive system include, but are not limited to, anti-dementia drugs, anti-Alzheimer's drugs, and anti-psychotic drugs.

[0156] Hydrophilic Drugs Exemplary hydrophilic drugs that can be used in the system include risperidone, cetirizine, memantine, and olanzapine.

[0157] Hydrophobic Drugs Exemplary hydrophobic drugs that can be used in the system include aripiprazole, ivermectin, rosuvastatin, citalopram, and escitalopram.

[0158] Drug loading of elongated members and segments The elongate member, or a segment contained therein, comprises a drug or a pharma- ceutically acceptable salt thereof. In some embodiments, the drug or a salt thereof (e.g., a drug) constitutes about 10 to about 40% of the weight of the elongate member or segment, and thus the carrier polymer and any other components of the elongate member or segment that are blended into the carrier polymer together constitute the remainder of the weight of the elongate member or segment. In some embodiments, the drug or a salt thereof constitutes about 10 to about 35%, about 10 to about 30%, about 10 to about 25%, about 10 to about 20%, about 10 to about 15%, about 15 to about 40%, about 20 to about 40%, about 25 to about 40%, about 30 to about 40%, about 35 to about 40%, about 15 to about 35%, about 20 to about 35%, or about 25 to about 40% of the weight of the elongate member or segment.

[0159] Further embodiments of elongate strips or segments in which the drug or salt thereof constitutes greater than about 40% of the weight of the elongate strip or segment are described below under "High Drug Loading of Elongate Strips and Segments."

[0160] High drug loading of elongated members and segments In some embodiments of the present invention, the elongate member or the segment in which it is included may have a high loading of drug or its pharma- ceutically acceptable salt. "High loading" generally refers to an elongate member or segment in which the drug or its salt (e.g., drug) constitutes more than about 40% of the weight of the elongate member or segment, and thus the carrier polymer and any other components of the elongate member or segment blended with the carrier polymer together constitute less than about 60% of the weight of the elongate member or segment. Any components of the elongate member or segment that are not blended with the carrier polymer are not included in the weight percentage calculation, for example, if the elongate member has one or more degradable matrices inserted between the segments of the elongate member, the weight of such matrices is not included as part of the weight of the elongate member in the calculation of the weight percentage of drug in the elongate member. As the loading of drug increases to about 60%, it becomes increasingly difficult to properly blend the drug with the carrier polymer, and phase separation of the drug and the polymer tends to occur. Thus, the drug loading in the elongate member or segment should not exceed about 60% of the total weight of the elongate member.

[0161] Thus, in some embodiments, the amount of drug by weight in the elongate member, or in a segment contained within the elongate member, may comprise at least about 40%, at least about 45%, at least about 50%, at least about 55%, or about 60%. In some embodiments, the amount of drug by weight in the elongate member, or in a segment contained within the elongate member, may comprise about 40 to about 60%, about 45 to about 60%, about 50 to about 60%, about 55 to about 60%, about 40 to about 55%, about 40 to about 50%, or about 40 to about 45%. In some embodiments, the amount of drug by weight in the elongate member, or in a segment contained within the elongate member, may comprise about 25 to about 60%, about 30 to about 60%, or about 35 to about 60%. In some embodiments, the amount of drug by weight in the elongate member, or in the segment comprising the elongate member, may comprise about 51 to about 60%, about 52 to about 60%, about 53 to about 60%, about 54 to about 60%, about 55 to about 60%, about 56 to about 60%, or about 57 to about 60%. In some embodiments, the drug or a pharma- ceutically acceptable salt thereof is present in an amount by weight of about 67 to about 150% of the weight of the carrier polymer.

[0162] The combination of high drug or drug salt loading with a release rate controlling polymer film provides a gastroretentive system with an increased amount of drug or drug salt while maintaining good release kinetics over the residence period of the system.

[0163] The release rate modifying polymer films can also be used with loadings lower than the high loading values ​​listed above, such as about 20 to about 35% of the elongate member, or the amount of drug by weight in the segment that the elongate member is in. Loading ranges covering both high loadings and loadings lower than high loadings can be used, such as, for example, about 20 to about 60%, about 25 to about 60%, about 30 to about 60%, about 35 to about 60%, about 20 to about 50%, about 20 to about 40%, or about 25 to about 50%.

[0164] Dispersing Agents for Modulation of Drug Release and Stability in Polymer Blends - Patent application The use of a dispersant in the carrier polymer-drug component provides many advantages. The dissolution rate of a drug from a carrier polymer-drug component is influenced by many factors, including the composition and properties of the carrier polymer (which itself may contain multiple polymeric and non-polymeric components); the physical and chemical properties of the drug; and the gastric environment, as previously described. Avoiding burst release of a drug, especially a hydrophilic drug, and maintaining sustained release of the drug over an effective release or residence period is an important feature of the system. The use of a dispersant according to the present invention allows for better control of the release rate and suppression of burst release. The burst release and release rate can be adjusted by using different concentrations of dispersants. For example, different concentrations of different dispersants and different excipients can adjust the burst release of cetirizine in simulated gastric fluid.

[0165] Dispersants that can be used in the present invention include silicon dioxide (silica, SiO2) (hydrophilic fumed); stearates, such as calcium stearate and magnesium stearate; microcrystalline cellulose; carboxymethylcellulose; hydrophobic colloidal silica; hypromellose; magnesium aluminum silicate; phospholipids; polyoxyethylene stearate; zinc acetate; alginic acid; lecithin; fatty acids; sodium lauryl sulfate; and non-toxic metal oxides, such as aluminum oxide. Porous inorganic materials and polar inorganic materials can be used. Hydrophilic fumed silicon dioxide is a preferred dispersant. One particularly useful silicon dioxide is sold by Cabot Corporation (Boston, Massachusetts, USA) under the registered trademark CAB-O-SIL® M-5P (CAS#112945-52-5), which is a hydrophilic fumed silicon dioxide with a BET surface area of ​​about 200 m2 / g±15 m2 / g. The mesh retainage of this product on a 45 micron sieve is less than about 0.02%.Typical primary agglomerate sizes are from about 150 to about 300 nm, with individual particle sizes ranging from about 5 to about 50 nm.

[0166] In addition to anti-agglomeration / anti-flocculation activity, dispersants can help prevent phase separation during manufacture and / or storage of the system, which is particularly useful for manufacture of systems by hot melt extrusion.

[0167] The weight / weight ratio of dispersant to drug substance can be about 0.1 to about 5%, about 0.1 to about 4%, about 0.1 to about 3%, about 0.1 to about 2%, about 0.1 to about 1%, about 1 to about 5%, about 1 to about 4%, about 1 to about 3%, about 1 to about 2%, about 2 to about 4%, about 2 to about 3%, about 3 to about 4%, about 4 to about 5%, or about 0.1%, about 0.5%, about 1%, about 2%, about 3%, about 4% or about 5%.

[0168] The dispersing agent may constitute from about 0.1 to about 4% of the carrier polymer-drug component, e.g., from about 0.1 to about 3.5%, from about 0.1 to about 3%, from about 0.1 to about 2.5%, from about 0.1 to about 2%, from about 0.1 to about 1.5%, from about 0.1 to about 1%, from about 0.1 to about 0.5%, or from about 0.2 to about 0.8%.

[0169] The dispersing agent can also be used to modulate the amount of burst release of the drug or its pharma- ceutically acceptable salt in the initial period when the gastroretentive system is administered. In an embodiment of a gastroretentive system administered once per week, the burst release over approximately the first 6 hours after the first administration is less than about 8%, preferably less than about 6%, of the total amount of drug (or its salt) in the system. In an embodiment of a gastroretentive system administered once per 3 days, the burst release over approximately the first 6 hours after the first administration is less than about 12%, preferably less than about 10%, of the total amount of drug (or its salt) in the system. In an embodiment of a gastroretentive system administered once per day, the burst release over approximately the first 6 hours after the first administration is less than about 40%, preferably less than about 30%, of the total amount of drug (or its salt) in the system. In general, if a new gastroretentive system is administered every D days and the total mass of drug (or salt thereof) is M, the gastroretentive system releases less than about [(M / D) x 0.5], preferably less than about [(M / D) x 0.4], or less than about [(M / D) x 3 / 8], more preferably less than about [(M / D) x 0.3], over approximately the first 6 hours after the first administration. In a further embodiment, the gastroretentive system releases at least about [(M / D) x 0.25] over approximately the first 6 hours after the first administration, i.e., the system releases at least about one-quarter of the daily dose over the first quarter of the first day of administration.

[0170] Stabilizers for use in gastroretentive systems - Patent Application 20070229633 Many drugs are susceptible to oxidative degradation when exposed to reactive oxygen species that may be present in the stomach.The drugs contained in the system may therefore be oxidized due to the long-term residence of the system in the stomach and the sustained release period of the drug from the system.Therefore, it is desirable to include a stabilizer or preservative in the system to stabilize the drug and prevent oxidative and other degradation.

[0171] Stabilizing agents such as antioxidants including tocopherol, alpha-tocopherol, ascorbic acid, ascorbyl palmitate, butylated hydroxytoluene, butylated hydroxyanisole, and fumaric acid may constitute from about 0.1 to about 4%, e.g., from about 0.1 to about 3.5%, from about 0.1 to about 3%, from about 0.1 to about 2.5%, from about 0.1 to about 2%, from about 0.1 to about 1.5%, from about 0.1 to about 1%, from about 0.1 to about 0.5%, or from about 0.2 to about 0.8% of the carrier polymer-drug component.

[0172] Antioxidant stabilizers that can be included in the system to reduce or prevent oxidation of the drug include alpha-tocopherol (about 0.01 to about 0.05% v / v), ascorbic acid (about 0.01 to about 0.1% w / v), ascorbyl palmitate (about 0.01 to about 0.1% w / v), butylated hydroxytoluene (about 0.01 to about 0.1% w / w), butylated hydroxyanisole (about 0.01 to about 0.1% w / w), and fumaric acid (up to 3600 ppm). Vitamin E, tocopherol, vitamin E esters, tocopherol esters, ascorbic acid, or carotenes such as alpha-tocopherol, vitamin E succinate, alpha-tocopherol succinate, vitamin E acetate, alpha-tocopherol acetate, vitamin E nicotinate, alpha-tocopherol nicotinate, vitamin E linoleate, or alpha-tocopherol linoleate can be used as antioxidant stabilizers.

[0173] Certain drugs may be pH sensitive, especially at the low pH present in the gastric environment. Buffering or pH stabilizing compounds that can be included in the system to reduce or prevent drug degradation at low pH include calcium carbonate, calcium lactate, calcium phosphate, sodium phosphate, and sodium bicarbonate. They are typically used in amounts up to about 2% w / w. The buffering or pH stabilizing compounds may constitute about 0.1 to about 4% of the carrier polymer-drug component, e.g., about 0.1 to about 3.5%, about 0.1 to about 3%, about 0.1 to about 2.5%, about 0.1 to about 2%, about 0.1 to about 1.5%, about 0.1 to about 1%, about 0.1 to about 0.5%, or about 0.2 to about 0.8%.

[0174] Antioxidant stabilizers, pH stabilizers, and other stabilizer compounds are blended into the polymer containing the drug (or its pharma- ceutically acceptable salt) by blending the stabilizer into the molten carrier polymer-drug or drug salt mixture. The stabilizer can be blended into the molten carrier polymer before blending the drug (or its salt) into the polymer-stabilizer mixture; or the stabilizer can be blended with the drug (or its salt) before incorporating the blended drug (or its salt)-stabilizer mixture into the carrier polymer; or the stabilizer, drug (or its salt), and molten carrier polymer can be blended simultaneously. The drug (or its salt) can also be blended with the molten carrier polymer before blending the stabilizer into the polymer-drug or drug salt mixture.

[0175] In one embodiment, less than about 10% of the drug (or salt thereof) remaining in the system is degraded or oxidized after about 24 hours of gastric retention. In one embodiment, less than about 10% of the drug (or salt thereof) remaining in the system is degraded or oxidized after about 48 hours of gastric retention. In one embodiment, less than about 10% of the drug (or salt thereof) remaining in the system is degraded or oxidized after about 72 hours of gastric retention. In one embodiment, less than about 10% of the drug (or salt thereof) remaining in the system is degraded or oxidized after about 96 hours of gastric retention. In one embodiment, less than about 10% of the drug (or salt thereof) remaining in the system is degraded or oxidized after about 5 days of gastric retention. In some embodiments, less than about 10% of the drug (or salt thereof) remaining in the system is degraded or oxidized after about 1 week of gastric retention. In some embodiments, less than about 10% of the drug (or its salt) remaining in the system is degraded or oxidized after about a two week gastric residence period.

[0176] In one embodiment, less than about 5% of the drug (or salt thereof) remaining in the system is degraded or oxidized after about 24 hours of gastric retention. In one embodiment, less than about 5% of the drug (or salt thereof) remaining in the system is degraded or oxidized after about 48 hours of gastric retention. In one embodiment, less than about 5% of the drug (or salt thereof) remaining in the system is degraded or oxidized after about 72 hours of gastric retention. In one embodiment, less than about 5% of the drug (or salt thereof) remaining in the system is degraded or oxidized after about 96 hours of gastric retention. In one embodiment, less than about 5% of the drug (or salt thereof) remaining in the system is degraded or oxidized after about 5 days of gastric retention. In some embodiments, less than about 5% of the drug (or salt thereof) remaining in the system is degraded or oxidized after about 1 week of gastric retention. In some embodiments, less than about 5% of the drug (or salt thereof) remaining in the system is degraded or oxidized after about 2 weeks of gastric retention.

[0177] Residence time The residence time of a gastric retention system is defined as the time between administration of the system to the stomach and the exit of the system from the stomach. In one embodiment, the gastric retention system has a residence time of about 24 hours, or up to about 24 hours. In one embodiment, the gastric retention system has a residence time of about 48 hours, or up to about 48 hours. In one embodiment, the gastric retention system has a residence time of about 72 hours, or up to about 72 hours. In one embodiment, the gastric retention system has a residence time of about 96 hours, or up to about 96 hours. In one embodiment, the gastric retention system has a residence time of about 5 days, or up to about 5 days. In one embodiment, the gastric retention system has a residence time of about 6 days, or up to about 6 days. In one embodiment, the gastric retention system has a residence time of about 7 days (about 1 week), or up to about 7 days (about 1 week). In one embodiment, the gastric retention system has a residence time of about 10 days, or up to about 10 days. In one embodiment, the gastroretentive system has a retention time of about 14 days (about 2 weeks), or up to about 14 days (about 2 weeks).

[0178] In one embodiment, the gastric retention system has a retention time of about 24 hours to about 7 days. In one embodiment, the gastric retention system has a retention time of about 48 hours to about 7 days. In one embodiment, the gastric retention system has a retention time of about 72 hours to about 7 days. In one embodiment, the gastric retention system has a retention time of about 96 hours to about 7 days. In one embodiment, the gastric retention system has a retention time of about 5 to about 7 days. In one embodiment, the gastric retention system has a retention time of about 6 to about 7 days.

[0179] In one embodiment, the gastric retention system has a retention time of about 24 hours to about 10 days. In one embodiment, the gastric retention system has a retention time of about 48 hours to about 10 days. In one embodiment, the gastric retention system has a retention time of about 72 hours to about 10 days. In one embodiment, the gastric retention system has a retention time of about 96 hours to about 10 days. In one embodiment, the gastric retention system has a retention time of about 5 to about 10 days. In one embodiment, the gastric retention system has a retention time of about 6 to about 10 days. In one embodiment, the gastric retention system has a retention time of about 7 to about 10 days.

[0180] In one embodiment, the gastric retention system has a retention time of about 24 hours to about 14 days. In one embodiment, the gastric retention system has a retention time of about 48 hours to about 14 days. In one embodiment, the gastric retention system has a retention time of about 72 hours to about 14 days. In one embodiment, the gastric retention system has a retention time of about 96 hours to about 14 days. In one embodiment, the gastric retention system has a retention time of about 5 to about 14 days. In one embodiment, the gastric retention system has a retention time of about 6 to about 14 days. In one embodiment, the gastric retention system has a retention time of about 7 to about 14 days. In one embodiment, the gastric retention system has a retention time of about 10 to about 14 days.

[0181] The gastric retention system releases a therapeutically effective amount of the agent (or salt thereof) during at least a portion of the residence time or period during which the system resides in the stomach. In one embodiment, the system releases a therapeutically effective amount of the agent (or salt thereof) during at least about 25% of the residence time. In one embodiment, the system releases a therapeutically effective amount of the agent (or salt thereof) during at least about 50% of the residence time. In one embodiment, the system releases a therapeutically effective amount of the agent (or salt thereof) during at least about 60% of the residence time. In one embodiment, the system releases a therapeutically effective amount of the agent (or salt thereof) during at least about 70% of the residence time. In one embodiment, the system releases a therapeutically effective amount of the agent (or salt thereof) during at least about 75% of the residence time. In one embodiment, the system releases a therapeutically effective amount of the agent (or salt thereof) during at least about 80% of the residence time. In one embodiment, the system releases a therapeutically effective amount of the agent (or salt thereof) during at least about 85% of the residence time. In one embodiment, the system releases a therapeutically effective amount of the agent (or salt thereof) for at least about 90% of the residence time. In one embodiment, the system releases a therapeutically effective amount of the agent (or salt thereof) for at least about 95% of the residence time. In one embodiment, the system releases a therapeutically effective amount of the agent (or salt thereof) for at least about 98% of the residence time. In one embodiment, the system releases a therapeutically effective amount of the agent (or salt thereof) for at least about 99% of the residence time.

[0182] radiopaque The system is optionally radiopaque so that location can be confirmed via abdominal x-ray if necessary. In some embodiments, one or more of the materials used for construction of the system are sufficiently radiopaque for x-ray visualization. In other embodiments, a radiopaque material is added to one or more materials of the system, or coated onto one or more materials of the system, or added to a small portion of the system. Examples of suitable radiopaque materials are barium sulfate, bismuth subcarbonate, bismuth oxychloride, and bismuth trioxide. These materials are preferably not blended into the polymers used to construct the gastroretentive system so as not to alter the drug release from the carrier polymer or the desired properties of other system polymers. Metallic stripes or chips such as tungsten can also be used on small portions of the system components.

[0183] Carrier Polymer-Drug / Drug Salt Combinations with Excipients and Other Additives The carrier polymer-drug or carrier polymer-drug salt blends may include a variety of excipients and other additives. Table CPE-1 below lists combinations of excipients and other additives that may be used in combination with the drug or its salt and carrier polymer in the composition that comprises the elongate member or a segment of the elongate member of the gastroretentive system. These excipients and other additives may be combined with the carrier polymer, such as polycaprolactone, and the drug or its salt (wherein the drug or drug salt comprises about 10 to about 60% by weight of the composition) that comprise the remainder of the composition. Excipients include the following, which may be used individually or in any combination, in an amount ranging from about 1 to about 30%, for example from about 5 to about 20%, by weight of the composition: Corifol P407 (Poloxamer 407, poly(ethylene glycol)-block-poly(propylene glycol)-block-poly(ethylene glycol)), Eudragit RS (Poly[ethyl acrylate, methyl methacrylate, trimethylammonioethyl methacrylate chloride] 1:2:0.1), Eudragit (poly[ethyl acrylate, methyl methacrylate, trimethylammonioethyl methacrylate chloride] 1:2:0.2), PDO (polydioxanone), PEG-PCL, SIF (FaSSIF / FaSSGF powder from BioRelevant), EPO (dimethylaminoethyl methacrylate-butyl methacrylate-methyl methacrylate copolymer), Kollidon VA64 (vinylpyrrolidone-vinyl acetate copolymer in a 6:4 mass ratio), polyvinyl acetate, and polyvinylpyrrolidine.

[0184] Other additives include silicon dioxide (e.g., comprising about 0.1 to about 5%, e.g., about 0.1 to 1% or about 0.5% by weight of the composition) and antioxidants, such as alpha-tocopherol (e.g., comprising about 0.1 to about 5%, e.g., about 0.1 to 1% or about 0.5% by weight of the composition). Each row in the table below represents a combination of excipients and other additives for use with the carrier polymer and the drug or its salt.

[0185] [Table 4]

[0186] Table CPE-2 lists specific amounts of excipients and other additives that can be used in combination with the drug or its salt and carrier polymer in the composition that makes up the elongate member or a segment of an elongate member of the gastroretentive system.

[0187] The amounts listed in Table CPE-2 may vary by plus or minus 20% of each component (e.g., 0.5% silica may vary from 0.4 to 0.6% silica, since 20% of 0.5% is 0.1%). Each row in the table below represents a combination of excipients and other additives for use with a carrier polymer and a drug or its salt.

[0188] [Table 5]

[0189] System manufacturing / assembly: 3D printing Three-dimensional printing of components of the gastroretentive system, such as arms or arm segments, is performed using commercially available equipment. Three-dimensional printing has been used for the preparation of pharmaceuticals; Khaled et al., "Desktop 3D printing of controlled release pharmaceutical bilayer tablets", International Journal of Pharmaceutics 461:105-111 (2014); U.S. Pat. No. 7,276,252; Alhnan et al., "Emergence of 3D Printed Dosage Forms: Opportunities and Challenges", Pharm. Res., May 18, 2016, PubMed PMID:27194002; Yu et al., "Three-dimensional printing in pharmaceutics: promises and problems", J.Pharm.Sci. 97(9):3666-3690 (2008); and Ursan et al., "Three-dimensional drug printing: A structured review,” J. Am. Pharm. Assoc. 53(2):136-44 (2013).

[0190] The starting feedstock for three-dimensional printing is a polymer or polymer blend (e.g., an enteric polymer, a time-dependent polymer, or a blend of one or more drugs, drug salts, drugs, excipients, etc. with a carrier polymer, an enteric polymer, or a time-dependent polymer). The polymers or components used for one region of the segment or elongated member to be produced are mixed and pelletized using hot melt extrusion. The polymer or blended polymer material is extruded through a circular die to create a cylindrical fiber that is wound around a spool.

[0191] Multiple spools are fed into a 3D printer (e.g., Hyrel Printer, available from Hyrel 3D, Norcross, Georgia, United States) and fed into their representative print head. The print head heats and melts the material at the nozzle to deposit a thin layer of material (polymer or polymer blend) at a specific location on the part being manufactured. The material cools and hardens within seconds, and the next layer is added until the complete structure is formed. The quality of the formulation depends on the feed rate, nozzle temperature, and printer resolution, and feed rate and nozzle temperature can be adjusted to obtain the desired quality.

[0192] Three-dimensional printing can be used to manufacture individual elongated members, or segments of elongated members. Similar to those produced by the co-extrusion methods described herein, three-dimensional printing can also be used to produce bulk configurations such as compressed "slabs". The bulk configurations can be cut into individual pieces (i.e., individual elongated members or individual segments) as needed.

[0193] In some embodiments of the invention, it is contemplated to fabricate the entire elongate member, or "arm", of the gastroretention system by three-dimensional printing of the elongate member. In some embodiments of the invention, it is contemplated to fabricate a segment of the elongate member, or "arm", of the gastroretention system by three-dimensional printing of a segment of the elongate member. In some embodiments, the elongate member or a segment thereof is fabricated by three-dimensional printing of a bulk configuration, such as a slab configuration, of the carrier polymer-drug or polymer-drug salt blend and adjacent portions of the linker material. Following three-dimensional printing, the bulk configuration can be cut into pieces having the desired shape of the elongate member or a segment thereof. Following three-dimensional printing, portions of the bulk configuration can be compression molded into pieces having the desired shape of the elongate member or a segment thereof.

[0194] Three-dimensional printing is often accomplished by feeding rods or fibers of solid material to a print head, which melts and deposits upon subsequent solidification in a technique known as fused deposition modeling (sometimes called extrusion deposition modeling) (see U.S. Patent Nos. 5,121,329 and 5,340,433). The methods described herein for the manufacture of carrier polymer-drug components can also be used to manufacture feed materials that can be used in the manufacture of components of gastroretentive systems via three-dimensional printing.

[0195] System manufacturing / assembly: Coextrusion The components of the gastroretentive system can be manufactured by coextrusion. Most of the various configurations of the segments discussed herein, such as the "islands-in-the-sea" configuration, can be made by either three-dimensional printing or coextrusion. However, coextrusion is less expensive and can be performed as a continuous process, as opposed to three-dimensional printing, which is generally performed as a batch process.

[0196] Coextrusion of "islands in the sea" configurations has been used in the textile industry and for the production of optical fibers, but has had little application in biomedical systems (see U.S. Pat. Nos. 3,531,368; 3,716,614; 4,812,012; and Haslauer et al., J. Biomed. Mater. Res. B Appl. Biomater. 103(5):1050-8 (2015).

[0197] Co-extrusion of components of the gastroretentive system, such as an elongated member (arm), or a segment of an elongated member (arm), can be performed using commercially available equipment in combination with customized co-extruder tubing and customized dies for the desired configuration. The starting feedstock for co-extrusion is a polymer or polymer blend (e.g., an enteric polymer, a time-dependent polymer, or a blend of one or more drugs, drug salts, drugs, excipients, etc. with a carrier polymer, an enteric polymer, or a time-dependent polymer). The polymers or components used for one region of the segment or elongated member to be produced are mixed and pelletized using hot melt extrusion. The polymer pellets thus formed are placed in a hopper above a single screw extruder and dried to remove surface moisture. The pellets are gravity fed into individual single screw extruders where they are melted and pressed for co-extrusion.

[0198] The appropriate molten polymer is then pumped through a custom designed die with multiple channels, which causes the molten polymer to form the required geometric shape. The composite polymer block is cooled (water cooled, air cooled, or both) and cut or stamped into the desired shape, such as, but not limited to, a triangular prism, a rectangular prism, or a cylinder (a pie wedge).

[0199] In some embodiments of the invention, it is contemplated that the entire elongate member, or "arm", of the gastroretentive system is manufactured by co-extruding the elongate member. In some embodiments of the invention, it is contemplated that segments of the elongate member, or "arm", of the gastroretentive system are manufactured by co-extruding segments of the elongate member. In some embodiments, the elongate member or segments thereof are manufactured by co-extruding adjacent portions of the carrier polymer-drug or carrier polymer-drug salt blend and the linker material in a bulk configuration, such as a slab configuration. Following co-extrusion, the bulk configuration can be cut into pieces having the desired shape of the elongate member or segments thereof. Following co-extrusion, portions of the bulk configuration can be compression molded into pieces having the desired shape of the elongate member or segments thereof.

[0200] In some embodiments, the elongate member or segments thereof are manufactured by co-extruding adjacent portions of the carrier polymer-drug or carrier polymer-drug salt blend and linker material in a bulk configuration, such as a slab configuration, while simultaneously co-extruding one or more additional polymers, linker materials, or both the carrier polymer-drug (or drug salt) blend and linker material within the carrier polymer-drug or carrier polymer-drug salt blend. The co-extruding one or more additional polymers, linker materials, or both the carrier polymer-drug (or drug salt) blend and linker material within the carrier polymer-drug or carrier polymer-drug salt blend can be performed in an islands in the sea configuration. Following co-extrusion, the bulk configuration can be cut into pieces having the desired shape of the elongate member or segments thereof. Following co-extrusion, portions of the bulk configuration can be compression molded into pieces having the desired shape of the elongate member or segments thereof.

[0201] Drug Particle Size and Grinding Control of particle size used in gastroretentive systems is important for both optimal drug release and mechanical stability of the system. Drug particle size influences the surface area of ​​drug available for dissolution when gastric fluid penetrates the carrier polymer-drug segment of the system. Also, because the "arms" (elongated members) of the system are relatively small in diameter (e.g., 1-5 millimeters), the presence of drug particles that are a few percent in excess of the diameter of the arms results in weaker arms, both before the drug elutes from the device, and after elution when voids remain in the spaces previously occupied by the drug particles. Such weakening of the arms is disadvantageous as it can lead to premature breakage and passage of the system before the end of the desired retention period.

[0202] In one embodiment, the drug particles used for blending into the carrier polymer-drug component are smaller than about 100 microns in diameter. In another embodiment, the drug particles are smaller than about 75 microns in diameter. In another embodiment, the drug particles are smaller than about 50 microns in diameter. In another embodiment, the drug particles are smaller than about 40 microns in diameter. In another embodiment, the drug particles are smaller than about 30 microns in diameter. In another embodiment, the drug particles are smaller than about 25 microns in diameter. In another embodiment, the drug particles are smaller than about 20 microns in diameter. In another embodiment, the drug particles are smaller than about 10 microns in diameter. In another embodiment, the drug particles are smaller than about 5 microns in diameter.

[0203] In one embodiment, at least about 80% of the drug particles used for blending into the carrier polymer-drug component are smaller than about 100 microns in diameter. In another embodiment, at least about 80% of the drug particles are smaller than about 75 microns in diameter. In another embodiment, at least about 80% of the drug particles are smaller than about 50 microns in diameter. In another embodiment, at least about 80% of the drug particles are smaller than about 40 microns in diameter. In another embodiment, at least about 80% of the drug particles are smaller than about 30 microns in diameter. In another embodiment, at least about 80% of the drug particles are smaller than about 25 microns in diameter. In another embodiment, at least about 80% of the drug particles are smaller than about 20 microns in diameter. In another embodiment, at least about 80% of the drug particles are smaller than about 10 microns in diameter. In another embodiment, at least about 80% of the drug particles are smaller than about 5 microns in diameter.

[0204] In one embodiment, at least about 80% of the mass of the drug particles used for blending into the carrier polymer-drug component have a size of about 1 to about 100 microns in diameter. In another embodiment, at least about 80% of the mass of the drug particles have a size of about 1 to about 75 microns in diameter. In another embodiment, at least about 80% of the mass of the drug particles have a size of about 1 micron to about 50 microns in diameter. In another embodiment, at least about 80% of the mass of the drug particles have a size of about 1 to about 40 microns in diameter. In another embodiment, at least about 80% of the mass of the drug particles have a size of about 1 to about 30 microns in diameter. In another embodiment, at least about 80% of the mass of the drug particles have a size of about 1 to about 25 microns in diameter. In another embodiment, at least about 80% of the mass of the drug particles have a size of about 1 to about 20 microns in diameter. In another embodiment, at least about 80% of the mass of the drug particles have a size of about 1 to about 10 microns in diameter. In another embodiment, at least about 80% by mass of the drug particles have a size of about 1 to about 5 microns in diameter.

[0205] In one embodiment, at least about 80% of the mass of the drug particles used for blending into the carrier polymer-drug component have a size of about 2 to about 100 microns in diameter. In another embodiment, at least about 80% of the mass of the drug particles have a size of about 2 to about 75 microns in diameter. In another embodiment, at least about 80% of the mass of the drug particles have a size of about 2 to about 50 microns in diameter. In another embodiment, at least about 80% of the mass of the drug particles have a size of about 2 to about 40 microns in diameter. In another embodiment, at least about 80% of the mass of the drug particles have a size of about 2 to about 30 microns in diameter. In another embodiment, at least about 80% of the mass of the drug particles have a size of about 2 to about 25 microns in diameter. In another embodiment, at least about 80% of the mass of the drug particles have a size of about 2 to about 20 microns in diameter. In another embodiment, at least about 80% of the mass of the drug particles have a size of about 2 to about 10 microns in diameter. In another embodiment, at least about 80% by mass of the drug particles have a size of from about 2 to about 5 microns in diameter.

[0206] In one embodiment, at least about 80% of the mass of the drug particles used for blending into the carrier polymer-drug component have a size of about 5 to about 100 microns in diameter. In another embodiment, at least about 80% of the mass of the drug particles have a size of about 5 to about 75 microns in diameter. In another embodiment, at least about 80% of the mass of the drug particles have a size of about 5 to about 50 microns in diameter. In another embodiment, at least about 80% of the mass of the drug particles have a size of about 5 to about 40 microns in diameter. In another embodiment, at least about 80% of the mass of the drug particles have a size of about 5 to about 30 microns in diameter. In another embodiment, at least about 80% of the mass of the drug particles have a size of about 5 to about 25 microns in diameter. In another embodiment, at least about 80% of the mass of the drug particles have a size of about 5 to about 20 microns in diameter. In another embodiment, at least about 80% of the mass of the drug particles have a size of about 5 to about 10 microns in diameter.

[0207] The particle size of a drug can be easily adjusted by milling. Several milling techniques are available to reduce larger particles to smaller particles of a desired size. Fluid energy milling is a dry milling technique that uses interparticle collisions to reduce the size of particles. One type of fluid energy milling, called air jet milling, pumps air into a cylindrical chamber in such a way as to maximize collisions between drug particles. Ball milling utilizes a rotating cylindrical chamber that rotates about its main axis. The drug and milling material (e.g., steel balls made from chrome steel or CR-NI steel, ceramic balls such as zirconia, or plastic polyamide) collide, causing a reduction in the particle size of the drug. Ball milling can be done dry or with the addition of a liquid to the cylinder where the drug and milling material are insoluble in the liquid. Further information on milling can be found in the chapter entitled "Particle Size Reduction" by R.W. Lee et al. in Water-Insoluble Drug Formulation, Second Edition (ed. Ron Liu), Boca Raton, Florida: CRC Press, 2008; and the chapter entitled "Granulation of Poorly Water-Soluble Drugs" by A.W. Brzeczko et al. in Handbook of Pharmaceutical Granulation Technology, Third Edition (ed. Dilip M. Parikh), Boca Raton, Florida: CRC Press / Taylor&Francis Group, 2010 (as well as other sections of this handbook). Fluid energy milling (i.e., air jet milling) is the preferred milling method as it is more amenable to scale-up compared to other dry milling techniques such as ball milling.

[0208] Grinding Additives Substances can be added to the drug material during milling to help obtain particles of the desired size and minimize agglomeration during handling. Silica (silicon dioxide, SiO2) is a preferred milling additive because it is inexpensive, widely available, and non-toxic. Other additives that can be used include silica, calcium phosphate, powdered cellulose, colloidal silicon dioxide, hydrophobic colloidal silica, magnesium oxide, magnesium silicate, magnesium trisilicate, talc, polyvinylpyrrolidone, cellulose ethers, polyethylene glycol, polyvinyl alcohol, and surfactants. In particular, hydrophobic particles with a diameter of less than 5 microns are particularly prone to agglomeration, and hydrophilic additives are used when milling such particles. About 0.1 to about 5% weight / weight of a grinding additive, such as silica, can be used for fluid grinding or ball mill grinding, or about 0.1 to about 4%, about 0.1 to about 3%, about 0.1 to about 2%, about 0.1 to about 1%, about 1 to about 5%, about 1 to about 4%, about 1 to about 3%, about 1 to about 2%, or about 0.1%, about 0.5%, about 1%, about 2%, about 3%, about 4%, or about 5% can be used.

[0209] Particle Sizing After grinding, the particles can be passed through a mesh of appropriate size to obtain particles of the desired size. To obtain particles of the maximum desired size, the particles are passed through a mesh with holes of the maximum desired size. Particles that are too large are retained on the mesh, and particles that pass through the mesh have the maximum desired size. To obtain particles of the minimum desired size, the particles are passed through a mesh with holes of the minimum desired size. Particles that pass through the mesh are too small, and the desired particles are retained on the mesh.

[0210] Linked Polymers A linking polymer is used to link one or more carrier polymer-drug components to one or more carrier polymer-drug components, to link one or more carrier polymer-drug components to one or more elastomeric components, or to link one or more elastomeric components to one or more elastomeric components. Thus, the linking polymer forms a linker region between the other components of the system. Enteric polymers and time-dependent polymers are preferred for use as linking polymers. In some embodiments, an enteric polymer is used as the linking polymer. In some embodiments, a time-dependent polymer that is pH-resistant, i.e., less sensitive to pH changes than an enteric polymer, is used as the linking polymer. In some embodiments, both an enteric polymer and a time-dependent polymer that is less sensitive to pH changes than an enteric polymer are used as the linking polymer.

[0211] The enteric polymer is relatively insoluble under acidic conditions such as those encountered in the stomach, but is soluble under weaker acidic to basic conditions encountered in the small intestine. Since the pH of the duodenum, the initial portion of the small intestine, is in the range of about 5.4 to 6.1, an enteric polymer that dissolves at about pH 5 or higher can be used as the linking polymer. If the gastric retention system passes intact through the pyloric valve, the enteric linking polymer dissolves and the components linked to the linking polymer are degraded, allowing the retention system to pass through the small intestine and large intestine. Thus, the gastric retention system is designed to be rapidly delinked in the intestinal environment by dissolution of the linking polymer within 48 hours, preferably within 24 hours, more preferably within 12 hours, and even more preferably within 1 to 2 hours, to avoid possible intestinal obstruction. If the gastric retention system must be removed quickly for any reason during treatment, the patient can drink a weakly basic aqueous solution (e.g., bicarbonate solution) to induce immediate delinking of the gastric retention system.

[0212] A "time-dependent polymer that is pH resistant" (or equivalently, a "pH resistant time-dependent polymer") means that under conditions where the enteric polymer is degraded to the point where it no longer links the components together, the time-dependent polymer still has sufficient mechanical strength to link the components together. In some embodiments, the time-dependent polymer retains about the same linking ability, i.e., about 100% of its linking strength, after exposure to a solution of about pH 7 to about pH 8, where the exposure is for about 1 hour, about 1 day, about 3 days, or about 1 week. In some embodiments, the time-dependent polymer retains at least about 90% of its linking strength after exposure to a solution of about pH 2 to about pH 3, after exposure to a solution of about pH 7 to about pH 8, where the exposure is for about 1 hour, about 1 day, about 3 days, or about 1 week. In some embodiments, the time-dependent polymer retains at least about 75% of the linkage strength after exposure to a solution of about pH 2 to about pH 3 after exposure to a solution of about pH 7 to about pH 8, where the exposure is for about 1 hour, about 1 day, about 3 days, or about 1 week. In some embodiments, the time-dependent polymer retains at least about 60% of the linkage strength after exposure to a solution of about pH 2 to about pH 3 after exposure to a solution of about pH 7 to about pH 8, where the exposure is for about 1 hour, about 1 day, about 3 days, or about 1 week. In some embodiments, the time-dependent polymer retains at least about 50% of the linkage strength after exposure to a solution of about pH 2 to about pH 3 after exposure to a solution of about pH 7 to about pH 8, where the exposure is for about 1 hour, about 1 day, about 3 days, or about 1 week. In some embodiments, the time-dependent polymer retains at least about 25% of its linkage strength after exposure to a solution of about pH 2 to about pH 3 after exposure to a solution of about pH 7 to about pH 8, where the exposure is for about 1 hour, about 1 day, about 3 days, or about 1 week. In some embodiments, the time-dependent polymer resists fracture under a bending force of about 0.2 Newtons (N), about 0.3 N, about 0.4 N, about 0.5 N, about 0.75 N, about 1 N, about 1.5 N, about 2 N, about 2.5 N, about 3 N, about 4 N, or about 5 N after exposure to a solution of about pH 7 to about pH 8, where the exposure is for about 1 hour, about 1 day, about 3 days, or about 1 week.Bond strength can be measured by any reasonable test that serves to test bond capabilities, such as the four-point bending deflection test (ASTM D790).

[0213] Exemplary linking polymers include, but are not limited to, cellulose acetate phthalate, cellulose acetate succinate, methylcellulose phthalate, ethylhydroxycellulose phthalate, polyvinyl acetate phthalate, polyvinyl butyrate acetate, vinyl acetate-maleic anhydride copolymer, styrene-maleic acid monoester copolymer, methacrylate-methyl methacrylate copolymer, methyl acrylate-methacrylic acid copolymer, methacrylate-methacrylic acid-octyl acrylate copolymer, and copolymers, mixtures, blends and combinations thereof. Some of the enteric polymers that can be used in the present invention are listed in the Enteric Polymers Table along with their dissolution pH. (See Mukherji, Gour and Clive G. Wilson, "Enteric Coating for Colonic Delivery," Chapter 18 in Modified-Release Drug Delivery Technology, edited by Michael J. Rathbone, Jonathan Hadgraft, Michael S. Roberts, Drugs and the Pharmaceutical Sciences Volume 126, New York: Marcel Dekker, 2002.) Preferably, an enteric polymer is used that dissolves at a pH of about 5 or about 5.5 or less. Poly(methacrylic acid-co-ethyl acrylate) (sold under the trade name Eudragit L100-55, Eudragit being a registered trademark of Evonik Rohm GmbH, Darmstadt, Germany) is a preferred enteric polymer. Another preferred enteric polymer is hydroxypropyl methylcellulose acetate succinate (hypromellose acetate succinate or HPMCAS; Ashland, Inc., Covington, Kentucky, USA), which has an adjustable pH cutoff of about 5.5 to about 7.0. Cellulose acetate phthalate, cellulose acetate succinate, and hydroxypropyl methylcellulose phthalate are also suitable enteric polymers.

[0214] In one embodiment, the enteric polymer used in the gastric retention system dissolves at a pH greater than about 4. In some embodiments, the enteric polymer used in the gastric retention system dissolves at a pH greater than about 5. In some embodiments, the enteric polymer used in the gastric retention system dissolves at a pH greater than about 6. In some embodiments, the enteric polymer used in the gastric retention system dissolves at a pH greater than about 7. In some embodiments, the enteric polymer used in the gastric retention system dissolves at a pH greater than about 7.5. In some embodiments, the enteric polymer used in the gastric retention system dissolves at a pH of about 4 to about 5. In some embodiments, the enteric polymer used in the gastric retention system dissolves at a pH of about 4 to about 6. In some embodiments, the enteric polymer used in the gastric retention system dissolves at a pH of about 4 to about 7. In some embodiments, the enteric polymer used in the gastric retention system dissolves at a pH of about 4 to about 7.5. In some embodiments, the enteric polymer used in the gastric retention system dissolves at a pH of about 5 to about 6. In some embodiments, the enteric polymer used in the gastric retention system dissolves at a pH of about 5 to about 7. In some embodiments, the enteric polymer used in the gastric retention system dissolves at a pH of about 5 to about 7.5. In some embodiments, the enteric polymer used in the gastric retention system dissolves at a pH of about 6 to about 7. In some embodiments, the enteric polymer used in the gastric retention system dissolves at a pH of about 6 to about 7.

[0215] [Table 6]

[0216] Additional preferred polymers for use as linking polymers are time-dependent polymers, i.e., polymers that degrade in a time-dependent manner in the gastric environment. For example, the liquid plasticizer triacetin is released from the polymer formulation in a time-dependent manner over a period of 7 days in simulated gastric fluid, while Plastoid B retains its strength over a period of 7 days in simulated gastric fluid. Thus, polymers that degrade in a time-dependent manner can be easily prepared by mixing Plastoid B and triacetin, and the degradation time of the Plastoid B-triacetin mixture can be extended by increasing the amount of Plastoid B used in the mixture (i.e., using less triacetin in the mixture), and the degradation time can be decreased by decreasing the amount of Plastoid B used in the mixture (i.e., using more triacetin in the mixture).

[0217] A variety of time-dependent mechanisms are available. Water-soluble time-dependent polymers degrade when water passes through the polymer. Examples of such polymers are hydroxypropyl methylcellulose and polyvinyl acetate. Acid-soluble time-dependent polymers degrade over time in an acidic environment. Examples include Eudragit EPO. Time-dependent polymers can use water-soluble plasticizers, and as the plasticizer is released, the remaining polymer becomes brittle and disintegrates under the forces of the stomach. Examples of such polymers include triacetin and triethyl citrate.

[0218] In some embodiments, the carrier polymer-drug component is an elongate member comprising segments attached by an enteric polymer. In some embodiments, the carrier polymer-drug component is attached to the elastomeric component of the system by an enteric polymer. In any of these embodiments, when an enteric polymer is used for both intersegment attachment and attachment of the elongate member to the elastomeric component, the enteric polymer used for intersegment attachment can be the same enteric polymer as the enteric polymer used for attachment of the elongate member to the elastomeric component, or the enteric polymer used for intersegment attachment can be a different enteric polymer than the enteric polymer used for attachment of the elongate member to the elastomeric component. The enteric polymers used for intersegment attachment can all be the same enteric polymer, or all different enteric polymers, or some of the enteric polymers in the intersegment attachments can be the same and some of the enteric polymers in the intersegment attachments can be different. That is, the enteric polymer used for each intersegment attachment and the enteric polymer used for attachment of the elongate member to the elastomeric component can be independently selected.

[0219] In some embodiments, the carrier polymer-drug component is a non-segmented elongate member attached to the elastomeric component of the system by an enteric polymer, a time-dependent linker, or a degradable matrix, or any combination of an enteric polymer, a time-dependent linker, and / or a degradable matrix.

[0220] In any of the embodiments of the gastroretentive system described herein, the linking polymer or linker may include hydroxypropyl methylcellulose acetate succinate (HPMCAS) and polycaprolactone (PCL). A blend of these may be used to form the degradable linker or degradable matrix. The ratio of HPMCAS to polycaprolactone in the degradable linker or degradable matrix may be about 80% HPMCAS:20% PCL to about 20% HPMCAS:80% PCL. The ratio of HPMCAS to polycaprolactone is about 80% HPMCAS:20% PCL to about 20% HPMCAS:80% PCL; about 70% HPMCAS:30% PCL to about 30% HPMCAS:70% PCL; about 60% HPMCAS:40% PCL to about 40% HPMCAS:60% PCL; about 80% HPMCAS:20% PCL to about 50% HPMCAS:50% PCL; about 80% HPMCAS:20% PCL to about 60% HPMCAS:40% PCL; about 70% HPMCAS:30% PCL to about 50% HPMCAS:50% PCL; about 70% HPMCAS:30% PCL to about 60% HPMCAS:40% PCL; about 20% It may be HPMCAS:80% PCL to about 40% HPMCAS:60% PCL; about 20% HPMCAS:80% PCL to about 50% HPMCAS:50% PCL; about 30% HPMCAS:70% PCL to about 40% HPMCAS:60% PCL; about 30% HPMCAS:70% PCL to about 50% HPMCAS:50% PCL; or about 80% HPMCAS:20% PCL, about 70% HPMCAS:30% PCL, about 60% HPMCAS:40% PCL, about 50% HPMCAS:50% PCL, about 40% HPMCAS:60% PCL, about 30% HPMCAS:70% PCL, or about 20% HPMCAS:80% PCL.The linker may further comprise a plasticizer selected from the group consisting of triacetin, triethyl citrate, tributyl citrate, poloxamer, polyethylene glycol, polypropylene glycol, diethyl phthalate, dibutyl sebacate, glycerin, castor oil, acetyl triethyl citrate, acetyl tributyl citrate, polyethylene glycol monomethyl ether, sorbitol, sorbitan, sorbitol-sorbitan mixtures, and diacetylated monoglycerides.

[0221] The linker is selected to weaken sufficiently after a specified period of time to allow the gastro-retention system to reach a point where it decouples and passes through the pylorus and out of the stomach after a desired retention period, or to weaken sufficiently that the gastro-retention system is no longer retained in the stomach. That is, the linker weakens to the point of decoupling (decoupling point) or to the point where the gastro-retention system can pass through the pylorus (pylorus crossing point, or crossing point). Thus, in one embodiment, a linker is used that decouples after about 2 days in the human stomach; about 3 days in the human stomach; about 4 days in the human stomach; about 5 days in the human stomach; about 6 days in the human stomach; about 7 days in the human stomach; about 8 days in the human stomach; about 9 days in the human stomach; about 10 days in the human stomach; or about 2 weeks in the human stomach. In one embodiment, a linker is used that decouples after about 2 days in a dog's stomach; about 3 days in a dog's stomach; about 4 days in a dog's stomach; about 5 days in a dog's stomach; about 6 days in a dog's stomach; about 7 days in a dog's stomach; about 8 days in a dog's stomach; about 9 days in a dog's stomach; about 10 days in a dog's stomach; or about 2 weeks in a dog's stomach. In one embodiment, a linker is used that decouples after about 2 days in a pig's stomach; about 3 days in a pig's stomach; about 4 days in a pig's stomach; about 5 days in a pig's stomach; about 6 days in a pig's stomach; about 7 days in a pig's stomach; about 8 days in a pig's stomach; about 9 days in a pig's stomach; about 10 days in a pig's stomach; or about 2 weeks in a pig's stomach. In one embodiment, a linker is used that decouples after about 2 days in fasted simulated gastric fluid; after about 3 days in fasted simulated gastric fluid; after about 4 days in fasted simulated gastric fluid; after about 5 days in fasted simulated gastric fluid; after about 6 days in fasted simulated gastric fluid; after about 7 days in fasted simulated gastric fluid; after about 8 days in fasted simulated gastric fluid; after about 9 days in fasted simulated gastric fluid; after about 10 days in fasted simulated gastric fluid; or after about 2 weeks in fasted simulated gastric fluid. In one embodiment, a linker is used that decouples after about 2 days in fed state simulated gastric fluid; after about 3 days in fed state simulated gastric fluid; after about 4 days in fed state simulated gastric fluid; after about 5 days in fed state simulated gastric fluid; after about 6 days in fed state simulated gastric fluid; after about 7 days in fed state simulated gastric fluid; after about 8 days in fed state simulated gastric fluid; after about 9 days in fed state simulated gastric fluid; after about 10 days in fed state simulated gastric fluid; or after about 2 weeks in fed state simulated gastric fluid.In one embodiment, a linker is used that decouples after about 2 days in water at pH 2; about 3 days in water at pH 2; about 4 days in water at pH 2; about 5 days in water at pH 2; about 6 days in water at pH 2; about 7 days in water at pH 2; about 8 days in water at pH 2; about 9 days in water at pH 2; about 10 days in water at pH 2; or about 2 weeks in water at pH 2. In one embodiment, a linker is used that decouples after about 2 days in water at pH 1; about 3 days in water at pH 1; about 4 days in water at pH 1; about 5 days in water at pH 1; about 6 days in water at pH 1; about 7 days in water at pH 1; about 8 days in water at pH 1; about 9 days in water at pH 1; about 10 days in water at pH 1; or about 2 weeks in water at pH 1.

[0222] The decoupling point or pylorus crossing point in humans, dogs, or pigs occurs when the system leaves the stomach, i.e., passes through the pylorus. For in vitro measurements in simulated gastric fluid or acidic water, the decoupling point or pylorus crossing point occurs when the linker weakens to a point where it breaks under the normal compressive forces of the stomach, typically about 0.1-0.2 Newtons. The link strength (breaking point) can be measured by any reasonable test that serves to test the linking ability, i.e., the force required to break the linker, such as the four-point bending deflection test (ASTM D790) described in Example 18 of International Patent Application No. WO2017 / 070612, or Examples 12, 13, 15, 17, or 18 of International Patent Application No. WO2017 / 100367. In one embodiment, the decoupling point or pylorus crossing point is reached when the linker decoupling at a force of about 0.2 N. In another embodiment, the decoupling point or pylorus crossing point is reached when the linker decouplings at a force of about 0.1 N.

[0223] The gastroretentive system can reach the pylorus crossing point without any or all of the linkers actually breaking down. If the linkers weaken or degrade to the point where they can no longer hold the gastroretentive system in the stomach, the gastroretentive system will pass through the pylorus into the small intestine (pylorus crossing point or crossing point) even if one, some, or all of the linkers do not break down. In some embodiments, linkers are used that weaken to the crossing point after about 2 days in the human stomach; about 3 days in the human stomach; about 4 days in the human stomach; about 5 days in the human stomach; about 6 days in the human stomach; about 7 days in the human stomach; about 8 days in the human stomach; about 9 days in the human stomach; about 10 days in the human stomach; or about 2 weeks in the human stomach. In some embodiments, a linker is used that weakens to a cross-point after about 2 days in a dog's stomach; about 3 days in a dog's stomach; about 4 days in a dog's stomach; about 5 days in a dog's stomach; about 6 days in a dog's stomach; about 7 days in a dog's stomach; about 8 days in a dog's stomach; about 9 days in a dog's stomach; about 10 days in a dog's stomach; or about 2 weeks in a dog's stomach. In some embodiments, a linker is used that weakens to a cross-point after about 2 days in a pig's stomach; about 3 days in a pig's stomach; about 4 days in a pig's stomach; about 5 days in a pig's stomach; about 6 days in a pig's stomach; about 7 days in a pig's stomach; about 8 days in a pig's stomach; about 9 days in a pig's stomach; about 10 days in a pig's stomach; or about 2 weeks in a pig's stomach. In some embodiments, a linker is used that weakens to the cut-off point after about 2 days in fasted simulated gastric fluid; after about 3 days in fasted simulated gastric fluid; after about 4 days in fasted simulated gastric fluid; after about 5 days in fasted simulated gastric fluid; after about 6 days in fasted simulated gastric fluid; after about 7 days in fasted simulated gastric fluid; after about 8 days in fasted simulated gastric fluid; after about 9 days in fasted simulated gastric fluid; after about 10 days in fasted simulated gastric fluid; or after about 2 weeks in fasted simulated gastric fluid. In some embodiments, a linker is used that weakens to the cut-off point after 2 days in fed state simulated gastric fluid; after 3 days in fed state simulated gastric fluid; after 4 days in fed state simulated gastric fluid; after 5 days in fed state simulated gastric fluid; after 6 days in fed state simulated gastric fluid; after 7 days in fed state simulated gastric fluid; after 8 days in fed state simulated gastric fluid; after 9 days in fed state simulated gastric fluid; after 10 days in fed state simulated gastric fluid; or after about 2 weeks in fed state simulated gastric fluid.In some embodiments, linkers are used that weaken to a cut-off point after about 2 days in water at pH 2; about 3 days in water at pH 2; about 4 days in water at pH 2; about 5 days in water at pH 2; about 6 days in water at pH 2; about 7 days in water at pH 2; about 8 days in water at pH 2; about 9 days in water at pH 2; about 10 days in water at pH 2; or about 2 weeks in water at pH 2. In some embodiments, linkers are used that weaken to a cut-off point after about 2 days in water at pH 1; about 3 days in water at pH 1; about 4 days in water at pH 1; about 5 days in water at pH 1; about 6 days in water at pH 1; about 7 days in water at pH 1; about 8 days in water at pH 1; about 9 days in water at pH 1; about 10 days in water at pH 1; or about 2 weeks in water at pH 1.

[0224] Elastomer Elastomers (also referred to as elastic or tensile polymers) allow the gastroretentive system to be compacted, such as by folding or compressing into a suitable form for administration to the stomach by swallowing a container or capsule containing the compacted system. Upon dissolution of the capsule in the stomach, the gastroretentive system expands into a shape that prevents the system from passing through the patient's pyloric sphincter for the desired residence time of the system. Thus, the elastomer must be capable of being stored in a compacted configuration in a capsule for a reasonable shelf life and expanding to its original shape, or approximately its original shape, upon release from the capsule. In one embodiment, the elastomer is a silicone elastomer. In one embodiment, the elastomer is formed from a liquid silicone rubber (LSR), such as that sold as QP-1 Liquid Silicone Rubber Kit by Dow Corning. In one embodiment, the elastomer is a crosslinked polycaprolactone. In one embodiment, the elastomer is an enteric polymer, such as an enteric polymer listed in the Enteric Polymers Table. In some embodiments, the linking polymer used in the system is also an elastomer. Elastomers are preferred for use as the central polymer in the star or star-like design of the gastroretentive system.

[0225] In one embodiment, both the linking polymer and the elastomer are enteric polymers, which provide for more complete breakdown of the system into carrier polymer-drug particles when the system enters the intestine or when the patient drinks a mildly basic solution to induce passage of the system.

[0226] Examples of elastomers that can be used include silicones, such as those formed using the Dow Corning QP-1 kit; urethane crosslinked polycaprolactone; poly(acryloyl 6-aminocaproic acid) (PA6ACA); poly(methacrylic acid-co-ethyl acrylate) (Eudragit L100-55); and a mixture of poly(acryloyl 6-aminocaproic acid) (PA6ACA) and poly(methacrylic acid-co-ethyl acrylate) (Eudragit L100-55).

[0227] A flexible linked polymer, i.e., an elastomeric linked polymer or elastomer, is used as the central polymer in the star or star-shaped design of the gastroretentive system. A particularly preferred elastomer for use as the central elastomer in the star or star-shaped configuration is silicone rubber. Liquid silicone rubber (LSR) can be easily molded and cured into the desired shape. Dow Corning QP-1 series, which includes crosslinked dimethyl and methyl-vinyl siloxane copolymers and reinforcing silica, is an example of such a silicone rubber polymer (see, for example, the website www.dowcorning.com / DataFiles / 090276fe8018ed07.pdf). A non-segmented elongate member or an elongate member including carrier polymer-drug component segments can then be attached to the central silicone rubber elastomer. Another elastomer that can be used as the central elastomer in the star-shaped design is crosslinked polycaprolactone.

[0228] Particular configurations of gastroretention systems are disclosed in International Patent Application WO2017 / 100367, and any of those configurations may be used for the gastroretention systems disclosed herein.

[0229] System Dimensions The system must be capable of adopting a compacted state having dimensions that allow the patient to swallow the system (or allow the system to be introduced into the stomach by alternative means, such as a feeding tube or gastrostomy tube). Typically, the system is held in the compacted state by a container, such as a capsule. Once the system is in the stomach, it is released from the container and adopts a non-compacted state, i.e., an expanded conformation, the dimensions of which prevent the system from passing through the pyloric sphincter and allow retention of the system in the stomach.

[0230] Thus, the system should be capable of being placed into a standard size capsule of the type commonly used in pharmacies. Standard capsule sizes used in the United States are provided below in the capsule table below (see "Draft Guidance for Industry on Size, Shape, and Other Physical Attributes of Generic Tablets and Capsules" at URL www.regulations.gov / #!documentDetail;D=FDA-2013-N-1434-0002). Since these are the outer dimensions of the capsules and dimensions vary slightly between capsule manufacturers, the system should be capable of being configured to be approximately 0.5-1 mm smaller than the outer diameter shown and approximately 1-2 mm shorter than the length shown in the capsule table.

[0231] [Table 7]

[0232] The capsules can be made from materials well known in the art, such as gelatin or hydroxypropylmethylcellulose, hi one embodiment, the capsules are made from a material that dissolves in the gastric environment, but not in the oral or esophageal environment, preventing premature release of the system before it reaches the stomach.

[0233] In one embodiment, the system is folded or compressed into a compacted state to fit into a capsule, for example, in the manner shown in Figure IB. Once the capsule dissolves in the stomach, the system assumes a configuration suitable for retention in the stomach, for example, in the manner shown in Figure IA. Preferred capsule sizes are 00 and 00el (a 00el size capsule has the approximate length of a 000 capsule and the approximate width of a 00 capsule), which then constrains the length and diameter of the folded system.

[0234] When the system is released from the container, the system assumes an uncompacted state having dimensions suitable for preventing the gastroretention system from passing through the pyloric sphincter. In one embodiment, the system has at least two orthogonal dimensions, each of which is at least 2 cm long, i.e., the gastroretention system has a length of at least about 2 cm across at least two orthogonal directions. In another embodiment, the circumference of the system in the uncompacted state, when projected onto a plane, has two orthogonal dimensions, each of which is at least 2 cm long. The two orthogonal dimensions may independently have a length of about 2 to about 7 cm, about 2 to about 6 cm, about 2 to about 5 cm, about 2 to about 4 cm, about 2 to about 3 cm, about 3 to about 7 cm, about 3 to about 6 cm, about 3 to about 5 cm, about 3 to about 4 cm, about 4 to about 7 cm, about 4 to about 6 cm, about 4 to about 5 cm, or about 4 to about 4 cm. These dimensions prevent the gastroretention system from passing through the pyloric sphincter. For star polymers having N arms (where N is greater than or equal to 3, e.g., N=6), the arms may have dimensions such that the system has at least two orthogonal dimensions, each of which is a length as described above. These two orthogonal dimensions are selected as described above to promote retention of the gastroretentive system.

[0235] The systems are designed to eventually degrade in the stomach at the end of a desired residence time (retention period), at which point the remaining components of the system are of a size that allows the system to pass through the pyloric sphincter, small intestine, and large intestine, and the system is then removed from the body by defecation or by eventual complete dissolution of the system in the small intestine and large intestine. Thus, the linking polymer or degradable matrix is ​​arranged in the gastroretentive systems of the present invention in a configuration such that when the linking polymer or degradable matrix breaks down or dissolves at the end of the desired residence period, the delinked components of the gastroretentive system have a size suitable for passing through the pyloric sphincter and being removed from the gastrointestinal tract.

[0236] Polymer composition of the system The selection of individual polymers for the carrier polymer, linking polymer, and elastomer affects many properties of the system, such as the drug elution rate (which depends on the carrier polymer as well as other factors), the residence time of the system (which depends on the degradation of either of the polymers, primarily the linking polymer), the decoupling time of the system as it passes into the intestine (which depends primarily on the intestinal degradation rate of the linking polymer, as discussed herein), and the shelf life of the system in a compressed form (which depends primarily on the properties of the elastomer). Because the system is administered to the gastrointestinal tract, all of the system components should be biocompatible with the gastrointestinal environment.

[0237] The dissolution rate of a drug from a carrier polymer-drug component is influenced by a number of factors, including the composition and properties of the carrier polymer, which itself may be a mixture of several polymeric and non-polymeric components; the properties of the drug, such as hydrophilicity / hydrophobicity, charge state, pKa, and hydrogen bonding ability; and the properties of the stomach environment. In the aqueous environment of the stomach, the challenge is to avoid burst release of the drug, especially of hydrophilic drugs (burst release refers to a high initial delivery of the active pharmaceutical ingredient when the system is first placed in the stomach), and to maintain sustained release of the drug over a period of several days to one or two weeks.

[0238] The residence time of the system in the stomach is adjusted by the selection of the linking polymer used in the linker region. The mechanical action and fluctuating pH of the stomach will eventually weaken the enteric linking polymer, so the system will eventually degrade in the stomach regardless of the use of an enteric linking polymer. Linking polymers that degrade in a time-dependent manner in the stomach can also be used to adjust the time it takes for the system to degrade and therefore the residence time. Once the system has degraded, it will be removed after passing into the intestine.

[0239] The elastomers used in the system are central to the shelf life of the system. When the system is compressed, the elastomers are exposed to mechanical stresses. The stresses can then cause polymer creep, which, if sufficiently large, can prevent the system from returning to its non-compacted configuration when released from a capsule or other container, which in turn leads to premature passage of the system from the stomach. Polymer creep can also be temperature dependent, so the expected storage conditions of the system must also be considered when selecting the elastomers and other polymeric components.

[0240] The system components and polymers should not swell or have minimal swelling in the gastric environment: the components should swell no more than about 20%, no more than about 10%, or preferably no more than about 5% when in the gastric environment over the period of residence.

[0241] Methods for preparing carrier polymer-drug (or drug salt) components Blending temperatures for incorporation of the drug (or pharma- ceutically acceptable salt thereof) into the polymer matrix are typically in the range of about 80 to about 120°C, although higher or lower temperatures can be used for polymers that blend best at temperatures outside that range. If a particular size of drug (or salt thereof) particles is used and it is desired that the size of the particles be maintained during and after blending, blending can be performed at a temperature below the melting point of the drug (or salt thereof) so as to maintain the desired size of the particles. Alternatively, a temperature that melts both the polymer and the drug (or salt thereof) can be used. The blending temperature should be below the decomposition temperature of the drug (or salt thereof). In one embodiment, less than about 2% of the drug (or salt thereof) is degraded during manufacturing. In one embodiment, less than about 1.5% of the drug (or salt thereof) is degraded during manufacturing. In one embodiment, less than about 1% of the drug (or salt thereof) is degraded during manufacturing. In one embodiment, less than about 0.75% of the drug (or salt thereof) is degraded during manufacturing. In one embodiment, less than about 0.5% of the drug (or salt thereof) is degraded during manufacturing. In one embodiment, less than about 0.4% of the drug (or salt thereof) is degraded during manufacturing. In one embodiment, less than about 0.3% of the drug (or salt thereof) is degraded during manufacturing. In one embodiment, less than about 0.2% of the drug (or salt thereof) is degraded during manufacturing. In one embodiment, less than about 0.15% of the drug (or salt thereof) is degraded during manufacturing. In one embodiment, less than about 0.1% of the drug (or salt thereof) is degraded during manufacturing. In one embodiment, less than about 0.05% of the drug (or salt thereof) is degraded during manufacturing. In one embodiment, less than about 0.04% of the drug (or salt thereof) is degraded during manufacturing. In one embodiment, less than about 0.03% of the drug (or salt thereof) is degraded during manufacturing. In one embodiment, less than about 0.02% of the drug (or salt thereof) is degraded during manufacturing. In one embodiment, less than about 0.01% of the Drug (or its salt) is degraded during manufacturing.

[0242] Hot melt extrusion can be used to prepare the carrier polymer-drug (or drug salt) component. Single screw, or preferably twin screw system can be used. As described, if it is desired to maintain the particle size during and after blending, a carrier polymer that can melt at a temperature that does not degrade the drug or its salt should be used. Alternatively, a temperature that melts both the polymer and the drug or its salt can be used.

[0243] Melting and casting can also be used to prepare the carrier polymer-drug (or salt thereof) composition. The carrier polymer and the drug (or salt thereof) and any other desired ingredients are mixed together. The carrier polymer is melted, the melt is mixed so that the drug (or salt thereof) particles are uniformly distributed in the melt, poured into a mold, and allowed to cool.

[0244] Solvent casting can also be used to prepare the carrier polymer-drug (or its salt) component. The polymer is dissolved in a solvent and the drug (or its salt) particles are added. If the size of the drug (or its salt) particles is to be maintained, a solvent that does not dissolve the drug (or its salt) particles should be used to avoid changing the size characteristics of the particles. Alternatively, a solvent that dissolves both the polymer and the drug (or its salt) particles can be used. The solvent-carrier polymer-drug (or its salt) particle mixture (or the solvent-carrier particle-drug / drug salt solution) is then mixed to distribute the particles evenly (or the solution is thoroughly mixed), poured into a mold, and the solvent is allowed to evaporate.

[0245] System manufacturing / assembly: Attachment of elongated members to central elastomer For star-shaped gastroretention systems such as that shown in FIG. 1A, the elongated members, or "arms," ​​of the gastroretention system can be attached to the central elastomer in a number of ways. The central polymer can be cast or molded with short "star" arms, and a linker polymer can be used to attach the elongated members to the star arms of the central elastomer. Alternatively, the central elastomer can be molded in a mold from which the proximal ends of the elongated members protrude. The elastomer sets and cures, or otherwise hardens, into its desired shape with the portions of the elongated members extending into the body of the central elastomer. Alternatively, the central elastomer can be made with a cavity into which the elongated members can be rigidly inserted.

[0246] The present invention therefore includes a method of manufacturing a gastroretentive system, comprising: making at least three elongated members formed from a material comprising any drug-carrier polymer-excipient blend as disclosed herein; and attaching the elongated members to a central elastomer to form the gastroretentive system. The elongated members may include at least one segment having a release rate controlling polymer film. The elongated members of the gastroretentive system project radially from the central elastomer in a "hub and spoke" configuration. The preferred number of elongated members or "arms" is six. However, star-shaped systems having 3, 4, 5, 7, or 8 elongated members can also be used.

[0247] In some embodiments, elongate members or "arms" comprising any carrier polymer-drug formulation, including arms comprising segments having a release rate modifying polymer film, can be heat welded, solvent welded, or otherwise attached to a degradable matrix, a linking polymer, or other elements comprising a connecting polymer, which are then attached to the central elastomer. In some embodiments, the arms are attached directly to the central elastomer. The degradable matrix, linking polymer, or connecting polymer segments can be welded or otherwise attached to the central elastomer prior to attachment of the elongate members.

[0248] In some embodiments, an arm containing any drug-carrier polymer-excipient formulation as disclosed herein can be heat welded to a polycaprolactone segment, such as a short polycaprolactone "star" arm attached to a central elastomer. A linker segment can be welded to the short "star" arm prior to attachment of the drug-carrier polymer-excipient formulation arm. Heat welding of the drug-carrier polymer-excipient formulation arm to a MW 80,000 PCL segment at a temperature of 140-170°C, followed by cooling at 8°C for 24 hours, resulted in a stronger weld. Thus, in one embodiment, attaching an elongate member comprising any drug-carrier polymer-excipient blend as disclosed herein to a central elastomer to form a gastroretentive system may include heat welding the elongate member to another system component, such as an asterisk arm or other segment comprising at least about 90%, at least about 95%, or at least about 99% polycaprolactone (e.g., PCL of MW 80,000) at a temperature of about 140 to about 170° C., followed by cooling the welded member attached to the other system component at a temperature of about 2 to about 14° C., such as about 5 to about 10° C., or about 8° C., for about 12 to about 48 hours. The other system component may alternatively be a linker element.

[0249] System manufacturing / assembly Once the elongate members of the gastroretention system are attached to the central elastomer, the system can be folded into a compact configuration and placed into a capsule for storage, transport, and ultimate administration. The system can be folded in an automated mechanical process or by hand and placed into a capsule of appropriate size and material. Further details regarding the manufacture and assembly of the gastroretention system and the packaging of the gastroretention system into a capsule can be found in International Patent Applications WO2015 / 191920, WO2015 / 191925, WO2017 / 070612, WO2017 / 100367, and PCT / US2017 / 034856.

[0250] Carrier polymer-drug / release rate controlling film combinations A variety of carrier polymer-drug segment formulations can be used with any given release rate controlling film to provide the desired release characteristics from the film coated segments. Similarly, a variety of release rate controlling films can be used with any given carrier polymer-drug segment formulation. One useful combination of carrier polymer-drug / film includes a segment comprising about 15 to about 40% drug, about 3 to about 15% excipients selected from one or more of P407, silica, and vitamin E succinate, the remainder being polycaprolactone (PCL); and a release rate controlling film comprising about 75 to about 95% polycaprolactone, the remainder being copovidone porogen, the weight of the film being about 0.5 to about 2% of the weight of the underlying segment, and / or the thickness of the film being within the range of about 3 to about 10 microns. An exemplary combination is 27.5% drug, 6% excipients (P407, silica, vitamin E succinate), and 66.5% PCL; the film is 90% PCL, 10% copovidone porogen, with the film weight being approximately 1% of the weight of the underlying segment.

[0251] Another useful carrier polymer-drug / film combination includes a segment comprising about 30 to about 50% drug, about 10 to about 30% plasticizer, about 0 to about 10% excipients selected from one or more of P407, silica, and vitamin E succinate, the remainder being polycaprolactone (PCL); and a release rate modifying film comprising about 75 to about 95% polycaprolactone, the remainder comprising copovidone porogen, the weight of the film being about 0.5 to about 3% of the weight of the base segment, and / or the thickness of the film being in the range of about 3 to about 12 microns.

[0252] Methods of Treatment Using a Gastroretentive System The gastric retention system can be used to treat conditions that require administration of a drug or agent over an extended period of time. In a preferred embodiment, the gastric retention system is administered to a human. For long-term administration of a drug or agent that is taken for months, years, or indefinitely, administration of the gastric retention system on a regular basis, such as once a week or once every two weeks, can provide substantial benefits in patient compliance and convenience. Thus, the gastric retention system of the present invention can be administered once every three days, once every five days, once a week, once every ten days, or once every two weeks. The frequency of administration is timed to coincide with the designed gastric retention period of the administered gastric retention system, so that a new gastric retention system is administered at approximately the same time as the gastric retention system passes through the stomach after its retention period.

[0253] When a gastroretentive system is administered to a patient, the system provides sustained release of the agent or drug for the period of gastric retention. After the period of gastric retention, the system degrades and passes through the stomach. Thus, for a system with a gastric retention period of one week, the patient would swallow (or be administered to the stomach via other methods) a new system every week. Thus, in one embodiment, a method of treating a patient with an agent or drug in a system using a gastroretentive system of the present invention having a gastric retention period of a number of days D (where D days is the number of days of the gastric retention period) over a total desired treatment period T-total (where T-total is the number of days of the desired length of treatment) comprises introducing a new gastroretentive system into the patient's stomach by oral administration or other methods every D days for the total desired treatment period. The number of gastroretentive systems administered to the patient is (T-total) divided by (D days). For example, if it is desired to treat a patient for one year (T-total=365 days) and the gastric retention period of the system is 7 days (D-day=7 days), then a new system would be administered once every 7 days, resulting in approximately 52 gastric retention systems being administered to the patient over the 365 days.

[0254] Alternatively, the patient can swallow (or be administered to the stomach via other methods) a new gastroretentive system at the end of the effective release period of the gastroretentive system. An "effective release period" or "effective release time" is the period during which the gastroretentive system releases an effective amount of the drug contained in the system. Thus, in one embodiment, a method of treating a patient with a drug in a system using a gastroretentive system of the present invention having an effective release period of a number of days E (where E days is the number of days of the effective release period) over a total desired treatment period T-total (where T-total is the number of days of the desired length of treatment) comprises introducing a new gastroretentive system into the patient's stomach by oral administration or other methods every E days over the total desired treatment period. The number of gastroretentive systems administered to the patient is (T-total) divided by (E days). For example, if it is desired to treat a patient for one year (T-total=365 days) and the effective release period of the system is 7 days (E-day=7 days), then a new system would be administered once every 7 days, resulting in approximately 52 gastroretentive systems being administered to the patient over the 365 days.

[0255] Pharmacokinetics of transgastric delivery of gastroretentive systems The gastroretentive system of the present invention has a significantly improved bioavailability, compared to that of conventional oral formulations of a drug, after administration of the system, in an AUC inf The system also provides for the maintenance of approximately constant or substantially constant plasma levels of the drug.

[0256] Relative bioavailability F of two different formulations, Formulation A and Formulation B REL is defined as follows: F REL =100×(AUC A ×Dose B ) / (AUC B ×Dose A ) (In the formula, AUC A is the area under the curve for Formulation A, AUC Bis the area under the curve for Formulation B, and Dose A is the dose of formulation A used, and Dose B is the dose of formulation B used). The area under the curve, AUC, for a plot of drug plasma concentration versus time is usually measured at the same time (t) after administration of each formulation to provide the relative bioavailability of the formulations at the same time point. AUC inf refers to the AUC measured or calculated over an "infinite" period of time, i.e., the period beginning with the first dose and ending when the plasma level of the drug has declined to negligible amounts.

[0257] In one embodiment, the substantially constant plasma level of a drug provided by the gastroretentive system of the present invention is equal to or greater than the trough plasma level of the drug when administered daily in a conventional oral formulation (i.e., the C of the drug administered daily in an immediate release formulation). min ) to below the peak plasma level of the drug when administered daily in a conventional oral formulation (i.e., the C max In some embodiments, the substantially constant plasma level of the drug provided by the gastroretentive system of the present invention can be in the range of up to the peak plasma level of the drug when administered daily in a conventional oral formulation (i.e., the C of the drug administered daily in an immediate release formulation). max The substantially constant plasma level of the drug provided by the gastroretentive system of the present invention can be about 50 to about 90% of the average plasma level of the drug when administered daily in a conventional oral formulation (i.e., the C of the drug administered daily in an immediate release formulation). ave The substantially constant plasma level of the drug provided by the gastroretentive system of the present invention can be about 75 to about 125% of the trough level of the plasma level of the drug when administered daily in a conventional oral formulation (i.e., the C of the drug administered daily in an immediate release formulation). min ) or more, for example, C min The amount of the ion exchange resin may be about 100 to about 150% of the amount of the ion exchange resin.

[0258] The gastroretentive systems of the present invention may provide a bioavailability of drug released from the system that is at least about 50%, at least about 60%, at least about 70%, or at least about 80% of the bioavailability provided by an immediate release form containing the same amount of drug. As noted above, bioavailability is measured by the area under the plasma concentration-time curve (AUCinf).

[0259] Dissolution profile, bioavailability and pharmacokinetics of gastroretentive systems Dissolution: The gastroretention systems described herein provide a steady release of the drug or its pharma- ceutically acceptable salt over an extended period of time. The systems are designed to release a therapeutically effective amount of the drug or its salt over the period of residence in the stomach. The release of the drug (or its salt) can be measured in vitro or in vivo to establish the dissolution profile (dissolution profile, release rate) of the drug (or its salt) from a given retention system in a particular environment. The dissolution profile can be specified as the percentage of the original amount of drug (or its salt) present in the system that dissolves from the system over a given period of time.

[0260] Thus, in some embodiments, the drug (or salt thereof) contained in the gastroretentive system may have a dissolution profile in a given environment of 10-20% release between 0 and 24 hours, i.e., over a 24 hour period following initial introduction of the gastroretentive system into the environment of interest, 10-20% of the starting drug (or salt thereof) contained in the system dissolves from the system.

[0261] The environment of interest can be 1) the patient's stomach (ie, an in vivo environment), or 2) simulated gastric fluids (ie, an in vitro environment).

[0262] The gastroretentive system of the present invention has a significantly improved bioavailability, compared to that of conventional oral formulations of a drug (or salt thereof), after administration of the system, in an AUC infThe system provides high bioavailability of the drug (or a salt thereof) as measured by: The system also provides for the maintenance of a substantially constant plasma level of the drug (or a salt thereof).

[0263] Parameters of interest for release include the linearity of release over the residence time of the gastroretention system, the standard deviation of release over the residence time (which relates to the linearity of release, with a standard deviation of 0 indicating that the release is linear over the entire residence time), the release over the first 6 hours of residence (i.e., burst release upon initial administration), and the total release of drug (or its salt) over the residence time. A preferred residence time is 7 days, although other periods, such as 2, 3, 4, 5, 6, 8, 9, 10, 11, 12, 13, or 14 days, may also be useful.

[0264] The linearity of drug (or its salt) release over the residence time refers to the amount released during each 24-hour period of residence. For a 7-day residence time, it is desirable that the approximate amount of drug (or its salt) is released each day, i.e., the linearity of drug (or its salt) release is maximized. This minimizes the standard deviation of drug or drug salt release per day over the residence time. In some embodiments, the intragastric release system has a variation (or standard deviation) of drug (or its salt) release per day over the residence time of less than about 100%, less than about 90%, less than about 80%, less than about 70%, less than about 60%, less than about 50%, less than about 40%, less than about 30%, less than about 25%, less than about 20%, less than about 15%, less than about 10%, or less than about 5%. In some embodiments, the residence time can be about 3 days, about 7 days, about 10 days, or about 2 weeks.

[0265] Minimizing burst release, i.e., release over the initial residence period (e.g., 6 hours, 12 hours, or 24 hours after administration of the gastric retention system), is desirable to maintain a predictable and stable release profile. If T is the total drug (or salt thereof) released over the residence period (in units of mass) and D is the number of days in the residence period, then a perfectly linear release means that approximately T / D mass of drug (or salt thereof) is released per day. If the period over which burst release is measured is the first 6 hours, then a linear release profile would result in 0.25×T / D mass of drug (or salt thereof) being released during the first 6 hours. In terms of percentage of the total amount of drug (or its salt) released over a D-day dwell period, the linear release is about 100 / D% of the drug (or its salt) per day, and 25 / D% over the first 6 hours (note that 100% in this context refers to the total amount of drug (or its salt) released, regardless of how much drug (or its salt) is contained in the initial formulation). Thus, for a 7-day dwell period, the linear release over the first 6 hours is about 3.6% of the total amount of drug (or its salt) released over the 7-day period.

[0266] In some embodiments, during the first 6 hours of residence after administration, the gastric retention system releases a 2×T / D of the total mass T of the drug (or salt thereof) released over a residence period of D days, or about 0.2 to about 1.75×T / D of the total mass T of the drug (or salt thereof) released over a residence period of D days, or about 0.2 to about 1.5×T / D of the total mass T of the drug (or salt thereof) released over a residence period of D days, or about 0.2 to about 1.2 .... about 0.2 to about 1 × T / D of the total mass T of the drug (or salt thereof) released per day, or about 0.2 to about 0.8 × T / D of the total mass T of the drug (or salt thereof) released over a residence period of D days, or about 0.2 to about 0.75 × T / D, or about 0.2 to about 0.7 × T / D, or about 0.2 to about 0.6 × T / D, or about 0.2 to about 0.5 × T / D, or about 0.2 to about 0.4 × T / D, or about 0.2 to about 0.3 × T / D, or about 0.25 to about 2 × T / D, or about 0.3 to about 2 × T / D, or about 0.4 to about 2 × T / D, or about 0.5 to about 2 × T / D, or is about 0.6 to about 2×T / D, or about 0.7 to about 2×T / D, or about 0.25 to about 1.5×T / D, or about 0.3 to about 1.5×T / D, or about 0.4 to about 1.5×T / D, or about 0.5 to about 1.5×T / D, or about 0.6 to about 1.5×T / D, or about 0.7 to about 1.5×T / D, or about 0.25 to about 1.25×T / D, or about 0.3 to about 1.25×T / D, or about 0.4 to about 1.25×T / D, or about 0.5 to about 1.25×T / D, or about 0.6 to about 1.25×T / D, or about 0.7 to about 1.25×T / D, or about 0.25 to about 1×T / D, or about 0.3 to about 1×T / D, or about 0.4 to about 1×T / D, or about 0.5 to about 1×T / D, or about 0.6 to about 1×T / D, or about 0.7 to about 1×T / D, or about 0.25×T / D, or about 0.25 to about 0.8×T / D, or about 0.3 to about 0.8×T / D, or about 0.4 to about 0.8×T / D, or about 0.5 to about 0.8×T / D, or about 0.6 to about 0.8×T / D, or about 0.7 to about 0.8×T / D, or about 0.8×T / D, about 1×T / D, about 1.25×T / D, about 1.5×T / D, or about 2×T / D.

[0267] In some embodiments of the gastric retention system, during the first 6 hours of retention after administration, the gastric retention system releases about 2 to about 10%, or about 3 to about 10%, or about 4 to about 10%, or about 5 to about 10%, or about 6 to about 10%, or about 7 to about 10%, or about 8 to about 10%, or about 9 to about 10%, or about 2 to about 9%, or about 2 to about 8%, or about 2 to about 7%, or about 2 to about 6%, or about 2 to about 5%, or about 2 to about 4%, or about 2 to about 3% of the total mass of drug (or salt thereof) released over the retention period.

[0268] In some embodiments of a gastric retention system where the gastric retention system has a retention period of about 7 days, during the first 6 hours of retention after administration, the gastric retention system releases about 2 to about 10%, or about 3 to about 10%, or about 4 to about 10%, or about 5 to about 10%, or about 6 to about 10%, or about 7 to about 10%, or about 8 to about 10%, or about 9 to about 10%, or about 2 to about 9%, or about 2 to about 8%, or about 2 to about 7%, or about 2 to about 6%, or about 2 to about 5%, or about 2 to about 4%, or about 2 to about 3% of the total mass of the drug (or salt thereof) released over the 7 day retention period.

[0269] In some embodiments, during the first 24 hours of residence after administration, the gastric retention system releases about 10 to about 35%, or about 10 to about 30%, or about 10 to about 25%, or about 10 to about 20%, or about 10 to about 15%, or about 15 to about 35%, or about 15 to about 35%, or about 15 to about 30%, or about 20 to about 30%, or about 25 to about 35%, or about 25 to about 30%, or about 30 to about 35% of the total mass of drug (or salt thereof) released over the residence period.

[0270] In some embodiments where the gastric retention system has a retention period of about 7 days, during the first 24 hours of retention after administration, the gastric retention system releases about 10 to about 35%, or about 10 to about 30%, or about 10 to about 25%, or about 10 to about 20%, or about 10 to about 15%, or about 15 to about 35%, or about 15 to about 35%, or about 15 to about 30%, or about 20 to about 30%, or about 25 to about 35%, or about 25 to about 30%, or about 30 to about 35% of the total mass of drug (or salt thereof) released over the 7 day retention period.

[0271] Reduced effect of pH on release rate The gastroretention systems, and segments of gastroretention systems described herein that contain a release rate modifying polymer film, have reduced variability in the release of a drug or a pharma- ceutically acceptable salt thereof at different pH values ​​compared to the release from a gastroretention system or segment of a gastroretention system of similar composition but lacking the release rate modifying polymer film.

[0272] The solubility of a certain drug or its salt may be different at different pH values. For example, the solubility of risperidone is significantly higher at the more acidic end of the gastric pH range (e.g., pH 1.5) than at the less acidic end of the gastric pH range (e.g., pH 4.8). Risperidone therefore has a faster dissolution rate at lower pH and tends to be released faster from gastric retention systems at lower pH. Because gastric pH may vary over time due to a number of factors, reducing the variation in the release rate of a given drug or its salt at different pH values ​​helps provide a linear dissolution profile over a given period of time.

[0273] The pH-dependent release rate ratio RR for a given drug or salt thereof at a given first pH value and a given second pH value pH can be expressed as: RR pH = (release rate at first pH) / (release rate at second pH) If the release rates at the first and second pH are the same, then RRpH If the release rate at the first pH is higher than the release rate at the second pH, then RR pH is greater than 1 and the release rate at the first pH is lower than the release rate at the second pH, then RR pH is smaller than 1. In order to reduce the variability in release at different pH values, R is set as close to 1 as possible. pH A value of is preferred.

[0274] pH-dependent release rate ratio factor (RRF) pH RRF can be defined as the coefficient of difference between the release rates at two pH values. pH RR pH If is greater than 1, RR pH is the same as RR pH If is less than 1, RR pH is the reciprocal of.

[0275] The release rate ratio of the gastroretentive system can be measured at any two different pH values ​​between about 1 and about 6, and generally at pH values ​​that are at least about 1 pH unit apart, for example, at least about 2 pH units apart, at least about 3 pH units apart, or at least about 4 pH units apart. Two useful values ​​are a first pH of about 1.5 and a second pH of about 4.8, which represent the typical low and high pH extremes of gastric pH. The release rate ratio can be measured in simulated gastric fluid adjusted to the desired pH, such as FaSSGF, including FaSSGF at about pH 1 to pH 2, for example, pH 1.5. The release rate ratio can also be measured in a buffer system of the desired pH, such as ammonium acetate (e.g., about pH 4.8). The release rate ratio can be calculated by measuring the release from the gastroretentive system at two different pH values ​​over a period of time, such as about 1 hour, about 2 hours, about 3 hours, about 6 hours, about 12 hours, about 24 hours, about 48 hours, about 72 hours, about 96 hours, about 5 days, about 6 days, about 7 days, about 8 days, about 9 days, about 10 days, or about 2 weeks.

[0276] The gastroretentive systems and segments of gastroretentive systems described herein, including release rate modifying films, may have a release rate of greater than about 1, greater than about 2, greater than about 3, greater than about 4, greater than about 5, greater than about 6, greater than about 10, greater than about 20, or from about 1 to about 20, from about 1 to about 10, from about 1 to about 6, from about 1 to about 4, from about 1 to about 3, from about 1 to about 2.5, from about 1 to about 2.2, from about 1 to about 2, from about 1 to about 1.9, from about 1 to about 1.8, from about 1 to about 1 the first pH is 1.5 and the second pH is 4.8, or alternatively the first pH and the second pH are both between about pH 1 and about pH 6 and are at least about 3 pH units apart; pH may have:

[0277] The gastric retention systems and segments of the gastric retention systems described herein, including the release rate controlling film, may be from about 0.05 to about 20, from about 0.1 to about 10, from about 0.2 to about 5, from about 0.25 to about 4, from about 0.3 to about 3, from 0.4 to about 2.5, from about 0.5 to about 2, from about 0.6 to about 2, from about 0.7 to about 2, from about 0.8 to about 2, from about 0.9 to about 2, from about 1 to about 20, from about 1 to about 10, from about 1 to about the first pH is about 1.5 and the second pH is about 4.8, or alternatively the first pH and the second pH are both about pH 1 to about pH 6 and are at least about 3 pH units apart; pHThe gastroretentive systems and segments of the gastroretentive systems described herein that include a release rate modifying film may have a pH dependent release rate ratio RR of about 1 to about 2.5, about 1 to about 2.2, about 1 to about 2, about 1 to about 1.9, about 1 to about 1.8, about 1 to about 1.7, about 1 to about 1.6, about 1 to about 1.5, about 1 to about 1.4, about 1 to about 1.3, about 1 to about 1.2, or about 1 to about 1.1; or greater than about 1, greater than about 1.5, greater than about 2, greater than about 3, greater than about 4, greater than about 5, greater than about 10, or greater than about 20, wherein the first pH is 1.5 and the second pH is 4.8, or alternatively the first pH and the second pH are both between about pH 1 and about pH 6 and are separated by at least about 3 pH units. pH The gastroretentive systems and segments of the gastroretentive systems described herein that include a release rate modifying film may have a pH dependent release rate ratio RR of about 0.05 to about 1, about 0.1 to about 1, about 0.25 to about 1, about 0.3 to about 1, about 0.4 to about 1, about 0.5 to about 1, about 0.6 to about 1, about 0.7 to about 1, about 0.8 to about 1, or about 0.9 to about 1; or less than about 0.9, less than about 0.8, less than about 0.7, less than about 0.6, less than about 0.5, less than about 0.4, less than about 0.3, less than about 0.2, less than about 0.1, or less than about 0.05, where the first pH is 1.5 and the second pH is 4.8, or alternatively the first pH and the second pH are both between about pH 1 and about pH 6 and are separated by at least about 3 pH units. pH may have:

[0278] The pH-dependent release rate ratio of a drug and its pharma- ceutically acceptable salt from a gastroretentive system tends to deviate from the ideal value of 1 when there is a significant difference in the solubility of the drug or its salt at different pH values. The difference in solubility of a drug or its pharma- ceutically acceptable salt at two different pH values ​​used in the gastroretentive systems described herein may be approximately a factor of about 1.25 or more, about 1.5 or more, about 3 or more, about 4 or more, about 5 or more, about 10 or more, about 20 or more, about 30 or more, about 40 or more, about 50 or more, about 60 or more, about 70 or more, about 80 or more, about 90 or more, about 10 ... or by a factor of about 2 to about 100, about 2 to about 75, about 2 to about 50, about 2 to about 20, about 2 to about 10, about 5 to about 100, about 5 to about 75, about 5 to about 50, about 5 to about 20, or about 5 to about 10, where the two different pH values ​​are about pH 1 to about pH 6, e.g., about pH 1.5 and about pH 4.8, or where the first pH and the second pH are separated by at least about 3 pH units. Generally, the greater the difference in the solubility of the drug or pharma- ceutically acceptable salt thereof at the two different pH values, the more useful the release rate modifying polymer film is for reducing differences in pH-dependent release rates from a gastroretentive system. For example, when the difference in solubility of a drug or a pharma- ceutically acceptable salt thereof at two different pH values ​​between about pH 1 and about pH 6 (e.g., about pH 1.5 and about pH 4.8) is a factor of about 5 or greater, or when the difference in solubility of a drug or a pharma- ceutically acceptable salt thereof at a first pH value and a second pH value whose values ​​are at least about 3 pH units apart is a factor of about 5 or greater (e.g., a drug having a solubility of 12 mg / ml at pH 1.5 and a solubility of 2 mg / ml at pH 4.8 has a solubility difference at two different pH values ​​of a factor of 6), release rate controlling polymeric films are highly useful in reducing differences in pH-dependent release rates from gastroretentive systems.However, the release rate modifying polymer film can be used to shift the pH-dependent release rate ratio closer to 1 when there is some difference in the solubility of the drug or its pharma- ceutically acceptable salt at two different pH values, and the release rate modifying polymer film can be used for other purposes disclosed herein, even when there is no significant difference in the solubility of the drug at different pH values.

[0279] The release rate modifying polymer films used for the gastroretentive systems and segments of the gastroretentive systems described herein reduce the pH dependent release rate ratio factor RRF of the gastroretentive system by about 10%, about 25%, about 33%, about 50%, about 75%, or a factor of about 1.25, about 1.5, about 2, or about 3, compared to the deviation in the same gastroretentive system lacking the release rate modifying film. pH The deviation from the ideal value of 1 in pH-dependent release rate ratio factor RRF pH The deviation of (RRF pH −1), which is also known as the pH-dependent release rate ratio factor RRF pH For example, if a first gastroretentive system lacking a release rate modifying polymer film has a release rate of 9 arbitrary units at pH 1.5 and 3 arbitrary units at pH 4.8, its pH-dependent release rate ratio factor RRF pH is (9 / 3)=3, which deviates by 2 units from the ideal value of 1 (equal release rates at the two pH values). If a second gastroretentive system has the same components as the first gastroretentive system, but also includes a release rate modifying polymer film, and has a release rate of 4 arbitrary units at pH 1.5 and 2 arbitrary units at pH 4.8, then its pH-dependent release rate ratio factor RRF pH is (4 / 2)=2, which deviates by 1 unit from the ideal value of 1. Thus, since the deviation from the ideal value for the system lacking the film is 2 units and the deviation from the ideal value for the system with the film is 1 unit, the release rate modifying polymer coating deviates the pH dependent release rate ratio factor RRF from the ideal value by a factor of 2.pH This reduced deviations.

[0280] Kits and manufactured products A kit for treating a patient using the gastroretentive system of the present invention is also provided herein. The kit may, for example, contain a sufficient number of gastroretentive systems for regular administration to a patient over a desired total treatment period. If the number of days of the total treatment period is (T-total) and the gastroretentive system has a residence time of (D days), the kit contains a number of gastroretentive systems equal to ((T-total) / (D days)) (rounded to an integer) for administration every D days. Alternatively, if the number of days of the total treatment period is (T-total) and the gastroretentive system has an effective release period of (E days), the kit contains a number of gastroretentive systems equal to ((T-total) / (E days)) (rounded to an integer) for administration every E days. The kit may, for example, contain a number of gastroretention systems in a container (which may be a capsule) and may optionally also contain printed or computer readable instructions regarding the dosing regimen, duration of treatment, or other information related to the use of the gastroretention system and / or the agent or drug contained therein. For example, if the total treatment period prescribed for a patient is one year and the gastroretention system has a one week residence time or one week effective release period, the kit may contain 52 capsules, each containing one gastroretention system, with instructions to swallow one capsule once a week on the same day of the week (e.g., every Saturday).

[0281] Also included in the invention is an article of manufacture that includes a sufficient number of gastroretentive systems for regular administration to a patient over the total desired treatment period, and optionally includes instructions on the administration regimen, treatment period, or other information related to the use of the gastroretentive systems and / or the drug or medication contained therein. The article of manufacture may be supplied in suitable packaging, such as a dispenser, tray, or other packaging that assists the patient in administering the gastroretentive systems at prescribed intervals.

[0282] Exemplary embodiments The invention is further described by the following embodiments, the features of each embodiment may be combined with any of the other embodiments where appropriate and practical.

[0283] Embodiment 1. A segment of a gastroretentive system, the segment comprising: a carrier polymer; a drug or salt thereof; and a release rate controlling polymer film configured to control the release rate of the drug or salt thereof, wherein over a 7 day incubation of the segment in simulated gastric fluid, the amount of drug or salt thereof released from the segment during the 5th day is at least about 40% of the amount of drug or salt thereof released during the 2nd day; and at least about 7% of the total amount of drug or salt thereof in the segment is released on the 2nd day and at least about 7% of the total amount of drug or salt thereof is released on the 5th day.

[0284] Embodiment 2. A segment of a gastric retention system, the segment comprising a carrier polymer; a drug or salt thereof; and a release rate controlling polymer film configured to control the release rate of the drug or salt thereof, wherein over a 7 day incubation of the segment in simulated gastric fluid, the amount of drug or salt thereof released from the segment during the 7th day is at least about 20% of the amount of drug or salt thereof released during the 1st day; and at least about 4% of the total amount of drug or salt thereof in the segment is released on the 1st day and at least about 4% of the total amount of drug or salt thereof is released on the 7th day.

[0285] Embodiment 3. A segment of a gastroretentive system, the segment comprising a carrier polymer, a drug or its salt; and a release rate controlling polymer film configured to control the release rate of the drug or its salt, wherein the release rate controlling polymer film is configured such that the release of the drug or its salt from the segment in 40% ethanol / 60% simulated gastric fluid over 1 hour is not more than about 40% higher than the release of the drug or its salt from a comparable segment in 100% simulated gastric fluid over 1 hour.

[0286] Embodiment 4. A segment of a gastroretentive system, the segment comprising a carrier polymer, a drug or its salt; and a release rate controlling polymer film configured to control the release rate of the drug or its salt, wherein the release rate controlling polymer film is configured such that the release of the drug or its salt from the segment in 40% ethanol / 60% simulated gastric fluid over 1 hour is at least about 40% lower than the release of the drug or its salt from a second segment in 40% ethanol / 60% simulated gastric fluid over 1 hour, the second segment comprising the same combination of carrier polymer and drug or its salt but lacking the release rate controlling polymer film.

[0287] Embodiment 5. A segment of a gastroretentive system, the segment comprising a carrier polymer, a drug or salt thereof; and a release rate controlling polymer film configured to control the release rate of the drug or salt thereof, wherein the release rate controlling polymer film is configured such that the release of the drug or salt thereof from the segment in simulated gastric fluid over an initial 6 hour period is at least about 40% lower than the release of the drug or salt thereof from a second segment in simulated gastric fluid over an initial 6 hour period, the second segment comprising the same combination of carrier polymer and drug or salt thereof but lacking the release rate controlling polymer film; and the release of the drug or salt thereof from the segment in simulated gastric fluid over a 7 day period is at least about 60% of the total amount of the drug or salt thereof originally present in the segment.

[0288] Embodiment 6. The segment of embodiment 5, wherein release of the agent or salt thereof from the segment in simulated gastric fluid over a period of 7 days is a release of at least about 70% of the total amount of the agent or salt thereof originally present in the segment.

[0289] Embodiment 7. The segment of embodiment 5, wherein release of the agent or salt thereof from the segment in simulated gastric fluid over a period of 7 days is at least about 80% release of the total amount of the agent or salt thereof originally present in the segment.

[0290] Embodiment 8. A segment of a gastroretentive system, the segment comprising a carrier polymer; a drug or a salt thereof; and a release rate modifying polymer film, wherein a best-fit linear regression model of the release rate of the drug or a salt thereof from the segment in simulated gastric fluid has a coefficient of determination R of at least about 0.8 over a period of an initial 7 days. 2 and wherein the polymer film is configured to control the release rate of the drug or a salt thereof such that the polymer film has a release rate of about 40 to about 60% of the drug or a salt thereof in about 40 to about 60% of the time over a 7 day period.

[0291] Embodiment 9. The best-fit linear regression model of the release rate of the drug or its salt from the segments in simulated gastric fluid has a coefficient of determination R of at least about 0.9 over the first 7 day period. 2 and the segment releases about 40 to about 60% of the drug or salt thereof in about 40 to about 60% of the time over a 7 day period.

[0292] Embodiment 10. A segment of a gastric retention system comprising: a carrier polymer; a drug or salt thereof; and a release rate controlling polymer film, wherein the polymer film is configured to control the release rate of the drug or salt thereof from the segment over a 7 day period in simulated gastric fluid such that the release rate from the segment over any one day of the 7 day period varies by no more than about 25% from the average total daily release from the segment over the 7 day period.

[0293] Embodiment 11. A segment of a gastroretentive system described in any one of embodiments 1 to 10, wherein the release rate controlling polymer film comprises one or more polyester materials.

[0294] Embodiment 12. The polymer film is -R 1 -OC(=O)-(where R 1 is C1~C 12The segment of embodiment 11, comprising a polyester having repeat units of the form: selected from the group consisting of an alkylene group, an ether containing from 2 to 12 carbon atoms, and a polyether containing from 3 to 12 carbon atoms.

[0295] Embodiment 13. The segment of embodiment 11, wherein the polymer film comprises polycaprolactone or polydioxanone.

[0296] Embodiment 14. The segment of embodiment 11, wherein the polymer film comprises polycaprolactone having an Mn of about 10,000 to about 150,000.

[0297] Embodiment 15. The segment of embodiment 11, wherein the polymer film comprises polycaprolactone having an Mn of about 80,000 to about 110,000.

[0298] Embodiment 16 The segment of embodiment 11, wherein the polymer film comprises polycaprolactone having about 90,000 Mn.

[0299] Embodiment 17. The segment of embodiment 11, wherein the polymeric film comprises polycaprolactone having an intrinsic viscosity of about 1.5 to about 2.1 dL / g.

[0300] Embodiment 18. The segment of any one of embodiments 1 to 17, wherein the polymer film further comprises a porogen.

[0301] Embodiment 19. The segment of any one of embodiments 1 to 17, wherein the porogen comprises a water soluble polymer, a water soluble small molecule, an inorganic salt, or an organic salt.

[0302] Embodiment 20. The segment of any one of embodiments 1 to 17, wherein the porogen comprises about 1 to about 30% by weight of the film.

[0303] Embodiment 21. The porogen is selected from the group consisting of alkali metal salts, sodium chloride, sodium bromide, potassium chloride, potassium sulfate, potassium phosphate, sodium benzoate, sodium acetate, sodium citrate, potassium nitrate, alkaline earth metal salts, calcium chloride, calcium nitrate, transition metal salts, ferric chloride, ferrous sulfate, zinc sulfate, cupric chloride, saccharides, sugars such as sucrose, glucose, fructose, mannose, galactose, aldohexose, altrose, talose, lactose, cellulose, monosaccharides, disaccharides, water soluble polysaccharides, sorbitol, mannitol, organic fatty and aromatic oils, diols and polyols, polyhydric alcohols, poly(alkylene glycols), polyglycols, alkylene glycols, poly(a,m) alkylene diol esters, alkylene glycols, polyvinyl alcohols, polyvinylpyrrolidone, water soluble polymers. 18. The segment of any one of embodiments 1 to 17, wherein the material is selected from the group consisting of poloxamer, hypromellose (HPMC), Corifol RH40, polyvinyl caprolactam, polyvinyl acetate (PVAc), polyethylene glycol (PEG), Soluplus (copolymer of polyvinyl caprolactam, polyvinyl acetate, and polyethylene glycol), copovidone, Eudragit (E,RS,RL), poly(methyl vinyl ether-alt-maleic anhydride), polyoxyethylene alkyl ether, polysorbate, polyoxyethylene stearate, polydextrose, polyacrylic acid, alginate, sodium starch glycolate, cross-linked polyacrylic acid (Carbopol), cross-linked PVP (Crospovidone), cross-linked cellulose (Croscarmellose), calcium silicate, xanthan gum, and gellan gum.

[0304] Embodiment 22. The segment of any one of embodiments 1 to 17, wherein the porogen is selected from the group consisting of povidone, copovidone, and polyoxyl castor oil.

[0305] Embodiment 23. A segment of a gastroretentive system, the segment comprising: a carrier polymer; a drug or a salt thereof; and a release rate controlling polymer film, the polymer film comprising one or more polyester materials.

[0306] Embodiment 24. The polymer film is -R 1 -OC(=O)-(where R 1 is C1~C 12 24. The segment of embodiment 23, comprising a polyester having repeat units of the form: selected from the group consisting of an alkylene group, an ether containing 2 to 12 carbon atoms, and a polyether containing 3 to 12 carbon atoms.

[0307] Embodiment 25. The segment of embodiment 23, wherein the polymer film comprises polycaprolactone or polydioxanone.

[0308] Embodiment 26. The segment of embodiment 23, wherein the polymer film comprises polycaprolactone having an Mn of about 10,000 to about 150,000.

[0309] Embodiment 27. The segment of embodiment 23, wherein the polymer film comprises polycaprolactone having an Mn of about 80,000 to about 110,000.

[0310] Embodiment 28. The segment of embodiment 23, wherein the polymer film comprises polycaprolactone having about 90,000 Mn.

[0311] Embodiment 29. The segment of embodiment 23, wherein the polymeric film comprises polycaprolactone having an intrinsic viscosity of about 1.5 to about 2.1 dL / g.

[0312] Embodiment 30. A segment of a gastroretentive system, the segment comprising a carrier polymer; a drug or a salt thereof; and a release rate controlling polymer film, the polymer film comprising a material selected from the group consisting of polycaprolactone, cellulose acetate, and ethylcellulose.

[0313] Embodiment 31. A segment of a gastroretentive system, the segment comprising a carrier polymer; a drug or a salt thereof; and a release rate controlling polymer film, the polymer film constituting about 0.1 to about 10% of the total weight of the segment.

[0314] Embodiment 32. The segment of embodiment 31, wherein the polymeric film comprises about 0.1 to about 5% of the total weight of the segment.

[0315] Embodiment 33. The segment of embodiment 31, wherein the polymeric film comprises about 0.5 to about 5% of the total weight of the segment.

[0316] Embodiment 34. The segment of embodiment 31, wherein the polymeric film comprises about 0.5 to about 2% of the total weight of the segment.

[0317] Embodiment 35. The segment of embodiment 31, wherein the polymeric film comprises about 1 to about 2% of the total weight of the segment.

[0318] Embodiment 36. A segment of a gastroretentive system, the segment comprising a carrier polymer; a drug or a salt thereof; and a release rate controlling polymer film, the polymer film having a thickness of about 1 to about 20 microns.

[0319] Embodiment 37. The segment of embodiment 36, wherein the polymeric film has a thickness of about 5 to about 15 microns.

[0320] Embodiment 38. The polymer film is -R 1 -OC(=O)-(where R 1 is C1~C 12 38. The segment of any one of embodiments 31 to 37, comprising a polyester having a repeat unit of the form: selected from the group consisting of an alkylene group, an ether containing 2 to 12 carbon atoms, and a polyether containing 3 to 12 carbon atoms.

[0321] Embodiment 39. The segment of any one of embodiments 31 to 37, wherein the polymer film comprises polycaprolactone or polydioxanone.

[0322] Embodiment 40. The segment of any one of embodiments 31 to 37, wherein the polymer film comprises polycaprolactone having an Mn of about 10,000 to about 150,000.

[0323] Embodiment 41. The segment of any one of embodiments 31 to 37, wherein the polymer film comprises polycaprolactone having an Mn of about 80,000 to about 110,000.

[0324] Embodiment 42. The segment of any one of embodiments 31 to 37, wherein the polymer film comprises polycaprolactone having about 90,000 Mn.

[0325] Embodiment 43. The segment of any one of embodiments 31 to 37, wherein the polymeric film comprises polycaprolactone having an intrinsic viscosity of about 1.5 to about 2.1 dL / g.

[0326] Embodiment 44. A segment of a gastroretentive system, the segment comprising a carrier polymer; a drug or a salt thereof; and a release rate controlling polymer film, the polymer film further comprising a porogen.

[0327] Embodiment 45 The segment of embodiment 44, wherein the porogen comprises a water soluble polymer, a water soluble small molecule, an inorganic salt, or an organic salt.

[0328] Embodiment 46. The segment of embodiment 44 or embodiment 45, wherein the porogen comprises about 1% to about 30% by weight of the film.

[0329] Embodiment 47. The porogen is selected from the group consisting of alkali metal salts, sodium chloride, sodium bromide, potassium chloride, potassium sulfate, potassium phosphate, sodium benzoate, sodium acetate, sodium citrate, potassium nitrate, alkaline earth metal salts, calcium chloride, calcium nitrate, transition metal salts, ferric chloride, ferrous sulfate, zinc sulfate, cupric chloride, saccharides, sugars such as sucrose, glucose, fructose, mannose, galactose, aldohexose, altrose, talose, lactose, cellulose, monosaccharides, disaccharides, water-soluble polysaccharides, sorbitol, mannitol, organic fatty and aromatic oils, diols and polyols, polyhydric alcohols, poly(alkylene glycols), polyglycols, alkylene glycols, poly(a,m) alkylene diol esters, alkylene glycols, polyvinyl alcohols, polyvinylpyrrolidone, water-soluble polymers. 47. The segment of any one of embodiments 44-46, wherein the material is selected from the group consisting of poloxamer, hypromellose (HPMC), Corifol RH40, polyvinylcaprolactam, polyvinylacetate (PVAc), polyethylene glycol (PEG), Soluplus (copolymer of polyvinylcaprolactam, polyvinylacetate, and polyethylene glycol), copovidone, Eudragit (E,RS,RL), poly(methylvinylether-alt-maleic anhydride), polyoxyethylene alkyl ether, polysorbate, polyoxyethylene stearate, polydextrose, polyacrylic acid, alginate, sodium starch glycolate, cross-linked polyacrylic acid (Carbopol), cross-linked PVP (Crospovidone), cross-linked cellulose (Croscarmellose), calcium silicate, xanthan gum, and gellan gum.

[0330] Embodiment 48. The segment of any one of embodiments 44 to 46, wherein the porogen is selected from the group consisting of povidone, copovidone, and polyoxyl castor oil.

[0331] Embodiment 49. The segment of any one of embodiments 44 to 48, wherein the polymeric film further comprises a plasticizer.

[0332] Embodiment 50. The segment of embodiment 49, wherein the plasticizer comprises about 1-40% by weight of the film.

[0333] Embodiment 51. The segment of embodiment 49 or embodiment 50, wherein the plasticizer is selected from the group consisting of phthalates, phosphates, citrates, tartrates, adipates, sebacates, sulfonamides, succinates, glycolates, glycerolates, benzoates, myristates, phenyl halides, triacetin, triethyl citrate, PEG, and poloxamers.

[0334] Embodiment 52. The segment of embodiment 49 or embodiment 50, wherein the plasticizer is selected from the group consisting of triethyl citrate and triacetin.

[0335] Embodiment 53. The polymer film is -R 1 -OC(=O)-(where R 1 is C1~C 12 53. The segment of any one of embodiments 44 to 52, comprising a polyester having a repeat unit of the form: selected from the group consisting of an alkylene group, an ether containing 2 to 12 carbon atoms, and a polyether containing 3 to 12 carbon atoms.

[0336] Embodiment 54. The segment of any one of embodiments 44 to 52, wherein the polymer film comprises polycaprolactone or polydioxanone.

[0337] Embodiment 55. The segment of any one of embodiments 44 to 52, wherein the polymer film comprises polycaprolactone having an Mn of about 10,000 to about 150,000.

[0338] Embodiment 56. The segment of any one of embodiments 44 to 52, wherein the polymer film comprises polycaprolactone having an Mn of about 80,000 to about 110,000.

[0339] Embodiment 57. The segment of any one of embodiments 44 to 52, wherein the polymer film comprises polycaprolactone having about 90,000 Mn.

[0340] Embodiment 58. The segment of any one of embodiments 44 to 52, wherein the polymeric film comprises polycaprolactone having an intrinsic viscosity of about 1.5 to about 2.1 dL / g.

[0341] Embodiment 59. A segment of a gastroretentive system, the segment comprising a carrier polymer; a drug or a salt thereof; and a release rate controlling polymer film, the polymer film further comprising a permeable component that is permeable to the drug or a salt thereof and permeable to water.

[0342] Embodiment 60 The segment of embodiment 59, wherein the permeable component is a polymer or a swellable material.

[0343] Embodiment 61. The segment of embodiment 59 or embodiment 60, wherein the permeable component comprises about 1 to about 30% by weight of the film.

[0344] Embodiment 62. A segment of any one of embodiments 59 to 61, wherein the permeable component is selected from the group consisting of SSG, crospovidone, croscarmellose, and carbopol (PAA).

[0345] Embodiment 63. The segment of any one of embodiments 59 to 62, wherein the polymeric film further comprises a plasticizer.

[0346] Embodiment 64. The segment of embodiment 63, wherein the plasticizer comprises about 1-40% by weight of the film.

[0347] Embodiment 65. The segment of embodiment 63 or embodiment 64, wherein the plasticizer is selected from the group consisting of phthalates, phosphates, citrates, tartrates, adipates, sebacates, sulfonamides, succinates, glycolates, glycerolates, benzoates, myristates, phenyl halides, triacetin, triethyl citrate, PEG, poloxamers, tributyl citrate, and dibutyl sebacate.

[0348] Embodiment 66. The segment of embodiment 63 or embodiment 64, wherein the plasticizer is selected from the group consisting of triethyl citrate and triacetin.

[0349] Embodiment 67. The polymer film is -R 1 -OC(=O)-(where R 1 is C1~C 12 67. The segment of any one of embodiments 59 to 66, comprising a polyester having a repeat unit of the form: selected from the group consisting of an alkylene group, an ether containing 2 to 12 carbon atoms, and a polyether containing 3 to 12 carbon atoms.

[0350] Embodiment 68. The segment of any one of embodiments 59 to 66, wherein the polymer film comprises polycaprolactone or polydioxanone.

[0351] Embodiment 69. The segment of any one of embodiments 59 to 66, wherein the polymer film comprises polycaprolactone having an Mn of about 10,000 to about 150,000.

[0352] Embodiment 70. The segment of any one of embodiments 59 to 66, wherein the polymer film comprises polycaprolactone having an Mn of about 80,000 to about 110,000.

[0353] Embodiment 71. The segment of any one of embodiments 59 to 66, wherein the polymer film comprises polycaprolactone having about 90,000 Mn.

[0354] Embodiment 72. The segment of any one of embodiments 59 to 66, wherein the polymeric film comprises polycaprolactone having an intrinsic viscosity of about 1.5 to about 2.1 dL / g.

[0355] Embodiment 73. A gastric retention system for administration to a patient, the gastric retention system comprising an elastomeric component and at least three elongated members attached to the elastomeric component, each elongated member comprising a proximal end, a distal end and an outer surface therebetween, the proximal end of each elongated member being attached to the elastomeric component and protruding radially from the elastomeric component, and each elongated member having a distal end not attached to the elastomeric component and located at a greater radial distance from the elastomeric component than the proximal end; at least one elongated member comprising a segment of any one of embodiments 1 to 72.

[0356] Embodiment 74. A gastroretentive system for administration to a patient comprising at least one segment of any one of embodiments 1 to 72.

[0357] Embodiment 75. A method for producing a segment of a gastroretentive system, comprising: coating a segment comprising a carrier polymer and a drug or a salt thereof with a solution of a polymer film formulation to produce a film-coated segment; and drying the film-coated segment.

[0358] Embodiment 76 The method of embodiment 75, wherein the coating is performed by dip coating.

[0359] Embodiment 77. The method of embodiment 75, wherein the coating is performed by pan coating.

[0360] Embodiment 78. The method of embodiment 75, wherein the coating is performed by spray coating.

[0361] Embodiment 79. The method of embodiment 75, wherein the coating is carried out by fluidized bed coating.

[0362] Embodiment 80. The method of any one of embodiments 75-79, wherein the solvent used in the solution of the polymer film formulation comprises an organic solvent.

[0363] Embodiment 81. The method of embodiment 80, wherein the solvent used in the polymeric film formulation comprises ethyl acetate, dichloromethane, acetone, isopropyl alcohol, or any combination thereof.

[0364] Embodiment 82. A method for producing a segment of a gastroretentive system, comprising co-extruding a polymer film and a mixture of a carrier polymer and a drug or a salt thereof.

[0365] Embodiment 83. The polymer film formulation comprises: -R 1 -OC(=O)-(where R 1 is C1~C 12 83. The method of any one of embodiments 75 to 82, comprising a polyester having repeat units of the form: selected from the group consisting of an alkylene group, an ether containing 2 to 12 carbon atoms, and a polyether containing 3 to 12 carbon atoms.

[0366] Embodiment 84. The method of any one of embodiments 75 to 82, wherein the polymeric film formulation comprises polycaprolactone or polydioxanone.

[0367] Embodiment 85. The method of any one of embodiments 75 to 82, wherein the polymer film formulation comprises a polycaprolactone having an Mn of about 10,000 to about 150,000.

[0368] Embodiment 86. The method of any one of embodiments 75 to 82, wherein the polymer film formulation comprises polycaprolactone of about 80,000 to about 110,000 Mn.

[0369] Embodiment 87. The method of any one of embodiments 75-82, wherein the polymer film formulation comprises polycaprolactone having about 90,000 Mn.

[0370] Embodiment 88. The method of any one of embodiments 75 to 82, wherein the polymeric film formulation comprises a polycaprolactone having an intrinsic viscosity of about 1.5 to about 2.1 dL / g.

[0371] Embodiment 89. The method of any one of embodiments 75 to 88, wherein the polymer film further comprises a porogen.

[0372] Embodiment 90. The method of any one of embodiments 75-88, wherein the porogen comprises a water soluble polymer, a water soluble small molecule, an inorganic salt, or an organic salt.

[0373] Embodiment 91. The method of any one of embodiments 75 to 88, wherein the porogen comprises about 1 to about 30% by weight of the film.

[0374] Embodiment 92. The porogen is selected from the group consisting of alkali metal salts, sodium chloride, sodium bromide, potassium chloride, potassium sulfate, potassium phosphate, sodium benzoate, sodium acetate, sodium citrate, potassium nitrate, alkaline earth metal salts, calcium chloride, calcium nitrate, transition metal salts, ferric chloride, ferrous sulfate, zinc sulfate, cupric chloride, saccharides, sugars such as sucrose, glucose, fructose, mannose, galactose, aldohexose, altrose, talose, lactose, cellulose, monosaccharides, disaccharides, water-soluble polysaccharides, sorbitol, mannitol, organic fatty and aromatic oils, diols and polyols, polyhydric alcohols, poly(alkylene glycols), polyglycols, alkylene glycols, poly(a,m) alkylene diol esters, alkylene glycols, polyvinyl alcohols, polyvinylpyrrolidone, water-soluble polysaccharides, The method of any one of embodiments 75 to 88, wherein the polymeric material is selected from the group consisting of poloxamer, hypromellose (HPMC), Corifol RH40, polyvinyl caprolactam, polyvinyl acetate (PVAc), polyethylene glycol (PEG), Soluplus (copolymer of polyvinyl caprolactam, polyvinyl acetate, and polyethylene glycol), copovidone, Eudragit (E,RS,RL), poly(methyl vinyl ether-alt-maleic anhydride), polyoxyethylene alkyl ether, polysorbate, polyoxyethylene stearate, polydextrose, polyacrylic acid, alginate, sodium starch glycolate, cross-linked polyacrylic acid (Carbopol), cross-linked PVP (Crospovidone), cross-linked cellulose (Croscarmellose), calcium silicate, xanthan gum, and gellan gum.

[0375] Embodiment 93. The method of any one of embodiments 75-88, wherein the porogen is selected from the group consisting of povidone, copovidone, and polyoxyl castor oil.

[0376] Embodiment 94. The gastroretentive system of embodiment 73, wherein the central elastomer is formed from liquid silicone rubber.

[0377] Embodiment 95. A gastric retention system of embodiment 73 or embodiment 94, wherein the elongated member is attached to the central elastomer via a degradable matrix.

[0378] Embodiment 96. The gastroretentive system of embodiment 95, wherein the degradable matrix comprises HPMC-AS and polycaprolactone.

[0379] Embodiment 97. A method of administering a gastric retention system to a patient, comprising administering to the patient a container containing the gastric retention system of any one of embodiments 73, 74, or 94-96 in a miniaturized state, wherein the container enters the patient's stomach and dissolves after entering the stomach to release the gastric retention system, which then assumes a non-miniaturized state.

[0380] Embodiment 98. The method of embodiment 97, wherein the patient is a human.

[0381] Embodiment 99. The method of embodiment 97 or 98, wherein the container containing the gastroretentive system is administered by swallowing, a feeding tube, or a gastrostomy tube.

[0382] Embodiment 100. The segment of any one of embodiments 1 to 72, the gastroretentive system of any one of embodiments 73, 74, 94, 95, or 96, or the method of any one of embodiments 75 to 93 or 97 to 99, wherein the drug or salt thereof is neither an adamantane-based drug nor a salt of an adamantane-based drug.

[0383] Embodiment 101. A gastroretentive system comprising a therapeutically effective amount of a drug or a pharma- ceutically acceptable salt thereof, the gastroretentive system having a miniaturized configuration and a non-miniaturized configuration,

[0384] A gastric retention system comprising a plurality of elongate members attached to a central elastomer, at least one of the elongate members comprising a carrier polymer, a drug or a pharma- ceutically acceptable salt thereof, and a release rate controlling polymer film coated on a surface of the at least one elongate member; the gastric retention system is configured to release the drug or a pharma- ceutically acceptable salt thereof over a specified gastric retention period.

[0385] Embodiment 102. The gastroretentive system of embodiment 101, wherein the drug is neither an adamantane-class drug nor a pharma- ceutically acceptable salt of an adamantane-class drug.

[0386] Embodiment 103. A gastric retention system of embodiment 101 or embodiment 102, wherein the elongated member is attached to the central elastomer via a linker, and the linker is configured to weaken or degrade to enable the gastric retention system to pass through the pylorus after a specified gastric retention period.

[0387] Embodiment 104. A gastric retention system of embodiment 101 or embodiment 102, wherein at least one elongated member comprises at least two segments connected by a linker, and the linker is configured to weaken or degrade to enable the gastric retention system to pass through the pylorus after a specified gastric retention period.

[0388] Embodiment 105. A gastric retention system described in any one of embodiments 101 to 104, wherein the release rate controlling polymer film comprises one or more polyester materials.

[0389] Embodiment 106. The polymer film is -R 1 -OC(=O)-(where R 1 is C1~C 12 The gastroretentive system of embodiment 105, comprising a polyester having a repeating unit of the form: selected from the group consisting of an alkylene group, an ether containing 2 to 12 carbon atoms, and a polyether containing 3 to 12 carbon atoms.

[0390] Embodiment 107. The gastroretentive system of embodiment 106, wherein the polymer film comprises polycaprolactone or polydioxanone.

[0391] Embodiment 108. The gastroretentive system of embodiment 107, wherein the polymer film comprises polycaprolactone having an Mn of about 10,000 to about 150,000.

[0392] Embodiment 109. The gastroretentive system of embodiment 107, wherein the polymer film comprises polycaprolactone having an Mn of about 80,000 to about 110,000.

[0393] Embodiment 110. The gastroretentive system of embodiment 107, wherein the polymer film comprises polycaprolactone having an Mn of about 90,000.

[0394] Embodiment 111. The gastroretentive system of embodiment 107, wherein the polymer film comprises polycaprolactone having an intrinsic viscosity of about 1.5 to about 2.1 dL / g.

[0395] Embodiment 112. The gastroretentive system of any one of embodiments 101 to 111, wherein the polymer film further comprises a porogen.

[0396] Embodiment 113. The gastroretentive system of embodiment 112, wherein the porogen comprises a water-soluble polymer, a water-soluble small molecule, an inorganic salt, or an organic salt.

[0397] Embodiment 114. The gastroretentive system of embodiment 112 or embodiment 113, wherein the porogen constitutes about 5 to about 30% by weight of the film.

[0398] Embodiment 115. The porogen is selected from the group consisting of alkali metal salts, sodium chloride, sodium bromide, potassium chloride, potassium sulfate, potassium phosphate, sodium benzoate, sodium acetate, sodium citrate, potassium nitrate, alkaline earth metal salts, calcium chloride, calcium nitrate, transition metal salts, ferric chloride, ferrous sulfate, zinc sulfate, cupric chloride, saccharides, sugars such as sucrose, glucose, fructose, mannose, galactose, aldohexose, altrose, talose, lactose, cellulose, monosaccharides, disaccharides, water-soluble polysaccharides, sorbitol, mannitol, organic fatty and aromatic oils, diols and polyols, polyhydric alcohols, poly(alkylene glycols), polyglycols, alkylene glycols, poly(a,m) alkylene diol esters, alkylene glycols, polyvinyl alcohols, polyvinylpyrrolidone, water-soluble polymeric materials. , poloxamer, hypromellose (HPMC), corifol RH40, polyvinylcaprolactam, polyvinylacetate (PVAc), polyethylene glycol (PEG), Soluplus (copolymer of polyvinylcaprolactam, polyvinylacetate, and polyethylene glycol), copovidone, Eudragit (E,RS,RL), poly(methyl vinyl ether-alt-maleic anhydride), polyoxyethylene alkyl ether, polysorbate, polyoxyethylene stearate, polydextrose, polyacrylic acid, alginate, sodium starch glycolate, cross-linked polyacrylic acid (Carbopol), cross-linked PVP (Crospovidone), cross-linked cellulose (Croscarmellose), calcium silicate, xanthan gum, and gellan gum.

[0399] Embodiment 116. The gastroretentive system of any one of embodiments 112 to 114, wherein the porogen is selected from the group consisting of povidone, copovidone, and polyoxyl castor oil.

[0400] Embodiment 117. The gastroretentive system of any one of embodiments 101 to 116, wherein the polymer film further comprises a plasticizer.

[0401] Embodiment 118. The gastroretentive system of embodiment 117, wherein the plasticizer comprises triethyl citrate, triacetin, PEG, poloxamer, tributyl citrate, or dibutyl sebacate.

[0402] Embodiment 119. The gastroretentive system of embodiment 117 or embodiment 118, wherein the plasticizer constitutes about 5 to about 30% by weight of the film.

[0403] Embodiment 120. The gastroretentive system of any one of embodiments 101 to 119, wherein the polymer film further comprises an anti-adhesive agent.

[0404] Embodiment 121. The gastroretentive system of embodiment 120, wherein the anti-adherent agent is selected from the group consisting of magnesium stearate, talc, and glycerol monostearate.

[0405] Embodiment 122. The gastroretentive system of any one of embodiments 101 to 121, wherein the carrier polymer comprises a polylactone.

[0406] Embodiment 123. The gastroretentive system of embodiment 122, wherein the polylactone comprises polycaprolactone.

[0407] Embodiment 124. Polycaprolactone has an average M of about 60,000 to about 100,000. n The gastric retention system of embodiment 123, comprising:

[0408] Embodiment 125. Polycaprolactone has an average M of about 75,000 to about 85,000. n The gastric retention system of embodiment 123, comprising:

[0409] Embodiment 126. The polycaprolactone has an average M of about 80,000. n The gastric retention system of embodiment 123, comprising:

[0410] Embodiment 127. The gastric retention system of any one of embodiments 101 to 126, wherein the elongate member further comprises at least one excipient.

[0411] Embodiment 128. The gastroretentive system of embodiment 127, wherein at least one excipient comprises a polyalkylene glycol.

[0412] Embodiment 129. The gastroretentive system of embodiment 128, wherein the polyalkylene glycol is selected from the group consisting of polyethylene glycol (PEG), polypropylene glycol (PPG), and block copolymers of PEG and PPG.

[0413] Embodiment 130. The gastroretentive system of embodiment 128, wherein the polyalkylene glycol comprises a block copolymer of PEG and PPG.

[0414] Embodiment 131. The block copolymer of PEG and PPG is H-(OCH2CH2) x -(O-CH(CH3)CH2) y -(OCH2CH2) z The gastroretentive system of embodiment 130, comprising -OH, wherein x and z are about 101 and y is about 56.

[0415] Embodiment 132. The gastric retention system of any one of embodiments 101 to 131, wherein the elongated member further comprises an antioxidant.

[0416] Embodiment 133. The gastric retention system of any one of embodiments 101 to 132, wherein the elongated member further comprises silica.

[0417] Embodiment 134. The gastric retention system of any one of embodiments 101 to 133, wherein the central elastomer comprises silicone rubber.

[0418] Embodiment 135. The gastric retention system of any one of embodiments 101 to 134, wherein the plurality of elongated members includes at least three elongated members.

[0419] Embodiment 136. The gastric retention system of any one of embodiments 101 to 134, wherein the plurality of elongated members is six elongated members.

[0420] Embodiment 137. The gastric retention system of any one of embodiments 101 to 136, wherein the system has a gastric retention period of about 4 to about 8 days when administered to a human patient.

[0421] Embodiment 138. The gastric retention system of any one of embodiments 101 to 136, wherein the system has a gastric retention period of about 7 to about 10 days when administered to a human patient.

[0422] Embodiment 139. The gastroretentive system of any one of embodiments 101 to 138, wherein the system is configured to have a dissolution profile characterized by dissolution of about 10 to 20% of the initial amount of the drug or a pharma- ceutically acceptable salt thereof present in the system within an initial 24-hour period in an aqueous environment.

[0423] Embodiment 140. The gastroretentive system of any one of embodiments 101 to 138, wherein the system is configured to have a dissolution profile characterized by dissolution of about 20 to 40% of the initial amount of the drug or pharma- ceutically acceptable salt thereof present in the system within an initial 48-hour period in an aqueous environment.

[0424] Embodiment 141. The gastric retention system of embodiment 139 or embodiment 140, wherein the aqueous environment is a mammalian stomach.

[0425] Embodiment 142. The gastroretentive system of embodiment 139 or embodiment 140, wherein the aqueous environment is the stomach of a human patient.

[0426] Embodiment 143. The gastroretentive system of embodiment 139 or embodiment 140, wherein the aqueous environment is simulated gastric fluid, fasted state simulated gastric fluid, or fed state simulated gastric fluid.

[0427] Embodiment 144. The gastroretentive system of any one of embodiments 101 to 143, wherein the system comprises from about 10 to about 400 mg of a drug or a pharma- ceutically acceptable salt thereof.

[0428] Embodiment 145. A gastroretentive system, comprising: a carrier polymer;

[0429] A gastroretentive system comprising: a drug or a salt thereof; and a release rate controlling polymer film configured to control the release rate of the drug or its salt; over a 7-day incubation of the system in simulated gastric fluid, the amount of the drug or its salt released from the system during the 5th day is at least about 40% of the amount of the drug or its salt released during the 2nd day; and at least about 7% of the total amount of the drug or its salt in the system is released on the 2nd day and at least about 7% of the total amount of the drug or its salt is released on the 5th day.

[0430] Embodiment 146. A gastroretentive system comprising: a carrier polymer; a drug or its salt; and a release rate controlling polymer film configured to control the release rate of the drug or its salt; over a 7-day incubation of the system in simulated gastric fluid, the amount of the drug or its salt released from the system during the 7th day is at least about 20% of the amount of the drug or its salt released during the 1st day; and wherein at least about 4% of the total amount of the drug or its salt in the system is released on the 1st day and at least about 4% of the total amount of the drug or its salt is released on the 7th day.

[0431] Embodiment 147. A gastric retention system comprising a carrier polymer, a drug or its salt; and a release rate controlling polymer film configured to control the release rate of the drug or its salt; wherein the release rate controlling polymer film is configured such that the release of the drug or its salt from the system in 40% ethanol / 60% simulated gastric fluid over 1 hour is not more than about 40% higher than the release of the drug or its salt from an equivalent segment in 100% simulated gastric fluid over 1 hour.

[0432] Embodiment 148. A gastroretention system comprising a carrier polymer, a drug or its salt; and a release rate controlling polymer film configured to control the release rate of the drug or its salt, wherein the release rate controlling polymer film is configured such that the release of the drug or its salt from the system in 40% ethanol / 60% simulated gastric fluid over 1 hour is at least about 40% lower than the release of the drug or its salt from a second system in 40% ethanol / 60% simulated gastric fluid over 1 hour, the second system comprising the same combination of carrier polymer and drug or its salt but lacking the release rate controlling polymer film.

[0433] Embodiment 149. A gastroretention system comprising a carrier polymer, a drug or its salt; and a release rate controlling polymer film configured to control the release rate of the drug or its salt, wherein the release rate controlling polymer film is configured such that the release of the drug or its salt from the system in simulated gastric fluid over an initial 6 hour period is at least about 40% lower than the release of the drug or its salt from a second system in simulated gastric fluid over an initial 6 hour period, the second system comprising the same combination of carrier polymer and drug or its salt but lacking the release rate controlling polymer film; and wherein the release of the drug or its salt from the system in simulated gastric fluid over a 7 day period is at least about 60% of the total amount of the drug or its salt originally present in the system.

[0434] Embodiment 150. The gastroretentive system of embodiment 149, wherein the release of the drug or its salt from the system in simulated gastric fluid over a period of 7 days is at least about 70% of the total amount of the drug or its salt originally present in the system.

[0435] Embodiment 151. The gastroretentive system of embodiment 149, wherein the release of the drug or its salt from the system in simulated gastric fluid over a period of 7 days is at least about 80% of the total amount of the drug or its salt originally present in the system.

[0436] Embodiment 152. A gastroretentive system, comprising: a carrier polymer; a drug or a salt thereof; and a release rate controlling polymer film, wherein a best-fit linear regression model of the release rate of the drug or a salt thereof from the system in simulated gastric fluid has a coefficient of determination R of at least about 0.8 over an initial 7-day period. 2 and wherein the polymeric film is configured to control the release rate of the drug or a salt thereof such that the polymeric film has a release rate of about 40 to about 60% of the drug or a salt thereof in about 40 to about 60% of the time over a seven day period.

[0437] Embodiment 153. A gastric retention system providing a sustained release drug dosage form, the gastric retention system comprising: a plurality of elongate members comprising a therapeutically effective amount of a drug or a pharma- ceutically acceptable salt thereof and a carrier polymer, wherein the drug or its salt is blended with the carrier polymer such that the drug or its pharma- ceutically acceptable salt is distributed throughout the elongate members; and a release rate controlling polymer film coating at least one of the elongate members; the plurality of elongate members are attached to a central elastomer; and the gastric retention system provides a sustained release of the drug or its pharma- ceutical acceptable salt.

[0438] Embodiment 154. The gastric retention system of embodiment 153, wherein the elongated member further comprises one or more additional components selected from the group consisting of excipients and antioxidants, and the one or more additional components are blended with the drug or its pharma- ceutically acceptable salt and the carrier polymer such that the drug or its pharma- ceutically acceptable salt and the one or more additional components are distributed throughout the elongated member.

[0439] Embodiment 155. The gastroretentive system of embodiment 153 or embodiment 154, wherein the carrier polymer is blended with the drug or a pharma- ceutically acceptable salt thereof, and, if present, one or more additional ingredients, by melting the carrier polymer, the drug or a pharma- ceutically acceptable salt thereof, and, if present, one or more additional ingredients, and mixing them together.

[0440] Embodiment 156. A gastric retention system of any one of embodiments 153 to 155, wherein the elongated member is attached to the central elastomer via a linker, and the linker is configured to weaken or degrade to enable the gastric retention system to pass through the pylorus after a specified gastric retention period.

[0441] Embodiment 157. A gastric retention system of any one of embodiments 153 to 155, wherein at least one elongated member comprises at least two segments connected by a linker, and the linker is configured to weaken or degrade to enable the gastric retention system to pass through the pylorus after a specified gastric retention period.

[0442] Embodiment 158. The gastric retention system of embodiment 156, wherein the release rate modifying polymer film is coated onto the elongated member by coating the elongated member with a solution of the polymer film formulation to produce a film-coated elongated member; and drying the film-coated elongated member.

[0443] Embodiment 159. The gastric retention system of embodiment 157, wherein the release rate modifying polymer film is coated onto the segment by coating the segment with a solution of the polymer film formulation to produce a film-coated segment; and drying the film-coated segment.

[0444] Embodiment 160. The gastroretentive system of embodiment 158 ​​or embodiment 159, wherein the coating is performed by dip coating.

[0445] Embodiment 161. The gastroretentive system of embodiment 158 ​​or embodiment 159, wherein the coating is performed by pan coating.

[0446] Embodiment 162. The gastroretentive system of embodiment 158 ​​or embodiment 159, wherein the coating is performed by spray coating.

[0447] Embodiment 163. The gastroretentive system of embodiment 158 ​​or embodiment 159, wherein the coating is performed by fluidized bed coating.

[0448] Embodiment 164. The gastroretentive system of any one of embodiments 158 to 163, wherein the solvent used in the solution of the polymer film formulation comprises an organic solvent.

[0449] Embodiment 165. The gastroretentive system of embodiment 164, wherein the solvent used in the polymer film formulation comprises ethyl acetate, dichloromethane, acetone, isopropyl alcohol, or any combination thereof.

[0450] Embodiment 166. A segment of a gastric retention system coated with a release rate controlling polymer film or an elongated member of a gastric retention system coated with a release rate controlling polymer film, made by co-extruding a polymer film and a mixture of a carrier polymer and a drug or a pharma- ceutically acceptable salt thereof to form a segment or an elongated member.

[0451] Embodiment 167. A method for producing a segment of a gastric retention system coated with a release rate modifying polymer film or an elongated member of a gastric retention system coated with a release rate modifying polymer film, comprising co-extruding a polymer film and a mixture of a carrier polymer and a drug or a pharma-ceutically acceptable salt thereof to form a segment or an elongated member.

[0452] Embodiment 168. A method for manufacturing a gastric retention system, comprising: blending a drug, including a drug or a salt thereof, with a carrier polymer to form a carrier polymer-drug blend or a carrier polymer-drug salt blend, such that the drug or a pharma-ceutically acceptable salt thereof is distributed throughout the carrier polymer-drug blend or the carrier polymer-drug salt blend; forming a plurality of elongated members from the carrier polymer-drug blend or the carrier polymer-drug salt blend, wherein the drug or a salt thereof is distributed throughout the elongated members; coating the plurality of elongated members with a release rate controlling polymer film; and attaching the plurality of elongated members to a central elastomer.

[0453] Embodiment 169. The method of embodiment 168, wherein at least one elongate member comprises at least two segments connected by a linker, and the linker is configured to no longer connect the at least two segments of each elongate member after a specified gastric residence period.

[0454] Embodiment 170. A method for manufacturing a gastric retention system, comprising: blending a drug, including a drug or a salt thereof, with a carrier polymer to form a carrier polymer-drug blend or a carrier polymer-drug salt blend, such that the drug or a pharma- ceutically acceptable salt thereof is distributed throughout the carrier polymer-drug blend or the carrier polymer-drug salt blend; forming a plurality of segments from the carrier polymer-drug blend or the carrier polymer-drug salt blend, wherein the drug or a salt thereof is distributed throughout the segments; coating the segments with a release rate controlling polymer film; forming a plurality of elongated members by linking at least two segments via a linker to create an elongated member; and attaching the plurality of elongated members to a central elastomer.

[0455] Embodiment 171. The method of any one of embodiments 168 to 170, further comprising blending one or more additional ingredients with the drug or its salt and the carrier polymer such that the one or more additional ingredients selected from the group consisting of a drug or a pharma- ceutically acceptable salt thereof and excipients and antioxidants are distributed throughout the carrier polymer-drug blend or carrier polymer-drug salt blend.

[0456] Embodiment 172. The method of any one of embodiments 168 to 171, wherein blending the drug or a pharma- ceutically acceptable salt thereof, and, if present, one or more additional ingredients, comprises melting the carrier polymer, the drug or a pharma- ceutically acceptable salt thereof, and, if present, one or more additional ingredients, and mixing them together.

[0457] Embodiment 173. The method of any one of embodiments 168 to 172, wherein the elongated member is attached to the central elastomer via a linker, and the linker is configured to no longer connect the elongated member to the central elastomer after a specified gastric residence period.

[0458] Embodiment 174. The method of any one of embodiments 168 to 173, wherein coating the release rate modifying polymer film onto the elongate strip or segment comprises: coating the elongate strip or segment with a solution of the polymer film formulation to produce a film-coated elongate strip or film-coated segment; and drying the film-coated elongate strip or film-coated segment.

[0459] Embodiment 175. The method of any one of embodiments 168 to 174, wherein the coating comprises dip coating.

[0460] Embodiment 176. The method of any one of embodiments 168-174, wherein the coating comprises pan coating.

[0461] Embodiment 177. The method of any one of embodiments 168-174, wherein the coating comprises spray coating.

[0462] Embodiment 178. The method of any one of embodiments 168 to 174, wherein the coating comprises fluidized bed coating.

[0463] Embodiment 179. The method of any one of embodiments 174 to 178, wherein the solvent used in the solution of the polymer film formulation comprises an organic solvent.

[0464] Embodiment 180. The method of embodiment 179, wherein the solvent used in the polymer film formulation comprises ethyl acetate, dichloromethane, acetone, isopropyl alcohol, or any combination thereof.

[0465] Embodiment 181. A gastroretentive system manufactured by any of the methods of embodiments 168 to 180.

[0466] Embodiment 182. A method for producing a segment of a gastric retention system coated with a release rate modifying polymer film or an elongated member of a gastric retention system coated with a release rate modifying polymer film, comprising co-extruding a polymer film and a mixture of a carrier polymer and a drug or a pharma-ceutically acceptable salt thereof to form a segment or an elongated member.

[0467] Embodiment 183. A gastric retention system providing a sustained release drug dosage form, the gastric retention system comprising a therapeutically effective amount of a drug or a pharma- ceutically acceptable salt thereof and a release rate controlling polymer film configured to provide a sustained release of the drug or its salt in an aqueous environment, the system having a dissolution profile characterized by dissolution of about 10-20% of the initial amount of drug present in the system within an initial 24 hour period in the aqueous environment.

[0468] Embodiment 184. The gastroretentive system of embodiment 183, wherein the system has a dissolution profile characterized by dissolution of about 20-40% of the initial amount of drug present in the system within an initial 48 hour period in an aqueous environment.

[0469] Embodiment 185. The gastroretentive system of embodiment 183 or embodiment 184, wherein the aqueous environment is the stomach of a human patient.

[0470] Embodiment 186. The gastroretentive system of embodiment 183 or embodiment 184, wherein the aqueous environment is simulated gastric fluid.

[0471] Embodiment 187. The gastric retention system of any one of embodiments 183 to 186, wherein the system has a gastric retention period of at least about 4 days when administered to a human patient.

[0472] Embodiment 188. The gastric retention system of embodiment 187, wherein the system has a gastric retention period of about 7 days.

[0473] Embodiment 189. The gastroretentive system of any one of embodiments 183 to 188, wherein the drug or a pharma- ceutically acceptable salt thereof is blended with a component configured to provide a sustained release of the drug or its salt.

[0474] Embodiment 190. The gastroretentive system of embodiment 189, wherein the gastroretentive system further comprises a carrier polymer and at least one excipient, and wherein the drug or a pharma- ceutically acceptable salt thereof and at least one excipient are dispersed within the carrier polymer.

[0475] Embodiment 191. A segment of a gastric retention system, the segment comprising a carrier polymer; a drug or its salt; and a release rate controlling polymer film configured to control the release rate of the drug or its salt, wherein over a 7-day incubation of the segment in simulated gastric fluid, the amount of drug or its salt released from the segment during the 5th day is at least about 40% of the amount of drug or its salt released during the 2nd day; and at least about 7% of the total amount of drug or its salt in the segment is released on the 2nd day and at least about 7% of the total amount of drug or its salt in the segment is released on the 5th day.

[0476] Embodiment 192. A gastric retention system providing a sustained release drug dosage form, the gastric retention system comprising a plurality of elongate members, at least one of which comprises a therapeutically effective amount of a drug or a pharma- ceutically acceptable salt thereof and a carrier polymer, and the drug or its salt is blended with the carrier polymer such that the drug or its pharma- ceutically acceptable salt is distributed throughout the at least one elongate member; the drug or its pharma- ceutically acceptable salt comprises about 40 to about 60% by weight of the at least one elongate member; the plurality of elongate members are attached to a central elastomer; and the gastric retention system provides a sustained release of the drug or its pharma- ceutical acceptable salt.

[0477] Embodiment 193. A gastric retention system providing a sustained release drug dosage form, the gastric retention system comprising: a plurality of elongated members, at least one of which comprises a therapeutically effective amount of a drug or a pharma- ceutically acceptable salt thereof and a carrier polymer, the drug or a salt thereof being blended with the carrier polymer such that the drug or a pharma- ceutically acceptable salt thereof is distributed throughout the at least one elongated member; and a release rate controlling polymer film coating the at least one elongated member; the drug or a pharma- ceutically acceptable salt thereof comprises about 40 to about 60% by weight of the at least one elongated member; the plurality of elongated members are attached to a central elastomer; and the gastric retention system provides a sustained release of the drug or a pharma- ceutical acceptable salt thereof.

[0478] Embodiment 194. The gastric retention system of any one of embodiments 101-144, 152-165, 181, 183-190, 192 or 193, or the segment of embodiment 166 or embodiment 191, wherein the drug or a pharma- ceutically acceptable salt thereof constitutes about 40 to about 60% of the weight of at least one elongate member of embodiments 101-144, 152-165, 181, 183-190, 192 or 193, or about 40 to about 60% of the weight of the segment of embodiment 166 or embodiment 191, excluding the weight of any elastomer or linker attached to at least one elongate member or segment.

[0479] Embodiment 195. The gastric retention system of any one of embodiments 101-144, 152-165, 181, 183-190, 192 or 193, or a segment of embodiment 166 or embodiment 191, wherein the drug or a pharma- ceutically acceptable salt thereof constitutes about 51 to about 60% by weight of at least one elongate member of embodiments 101-144, 152-165, 181, 183-190, 192 or 193, or about 51 to about 60% by weight of the segment of embodiment 166 or embodiment 191.

[0480] Embodiment 196. The gastroretentive system of any one of embodiments 145 to 152, wherein the drug or a pharma- ceutically acceptable salt thereof is present in an amount by weight of about 67 to about 150% of the weight of the carrier p...

Claims

1. 1. A gastroretentive system comprising a therapeutically effective amount of a drug or a pharma- ceutically acceptable salt thereof, the gastroretentive system having a compacted configuration within a container for administration to a patient and a non-compacted configuration upon release from the container within a stomach; the gastroretentive system includes a plurality of elongate members attached to a central elastomer; At least one elongate member Carrier polymer, A drug or a pharma- ceutically acceptable salt thereof, and A release rate controlling polymer film coated on the surface of at least one of the elongate members. Including, The release rate controlling polymer film is -R 1 -O-C(=O)- (In the formula, R 1 is C 1 ~C 12 alkylene groups, ethers containing 2 to 12 carbon atoms, and polyethers containing 3 to 12 carbon atoms. and wherein the gastroretentive system comprises a polyester having a repeat unit of the form: (with the proviso that the polyester is not polycaprolactone, polydioxanone, polylactic acid, or poly(lactic-co-glycolic acid)), and the gastroretentive system is configured to release a drug or a pharma- ceutically acceptable salt thereof over a specified gastroretentive period. Gastroretentive system.

2. The gastroretentive system of claim 1 , wherein the release rate controlling polymer film comprises one or more polyester materials.

3. The gastroretentive system of claim 1 , wherein the release rate controlling polymer film comprises at least two different polyester materials.

4. The gastroretentive system of any one of claims 1 to 3, wherein the polymer film further comprises a porogen.

5. The gastroretentive system of claim 4 , wherein the porogen comprises a water soluble polymer, a water soluble small molecule, an inorganic salt, or an organic salt.

6. The gastroretentive system of claim 4 or claim 5, wherein the porogen comprises about 5 to about 40% by weight of the film.

7. The gastroretentive system of claim 4 or claim 5, wherein the porogen comprises about 5 to about 30% by weight of the film.

8. The porogen may be selected from the group consisting of alkali metal salts, sodium chloride, sodium bromide, potassium chloride, potassium sulfate, potassium phosphate, sodium benzoate, sodium acetate, sodium citrate, potassium nitrate, alkaline earth metal salts, calcium chloride, calcium nitrate, transition metal salts, ferric chloride, ferrous sulfate, zinc sulfate, cupric chloride, saccharides, sugars such as sucrose, glucose, fructose, mannose, galactose, aldohexose, altrose, talose, lactose, cellulose, monosaccharides, disaccharides, water soluble polysaccharides, sorbitol, mannitol, organic fatty and aromatic oils, diols and polyols, polyhydric alcohols, poly(alkylene glycols), polyglycols, alkylene glycols, poly(a,m) alkylene diol esters, alkylene glycols, polyvinyl alcohols, polyvinylpyrrolidones, water soluble polymeric materials, polyols ...

8. The gastroretentive system of any one of claims 4 to 7, selected from the group consisting of loxamer, hypromellose (HPMC), Corifol RH40, polyvinylcaprolactam, polyvinylacetate (PVAc), polyethylene glycol (PEG), Soluplus (copolymer of polyvinylcaprolactam, polyvinylacetate, and polyethylene glycol), copovidone, Eudragit (E,RS,RL), poly(methyl vinyl ether-alt-maleic anhydride), polyoxyethylene alkyl ether, polysorbate, polyoxyethylene stearate, polydextrose, polyacrylic acid, alginate, sodium starch glycolate, cross-linked polyacrylic acid (Carbopol), cross-linked PVP (Crospovidone), cross-linked cellulose (Croscarmellose), calcium silicate, xanthan gum, and gellan gum.

9. The gastroretentive system of any one of claims 1 to 8, wherein the polymer film further comprises a plasticizer.

10. 10. The gastroretentive system of claim 9, wherein the plasticizer comprises triethyl citrate, triacetin, PEG, poloxamer, tributyl citrate, or dibutyl sebacate.

11. The gastroretentive system of claim 9 or claim 10, wherein the plasticizer comprises about 1% to about 30% by weight of the film.

12. The gastroretentive system of claim 9 or claim 10, wherein the plasticizer comprises about 5 to about 30% by weight of the film.

13. The gastroretentive system of any one of claims 1 to 12, wherein the polymer film further comprises an anti-adhesive agent.

14. 14. The gastroretentive system of claim 13, wherein the anti-adherent agent is selected from the group consisting of magnesium stearate, talc, and glycerol monostearate.

15. The gastroretentive system of any one of claims 1 to 14, wherein the polymer film further comprises a permeable component, the permeable component being permeable to a drug or a salt thereof, permeable to water, or permeable to a drug or a salt thereof and permeable to water.

16. 16. The gastroretentive system of claim 15, wherein the permeable component is selected from the group consisting of sodium starch glycolate (SSG), crospovidone, croscarmellose, and cross-linked polyacrylic acid.

17. The gastroretentive system of any one of claims 1 to 16, wherein the carrier polymer comprises a polylactone.

18. The gastroretentive system of claim 17 , wherein the polylactone carrier polymer comprises polycaprolactone.

19. The polycaprolactone of the carrier polymer has an average M n 20. The gastroretentive system of claim 18, comprising:

20. The polycaprolactone of the carrier polymer has an average M n 20. The gastroretentive system of claim 18, comprising:

21. The polycaprolactone of the carrier polymer has an average M n 20. The gastroretentive system of claim 18, comprising:

22. The gastric retention system of any one of claims 1 to 21, wherein the elongate member further comprises at least one excipient.

23. The at least one excipient is selected from the group consisting of P407, Eudragit E, PEG, polyvinylpyrrolidone (PVP), polyvinyl acetate (PVAc), polyvinyl alcohol (PVA), Eudragit RS, Eudragit RL, PLA, PLGA, PLA-PCL, polydioxanone, crospovidone, croscarmellose, HPMCAS, lecithin, taurocholate, SDS, Soluplus, fatty acids, Corifol RH40; and linear block copolymers of dioxanone and ethylene glycol; linear block copolymers of lactide and ethylene glycol; linear block copolymers of lactide, ethylene glycol, trimethyl carbonate, and caprolactone; linear block copolymers of lactide, glycolide, and ethylene glycol; glycolide, poly 23. The gastroretentive system of claim 22, wherein the block copolymer is selected from the group consisting of ethylene glycol, and linear block copolymers of ethylene glycol; linear copolymers of caprolactone and glycolide; polyaxial block copolymers of glycolide, caprolactone, and trimethylene carbonate; polyaxial block copolymers of glycolide, trimethylene carbonate, and lactide; polyaxial block copolymers of glycolide, trimethylene carbonate, and polypropylene succinate; polyaxial block copolymers of caprolactone, lactide, glycolide, and trimethylene carbonate; polyaxial block copolymers of glycolide, trimethylene carbonate, and caprolactone; and linear block copolymers of lactide, caprolactone, and trimethylene carbonate.

24. The gastroretentive system of claim 22 , wherein the at least one excipient comprises a polyalkylene glycol.

25. The gastric retention system of any one of claims 1 to 24, wherein the elongate member further comprises an antioxidant or further comprises silica.

26. The gastric retention system of any one of claims 1 to 25, wherein the central elastomer comprises silicone rubber.

27. 27. The gastric retention system of any one of claims 1 to 26, wherein the elongate members are attached to the central elastomer via linkers, the linkers being configured to weaken or degrade to allow the gastric retention system to pass through the pylorus after the specified gastric retention period.

28. 28. The gastric retention system of any one of claims 1 to 27, wherein at least one elongate member comprises at least two segments connected by a linker, the linker being configured to weaken or degrade to allow the gastric retention system to pass through the pylorus after the specified gastric retention period.

29. The gastroretentive system of claim 27 or claim 28, wherein the linker comprises hydroxypropylmethylcellulose-acetate succinate (HPMCAS) and polycaprolactone.

30. 30. The gastroretentive system of any one of claims 1 to 29, wherein the system has a gastric retention period of about 4 to about 10 days when administered to a human patient.

31. The gastroretentive system of any one of claims 1 to 30, wherein the drug or a pharma- ceutically acceptable salt thereof comprises about 25 to about 60% of the weight of the at least one elongate member.

32. The gastroretentive system of any one of claims 1 to 30, wherein the drug or a pharma- ceutically acceptable salt thereof comprises about 40 to about 60% of the weight of the at least one elongate member.

33. 2. A segment for use in a gastroretentive system according to claim 1, said segment comprising: Carrier polymer; A drug or a salt thereof; and Release rate controlling polymer film Including, The release rate controlling polymer film is i) constituting from about 0.1 to about 20% of the total weight of said segment; or ii) has a thickness of about 1 to about 40 microns; The release rate controlling polymer film is -R 1 -O-C(=O)- (In the formula, R 1 is C 1 ~C 12 alkylene groups, ethers containing 2 to 12 carbon atoms, and polyethers containing 3 to 12 carbon atoms. A segment comprising a polyester having a repeat unit of the form: with the proviso that the polyester is not polycaprolactone, polydioxanone, polylactic acid, or poly(lactic-co-glycolic acid).

34. The release rate controlling polymer film is i) constituting from about 0.1 to about 10% of the total weight of said segment; or ii) having a thickness of about 1 to about 20 microns; 34. A segment according to claim 33.

35. 10. A method of manufacturing a segment of a gastroretentive system for use in the gastroretentive system of claim 1, comprising the steps of: coating a segment comprising a carrier polymer and a drug or a salt thereof with a solution of the polymer film formulation to produce a film-coated segment; and drying the film-coated segments. Including, The film, -R 1 -O-C(=O)- (In the formula, R 1 is C 1 ~C 12 alkylene groups, ethers containing 2 to 12 carbon atoms, and polyethers containing 3 to 12 carbon atoms. with the proviso that the polyester is not polycaprolactone, polydioxanone, polylactic acid, or poly(lactic-co-glycolic acid).

36. 36. The method of claim 35, wherein the coating comprises dip coating, pan coating, spray coating, or fluidized bed coating.

37. 13. A method for producing a segment for use in a gastroretentive system according to claim 1 coated with a release rate modifying polymer film or an elongate member of a gastroretentive system according to claim 1 coated with a release rate modifying polymer film, comprising the steps of: co-extruding the polymer film and the mixture of carrier polymer and drug or a pharma- ceutically acceptable salt thereof to form said segments or elongated members. Including, The release rate controlling polymer film is -R 1 -O-C(=O)- (In the formula, R 1 is C 1 ~C 12 alkylene groups, ethers containing 2 to 12 carbon atoms, and polyethers containing 3 to 12 carbon atoms. with the proviso that the polyester is not polycaprolactone, polydioxanone, polylactic acid, or poly(lactic-co-glycolic acid).

38. A gastroretentive system according to any one of claims 1 to 32, or a segment of a gastroretentive system according to claim 33 or 34, wherein the drug or a pharmaceutical salt thereof is donepezil or a pharma- ceutically acceptable salt thereof.

39. A gastroretentive system according to any one of claims 1 to 32, or a segment of a gastroretentive system according to claim 33 or 34, wherein the drug or a pharmaceutical salt thereof is doxycycline or a pharma- ceutically acceptable salt thereof.

40. A gastroretentive system according to any one of claims 1 to 32, or a segment of a gastroretentive system according to claim 33 or 34, wherein the drug or a pharmaceutical salt thereof is risperidone or a pharma- ceutically acceptable salt thereof.

Citation Information

Patent Citations

  • Intermittently releasing tablet

    JP1991044318A

  • Device stayed in stomach

    JP1991163011A

  • gastrointestinal drug delivery system

    JP2000503316A

  • Novel gastric retention dosage forms containing GABA analogs and opioids

    JP2013530193A

  • Residence structures and related methods

    WO2015191920A1